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ABSTRACT 
 
 
Clusterin is a multifunctional glycoprotein widely expressed as two isoforms. One isoform, 
sCLU, is secreted, cytoplasmic and anti-apoptotic, the other, nCLU, is nuclear and pro-apoptotic. 
Seven genes, DKK3, TIMP1, CADM1, AKAP12, KLF4, RNASET2 and CLU were identified to 
be candidate tumour suppressor genes in cervical neoplasia. Following validation of expression 
and methylation patterns of these genes CLU was taken forward.  
 
The regulation and expression of CLU has been investigated at three sites of squamous cancer: 
the oral cavity, cervix and nasopharynx. Down-regulation of CLU at both transcriptional and 
protein levels was demonstrated in nasopharyngeal cancer (NPC) and oral cancer. Loss of one 
CLU allele and methylation of the other is demonstrated in the NPC cell line C666-1. This defect 
has been repaired in this NPC cell line and showed that CLU overexpression of the nuclear 
isoform of CLU resulted in reduced proliferation and decreased cell viability. 
 
Overexpression of both isoforms of CLU was achieved in C666-1 cells and their knockdown in 
HeLa cells regulates NF-kB activity. Further evidence that CLU may regulate NF-kB activity 
was demonstrated by stabilisation of IkB following CLU overexpression in C666-1. Although 
sCLU is now considered a promising therapeutic target because of its anti-apoptotic function, 
with an antisense oligonucleotide currently undergoing clinical evaluation, results suggest that 
further consideration needs to be given to the possible tumour suppressor function of nCLU. 
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1. Cancer 
Cancer accounts for around 13% of all deaths and it is estimated that 1 in 5 of us will die from 
cancer, with its incidence predicted to increase globally from 10 million in 2000 to 15 million by 
2010 (IARC-WHO). Cancer cells are neoplastic and proliferate in defiance of normal cell 
controls, preventing normal multicellular function and tissue and organ formation, with the 
potential to become malignant (invasive) and colonise surrounding tissues (Abbott, Forrest et al. 
2006).  
 
Cancers can be characterised by the tissue and cell type they occur in. Around 90% of cancers are 
classed as carcinomas, which arise from epithelial cells, and common sites of occurrence are the 
breast, prostate, lung and colon (Petersen, Gudjonsson et al. 2003). Carcinomas are thought to 
account for the majority of cancers as the epithelial cells are a site of active cell proliferation and 
are frequently exposed to both physical and chemical carcinogens. Tumours that arise from 
mesenchymal cells or connective tissue are termed sarcomas. A third type of cancers are 
lymphomas and leukaemias, which arise from hemopoietic cells. Other tumour types include 
germ cell tumours derived from totipotent cells, and blastomas that commonly occur in children 
and resemble embryonic tissue. All of these types of cancer can be further subdivided according 
to specific cell type, location in body and the structure of the tumour. 
 
The majority of cancers result from initial somatic hypermutation of a single cell that then must 
acquire a number of mutations in order to become cancerous, a process which has been described 
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in Hanahan and Weinberg’s ‘hypothesis of 6 cumulative alterations’ (Hanahan and Weinberg 
2000). Benign tumours can be removed surgically and consist of neoplastic cells which remain 
clustered together in a single mass. As more aggressive cancer cells divide, they may penetrate 
the basement membrane. This local invasion leads to neoplastic cell adherence to adjacent tissue, 
and through production of proteolytic enzymes and factors such as matrix metalloproteinases 
(MMPs) degradation of the extracellular matrix (ECM) is caused in surrounding tissue. This 
allows cancer cells to cross tissues into neighbouring stroma, facilitating deeper invasion and 
metastasis. It is through this process that a tumour becomes ‘malignant’, as the cells invade the 
surrounding tissue and cross the basal lamina to enter the blood stream. Metastatic tumours have 
the ability to survive in the circulation, and are able to travel through blood vessels to other 
organs and through the lymphatic vessels to lymph nodes. Consequently, development of 
secondary tumours at a site remote from the primary tumour is a hallmark of more aggressive 
cancers, making them much harder to eradicate (Laerum 1997; Liotta and Kohn 2001) .  
 
1.1 Pathogenesis of cancer 
Hanahan and Weinberg’s hypothesis of 6 cumulative alterations that define malignancy include 
self-sufficiency in growth signals, insensitivity to growth-inhibition signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion 
and metastasis (Hanahan and Weinberg 2000).  
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Normal cells require mitogenic growth factors to stimulate proliferation, but some cancer cells 
have acquired autonomy from this mode of down-regulation. Cancer cells can gain self-
sufficiency for growth signalling by overexpression or constitutive activation of growth factor 
receptors, synthesising their own growth factors and deregulating downstream signalling targets 
(Peters, Loud et al. 2001). Cancers cell must evade negative anti-growth signals, which act by 
forcing cells out of the cell cycle into a resting, quiescent state (G0), or by inducing cells to 
undergo differentiation into a post-mitotic state (Zeimet, Riha et al. 2000). This can also be 
achieved by abrogation of growth-inhibitory receptor function.  
 
Mechanism Example
Over production of platlet-derived growth factor (PDGF) by glioblastomas
Up-regulation of epidermal growth factor receptors (EGFR) by breast cancer
Alteration of Ras signalling proteins in cancers
Disruption of retinoblastoma protein (pRb)
down-regulation of TGFβ
Inactivation of TP53
Mutation of Caspase 8 in hepatocellular carcinomas
Limitless replicative potential Up-regulation of telomerase enzyme
Up-regulatuion of vascular endothelial growth factor (VEGF)
Up-regulation of fibroblast growth factors (FGF)
Down-regulation of thrombospondin-1 (THBS-1)
Loss of E-cadherin function
Isoform switch of N-CAM
Self-sufficency of growth signals
Insensitivity of anti-growth signals
Evading apoptosis
Sustained angiogenesis
Tissue invasion and metastasis
 
Table 1.1. Hanahan and Weinberg’s hypothesis of 6 cumulative alterations that define 
malignancy. 
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Cancer cells evade programmed apoptotic cell death by abrogation of pro-apoptotic ‘sensor’ 
receptor signalling that monitors the extracellular and intracellular environment, such as 
CD95/CD95L pathway (Strand and Galle 1998). Where abnormalities are detected or survival 
signals are insufficient, effector molecules, such as caspases, are triggered to execute 
programmed cell death, with over-expression of anti-apoptotic molecules such as Bcl-2. 
Telomere maintenance is evident in many malignant cells and provides a mechanism of 
controlling replicative potential, by up-regulating telomerase enzymes leading to cell 
immortalisation with stimulation of the alternative lengthening of telomerases (ALT) pathway 
(Kelland 2007). The survival of cells in virtually every tissue depends upon their close proximity 
to a blood vessel to supply oxygen and nutrients. Cancer cells have developed mechanisms of 
encouraging growth of new blood vessels from pre-existing vessels (angiogenesis), by changing 
the balance of angiogenesis inducers such as VEGF and inhibitors such as thrombospondin-1 
(Cheung, Singh et al. 1995; Hanahan and Folkman 1996).  
 
Eventually, tumours may acquire the ability to invade adjacent tissue and travel via the lymphatic 
and blood vessels to distant sites in the body to form secondary tumours where space and 
nutrients are not limiting. This is achieved through changes in the balance of cell-cell adhesion 
molecules, overexpression of extracellular proteases, such as matrix metalloproteases, and by 
suppression of protease inhibitors (Crawford and Matrisian 1994). 
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1.2. Causes of cancer 
Causes of cancer include a number of genetic and environmental factors such as carcinogens in 
tobacco smoke, hormones, chemicals, mutagens such as UV radiation, viral infection, all of 
which can lead to such oncogenic mechanisms as loss of heterozygosity and epigenetic changes 
affecting gene expression, including silencing of tumour suppressor genes (TSGs) and activation 
of proto-oncogenes (Braakhuis, Snijders et al. 2004; Fukui, Kondo et al. 2005). Activation of 
proto-oncogenes to oncogenes stimulates cell proliferation and transformation and prevents cells 
from undergoing normal programmed cell death by apoptosis. Inactivation of TSGs prevents the 
normal cellular control and inhibition of the cell cycle, DNA replication and cell adhesion.  
 
Smoking is considered to be the most significant risk factor for cancer; however this is closely 
followed by viral infection that can be attributed to 15% of all cancers. Many oncogenes and 
TSGs have been shown to interact with tumour virus proteins and carry corrupted genes into 
other host cells. An example of this is papillomaviruses and SV40 which sequester products of 
Retinoblastoma and p53 proteins, which would normally regulate cell division (Werness, Levine 
et al. 1990; Howley, Munger et al. 1991; Lechner, Mack et al. 1992; Tommasino and Crawford 
1995). 
 
1.2.1. Oncogenes 
Certain genes have the ability to acquire transforming potential, often as a result of alterations in  
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the gene coding regions of regulatory sequences or through an increase in copy number and are 
referred to as oncogenes. When present in normal cells they are referred to proto-oncogenes, and 
are sporadically modified to become an oncogene which results in changes in gene expression or 
product activity. A single mutant allele of an oncogene can affect the phenotype of the cell and 
there are several ways in which oncogenes can become activated, resulting in either an increased 
rate of production or production of an altered gene product. Overproduction can be achieved 
through gene amplification, such as amplification of the proto-oncogene ERBB2 in breast cancer 
(tyrosine kinase-type cell surface receptor HER2) (Singleton and Strickler 1992). Alternatively 
point mutations can lead to increased gene product activity. Activation can occur by translocation 
to create novel, chimeric proteins. Translocation into a transcriptionally active region of 
chromatin can cause oncogene activation, such MYC (Wiseman 2006). 
 
1.2.2. Tumour suppressor genes 
TSGs have been identified in a range of cellular processes and are regulators of normal growth 
and development. However, in carcinogenesis this function is lost. Mutation of TSGs usually 
exhibits recessive effects as the cell still contains one normal functioning gene copy (Payne and 
Kemp 2005). Inheritance of a mutation in combination with a single somatic hypermutation can 
lead to cancer by completely ameliorating TSG function. There is evidence that many TSGs 
undergo epigenetic inactivation (see 1.3) by DNA hypermethylation, demonstrating that mutation 
and chromosomal loss or intragenic deletion are not the sole mechanisms of TSG inactivation 
(Ibanez de Caceres and Cairns 2007). 
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Gene Oncogene/TSG Function Type of cancer
PDGFB Oncogene Platelet-derived growth factor Dermatofibrosarcoma
RAS Oncogene GTPase Pancreatic, colon, lung, ovarian and thyroid 
ERBB2 Oncogene Growth factor receptor Breast and ovarian
EGFR Oncogene Growth factor receptor Breast
SRC Oncogene Tyrosine kinase Colorectal
RAF Oncogene Serine/threonine kinase Renal cell carcinoma
MYC Oncogene Transcription factor Burkitt's lymphoma and breast carcinoma
FOS Oncogene Transcription factor Fibrous dysplasia
RB1 TSG Cell cycle Retinoblastoma, Wilm's tumoure, oestosarcoma
TP53 TSG DNA repair, apoptosis, allotoxin associated Hepatocellular carcinoma, osteogenic sarcoma, colorectal and lung
p16INK4A TSG cell cycle/p53 function Melanoma, pancreatic adenocarcinoma, leukaemia, bladder
BRAC2 TSG DNA repair Breast, ovarian and prostate
APC TSG Cell-cell recognition Colorectal  
       Table 1.2. Exampes of oncogenes and tumour suppressor genes 
                          (adapted from Kings and Robins, 2006). 
 
 
The gene most frequently altered in human cancers in p53. In normal cells p53 is thought to be a 
‘guardian of the genome’ as it protects DNA from damage by co-ordinately blocking cell 
proliferation, stimulating DNA repair and promoting apoptotic cell death (Wahl and Carr 2001). 
p53 inactivation can occur by mutation, which usually disrupts DNA binding, either directly by 
preventing interaction with DNA bases or indirectly by destabilising the loop structures required 
for this interaction (Lim, Lim et al. 2007) and may be responsible for the genetic instability of 
many full-blown metastasizing cancers (Wahl, Linke et al. 1997).  
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1.3. Epigenetics and cancer 
Epigenetics is defined as ‘heritable changes in gene expression that are not due to any alteration 
in the DNA sequence’(Tanaka, Watanabe et al. 2008). Epigenetic changes include methylation of 
DNA, histone deacetylation, ubiquitination, and phosphorylation. These mechanisms play an 
important role in regulating gene expression and are said to constitute an ‘epigenetic code’; for 
example depending on the type of modification a particular gene can either be expressed or 
silenced. DNA methylation plays an important role in normal cells and is responsible for X-
chromosome inactivation and silencing alleles of imprinted genes (Esteller 2007; Esteller 2008). 
 
1.3.1. DNA methylation 
DNA methylation, catalysed by the enzymic activity of DNA methyltransferases (DNMTs), is the 
addition of a methyl group from S-adenosylmethionine (SAM, a universal methyl donor) to the 
fifth carbon of a cytosine ring that precedes a guanine, known as a CpG dinucleotide (Bernstein, 
Meissner et al. 2007). CpG dinucleotide is under-represented in most of the genome, but stretches 
of sequence that are rich in cytosines proceeded by guanines are referred to as CpG islands. CpG 
islands span the 5’ region of nearly half of the genes in the mammalian genome and can be 
defined as less than 0.5kb stretches of DNA comprising of ≤55% CpGs, and an over expected 
frequency of the dincleotide CG greater than 0.6 (Gardiner-Garden and Frommer, 1987). In 
normal mammalian somatic cells most promoter associated CpG islands are unmethylated with 
an open, transcriptionally active chromatin structure, whereas CpG dinucleotides elsewhere in the 
genome, such as in repetitive elements, are generally methylated (Bestor, 2000). 
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1.3.2. Epigenetic mechanisms of transcriptional control 
A reciprocal relationship between density of methylated cytosine residues in the promoter region 
of genes and the transcriptional activity of a gene has been widely documented (Razin and Cedar, 
19991; Kass et al., 1997). In genes which have unmethylated promoters, nucleosomes are widely 
spaced and associated with a transcriptionally active state. Histone acetylases (HACs) are found 
in close proximity to unmethylated promoters and catalyse the addition of acetyl groups to lysine 
residues close to the N-terminus of histone proteins. Conversely, in genes that have methylated 
promoters, members of methylated cytosine DNA binding protein (MBP) family, such as 
MeCP2, MBD1, MBD2, MBD3 and MBD4, bind the DNA and recruit histone deacetylases 
(HDACs) and the chromatin remodelling complex human SWI/SNF (Meehan et al., 1989; 
Harikrishnan et al., 2005).  
 
DNA methylation leads to deactylation of histones by HDACs and can directly impede the 
binding of transcription factors to their target sites with a closed compacted chromatin structure, 
thereby preventing the transcription of genes (Nakayama and Takami 2001; Noma, Allis et al. 
2001). Other specific histone modifications include the methylation of lysine 9 on histone H3. 
Silencing of TSGs that are involved in molecular pathways including apoptosis, cell cycle control 
and DNA repair (e.g. RASSF1A) by DNA methylation plays an important role in multistep 
carcinogenesis, along with loss of heterozygosity. Tumour suppressor gene hypermethylation is 
accompanied in cancer cells by the deacetylation of histones H3 and H4, gain of H3K9 
methylation and H3K27 trimethylation, and the  loss of H3K4 trimethylation (Gronbaek, Hother 
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et al. 2007). CpG methylation and a series of chromatin remodelling enzymes together allow 
chromatin to adopt an open, transcriptionally active structure (Jenuwein and Allis, 2001; Strachan 
and Read, 2004). 
 
 
 
 
Figure 1.1. Methylation of CpG islands in gene promoter region regulates 
transcription.      
A. Unmethylated CpG nucleotides in the gene promoter region permit transcription 
and expression of the gene. B. Methylation of CpG nucleotides in the promoter 
region blocks transcription by rendering the area inaccessible to cellular transcription 
machinery. 
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1.3.3. Epigenetic events during normal development 
The pattern of DNA methylation is crucial for the normal function and development of 
mammalian organisms, and changes in DNA methylation processes have been associated with a 
wide range of human diseases (Robertson, 2005). The genomes of the primordial germ cells are 
largely methylated by pre-existing methylation marks become erased by a wave of genome-wide 
demethylation during development. During differentiation and germ cell development, 
reprogramming of gene expression patterns occurs by de novo methylation, with the sperm 
genome becoming more heavily methylated than the oocyte’s genome. After fertilisation a 
second wave of genome-wide demethylation occurs in the maternal genome in a replication 
dependent manner due to exclusion of DNMT1 from the nucleus (Mayer, Niveleau et al. 2000; 
Oswald, Engemann et al. 2000; Santos, Hendrich et al. 2002). In this way, the mammalian 
genome undergoes major reprogramming of modification patterns between parental germ cells 
and the developing embryo.  
 
Differences in gene expression can be seen between tissues of the body and are associated with 
methylation status, with tissue-specific expression of genes able to undergo hypomethylation as 
well as hypermethylation during tumour development. Sex-specific differences in the methylation 
pattern of germ cells occur at imprinted loci, where a specific parental allele is epigenetically 
modified to allow differential expression of the two alleles in somatic cells of offspring produced. 
There are at least 60 imprinted genes in mammals and errors in this process can lead to disease 
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and disorders such as Prader-Willi syndrome (PWS), Angelman syndrome (AS) and Beckwith-
Wiedemann syndrome (BWS).  
 
X-inactivation occurs during the pre-implantation stage of development in all female mammals, 
and results in the selective inactivation of one of the two X-chromosomes by hypomethylation; 
providing a mechanism to allow males and females to have equal expression of X-chromosome 
genes (Panning, Dausman et al. 1997; Riggs 2002). Incorrect X-chromosome inactivation can 
predispose females to recessive X-linked diseases such as incontinentia pigmenti (Bruckner, 
2004). DNA methylation also regulates diverse immune processes such as hematopoietic cell 
development and lineage decisions, immune competence, antigen reactivity and autoimmunity; in 
particular major histo-compatibility complex (MHC) and class II transactivator (CIITA) 
expression in antigen-specific immune responses and immune surveillance (Reiner, 2005). It has 
been suggested that genomic hypomethylation aids the acquisition of mutations in cancer cells by 
destabilising the genome and promoting loss of heterozygosity in regions containing tumour 
suppressor genes (Ehrlich, 2002; Feinberg and Tucko, 2004). 
 
It has been proposed that epigenetic modifications such as methylation primarily arose as a 
mechanism of host defence against inter-genomic parasites, which can cause gene dysregulation 
and mutation (Walsh et al., 1998). It has been suggested that Alu elements, short stretch of DNA 
that are the most abundant mobile elements in the human genome in the human genome, may act 
as modifiers of gene expression through changes in their own methylation status (Batzer and 
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Deininger, 2002), and inappropriate insertions of these elements accounts for at least 20 known 
human diseases (Ostertag and Kazazian, 2001). 
 
1.3.4. DNA methylation in cancer 
Both hypermethylation and hypomethylation have been observed in a number of cancers, with 
hypomethylation increasing with increased malignancy at a number of sites such as breast 
(Jackson, Yu et al. 2004). Hypomethylation causes chromatin decondensation and results in the 
upregulation of proto-oncogenes, increased recombination and mutation, X-chromosome 
inactivation, loss of imprinting, reactivation of transposable elements, and demethylation of 
xenobiotics; ultimately promoting cancer (Franco, Schoneveld et al. 2008). In relation to 
squamous cancer, TSGs have been shown to be hypermethylated in cervical carcinogenesis, such 
as CADM1 (Steenbergen, Kramer et al. 2004). It is well established that cervical squamous cell 
carcinoma is closely correlated with HPV infection, particularly that of HPV 16 and 18. DNMT1 
expression increases in cervical intra-epithelial neoplasia (CIN) and progression to cervical 
carcinoma. Interestingly in vitro studies have shown a direct interaction between HPV-16 E7 and 
DNMT1, stimulating its activity (Burgers, Blanchon et al. 2007).  
 
1.3.4.1. Hypomethylation in cancer 
In 1983 Feinberg and co-workers at the John Hopkins University reported widespread loss of 
CpG DNA methylation in tumour samples, which provided  the first evidence for the 
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involvement of aberrant methylation patterns in cancer (Feinberg and Vogelstein 1983). Loss of 
methylation at a genome wide level is a frequent and early event in cancer leading to increased 
mitotic recombination events and genome instability and in many tumour types correlates with 
disease severity and metastatic potential (Widschwendter, Jiang et al. 2004). In addition to the 
effects of widespread demethylation, specific genes may become hypomethylated at promoter-
associated CpG islands. Tumour-specific transcriptional activation by hypomethylation has been 
demonstrated for a number of key genes in caner; such as DNAJ domain-containing protein 9 
gene (MCJ), which is a marker of response to chemotherapy in ovarian cancer (Strathdee, Vass et 
al. 2005). 
 
1.3.4.2. Hypermethylation in cancer 
Gene silencing by promoter hypermethylation is a frequent and important mechanism of TSG 
inactivation in cancer, with the RB1 gene being the first TSG shown to be methylated in cancer 
(Ohtani-Fujita, Fujita et al. 1993). Hypermethylation exemplifies genes involved in tumour 
developmental processes, including cell-cycle regulation, apoptosis, DNA repair, cell signalling, 
invasion, chromatin remodelling and transcription (Robertson 2001; Robertson 2005). Nearly 
half of all genes mutated in inherited tumours are known to undergo silencing by methylation 
including the BRCA-1 gene in breast cancer (Esteller, Silva et al. 2000) and von Hippel-Lindau 
syndrome (VHL) in renal cancer (Herman, Latif et al. 1994). Critical TSG in cancer are 
inactivated by a combination of methylation and mutation, however there is emerging evidence 
of biallelic hypermethylation distant from regions of chromosomal loss, such as the protocadherin 
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10 gene (PCDF10) in nasopharyngeal carcinoma (Yin, Xie et al. 2002); demonstrating that 
epigenetic inactivation by promoter hypermethylation alone is sufficient to inactivate a TSG and 
promote tumourigenesis (Knudson 1971). It has been suggested that the dynamic process of 
promoter CpG island hypermethylation may gradually spread from the latent edges of heavily 
methylated DNA flanking a CpG island and progressively edge towards the transcription start site 
of the gene (Graff, Gabrielson et al. 2000). Methylation of RASSF1A in normal and cancer tissue 
is an example of diffusion of methylation from a normally methylated region into previously 
unmethylated promoter (Yan, Shi et al. 2003). 
 
1.3.5. Reversal of epigenetic modifications 
Genetic mutations are transmitted through DNA replication; however epigenetic modifications 
must be actively maintained and therefore are reversible. By inhibiting epigenetic maintenance 
molecules it is possible to reactivate genes vital to suppression of a malignant phenotype that 
have lost function by DNA hypermethylation-mediated gene silencing in cancer. 
Pharmacological agents can therefore be used to target DNA methyltransferase (DNMT) 
enzymes maintaining DNA methylation marks and HDAC enzymes responsible for modifying 
histones resulting in chromatin remodelling and transcriptional genes activity (Stresemann, 
Bokelmann et al. 2008; Stresemann and Lyko 2008). A number of HDAC inhibitors are currently 
being tested in phase I and II clinical trials and in 2004 the US Food and Drug Administration 
(FDA) licensed the archetypal DNMT inhibitor 5-azacytidine (Vidaza) for use as an anti-tumour 
agent in the pre-leukaemic disorder, myelodysplastic syndrome.  
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1.3.5.1. 5-Azacytidine 
5-Azacytidine is a cytosine nucleoside analogue that is incorporated into the DNA of dividing 
cells, where it inhibits methylation by forming a covalent bond with DNMT1 and preventing its 
activity. Over the past 20 years, many clinical trials have included the use of both 5-Azacytidine 
and 5-Aza-2'-deoxycytidine and a phase III trial showed great clinical benefit to patients with 
myelodysplastic syndrome treated with low dose 5’-Azacytidine (Kornblith, Herndon et al. 2002; 
Oki and Issa 2006; Oki, Aoki et al. 2007). A phase I trial demonstrated significant demethylation 
of the viral promoter in EBV-associated tumours with 5-Azacytidine, however there was no 
recordable clinical response with little reactivation in EBV expression (Ben-Sasson and Klein 
1981; Countryman, Gradoville et al. 2008). Nonetheless, the identification of hypermethylated 
DNA in a carrier of BRCA-1 mutation in breast cancer is of great potential use as a diagnostic 
tool since DNA hypermethylation is an early event in cancer.  
 
In vitro studies with 5-Azacytidine and its deoxyribose derivative 5-Aza-2’deoxycitidine in 
cancer cells have shown a time and dose dependent inhibition of proliferation, and multiple 
studies have demonstrated the restoration of gene function of methylated TSG during culture with 
these drugs. 5-Aza-2’deoxycitidine (Decitabine) is possibly a more specific DNMT inhibitor than 
5-Azacytidine as it can be directly incorporated into DNA; 5-Azacytidine needs to be converted 
to a deoxyribonucleoside first, and before this occurs it can be incorporated into RNA, affecting a 
variety of RNA functions independent of demethylation. However, both drugs have toxic effects 
and 5-Aza-2’deoxycitidine treatment induces myelosuppression with neutropenia-related fever 
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(Demakos and Linebaugh 2005). The inherent toxicity of cytosine nucleoside analogues has been 
the main factor limiting their use as anti-cancer agents. 
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1.4. Squamous cancer and adenocarcinoma 
Squamous cell carcinoma (SCC) is a malignant tumour of the squamous epithelium, affecting the 
mouth, skin, oesophagus, bladder, prostate, vagina and cervix. Human papillomavirus has been 
associated with SCC of the oropharynx, lung, fingers, and anogenital region. The incidence of 
SCC peaks at 66 years with males twice as likely to be affected as females and exposure to 
sunlight being a further risk factor in skin SCC. The majority of head and neck cancers are SCC 
and are associated with smoking, alcohol and HPV in 25% of mouth and 35% of throat cancers 
(Ragin and Taioli 2007). Adenocarcinoma originates from glandular tissue and develops in cells 
lining glandular types of internal organs, such as the lungs, breasts, colon, prostate, stomach, 
pancreas, and cervix. 10-15% of all adenocarcinomas are mucinous and aggressive at sites such 
as colon (Buetow, Buck et al. 1995).  
 
1.4.1. Cervical cancer 
Cervical carcinoma is strongly correlated with sexually transmitted HPV infection with disease  
incidence increased in women who have had multiple sexual partners or whose partner is 
promiscuous; the disease is absent in virgins. 471,000 new cases of cervical cancer are diagnosed 
each year worldwide, with approximately 2300 women per year in the UK. Around 80% of 
cervical cancers occur in the developing world where it is the most common cause of cancer 
related deaths (Beaudenon and Huibregtse 2008). Although cervical cancer is the second most 
common cause of cancer in women worldwide, first being breast cancer, the incidence overall is 
falling in the UK, as in the western world.  A 40% decrease in deaths from cervical cancer in the 
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last 20 years can be attributed to the implementation of cervical screening programmes (Herbert 
2007). The incidence of squamous cell cervical carcinoma is falling; however the incidence of 
adenocarcinoma is now increasing with 95% cases occurring in women over the age of 35.  
 
1.4.1.1. Histology of cervical cancer 
The normal cervix is comprised of columnar and stratified non-keratinising squamous  
epithelium, the ectocervix is lined by stratified squamous epithelium and the endocervix lined by 
mucinous columnar glandular epithelium with ciliated cells. Cell proliferation is normally 
restricted to the basal zone. Squamous metaplasia of the cervix is the process whereby columnar 
glandular epithelium of the transformation zone is gradually replaced by a mature squamous 
epithelium and is a normal process taking place during the reproductive years. The border 
between the metaplastic epithelium arising during the reproductive years and the original 
squamous epithelium is called the original squamous cell junction (Ehrmann 1996). The 
transformation zone, between the original and current squamocolumnar junctions, is the site of 
squamous metaplasia of the endocervical glands. Over 90% of cervical cancer arises from the 
transformation zone (Tranbaloc 2008). The risk of abnormal cell changes is increased by 
metaplasia during puberty and pregnancy due to the rapid cell turnover.  
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1.4.1.2. Classification of premalignant invasive lesions 
Proliferation of cells in the lower layers of the epithelium leads to a disordered development of 
the squamous epithelium, referred to as cervical intraepithelial neoplasia (CIN). (Richart 1973; 
Ambros and Kurman 1990). This is accompanied by an increase in nuclei size and mitoses, 
hyperchromasia and abnormal mitotic forms. Premalignant lesions can also be classified as low 
grade squamous intra-epithelial lesions (LSIL), equivalent to CIN I, and high grade squamous 
intra-epithelial lesions (LSIL), equivalent to CIN III; with the traditional CIN II classification 
falling between the two (La Vecchia, Tavani et al. 1997; Sherman, Tabbara et al. 1999; Saffer, 
Wahed et al. 2002; Ha and Califano 2006; Mokhtar, Delatour et al. 2008; Hunter, Duggan et al. 
2009; Lukic, Iannaccio et al. 2009) .   
 
1.4.1.2.1. CIN I/LSIL 
Proliferating parabasal-like cells are confined to the lower basal third of the epithelium, with the 
upper two thirds showing good differentiation; however a number of nuclear abnormalities 
persist and so superficial cells demonstrate koilocyte atypia. The vast majority of low grade 
lesions are transient and 65% of CIN I naturally regress, with only 15% progressing as far as CIN 
III (Moore, Cofer et al. 2007).  
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1.4.1.2.2. CIN II  
When proliferating parabasal-like cells have extended in the middle third of the epithelium, with 
a relative decrease in koilocytotic atypia this is referred to as moderate dysplasia, with 
differentiation and maturation of the upper half of the epithelium. When the upper one third of 
the epithelium becomes involved the dysplasia becomes severe. 50% of CIN II regress with 35% 
progression to high grade disease (Tranbaloc 2008). 
 
1.4.1.2.3. CIN III/HSIL  
In CIN III there is an aneuploid cell population, with proliferating cells having extended through 
the entire thickness of the epithelium. Keratinised dysplasia with nuclear abnormalities and 
mitotic figures are present throughout the epithelium, referred to as carcinoma in situ. 20% CIN 
III become invasive and a number of studies has shown that progression of CIN to invasive 
disease can take decades, with CIN incidence peaking at 30-34 years and that of invasive disease 
55-59 years.  
 
1.4.1.2.4. Adenocarcinoma in situ 
Less common than CIN, adenocarcinoma in situ is the precursor of most endocervical 
adenocarcinomas and is localised to the squamocolumnar junction (Christopherson 1979; Boon, 
Baak et al. 1981; Gloor and Hurlimann 1986; Farnsworth, Laverty et al. 1989). It is characterised 
by hyperchromasia, chromatin alteration, nuclear pseudo-stratification, decreased mucin 
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secretion, mitotic activity and apoptotic bodies. It has a 40-70% association with HSIL and strong 
association with HPV (Wilczynski, Walker et al. 1988; Farnsworth, Laverty et al. 1989; Duggan, 
McGregor et al. 1995).  
 
1.4.1.3. Squamous cell carcinoma of the cervix 
SCC is the most frequently diagnosed histological type of cervical cancer, accounting for 85% 
carcinomas and shows strong HPV association (Nair and Pillai 1992; Kwasniewska, Gozdzicka-
Jozefiak et al. 2004). It can be classified as keratising, large cell non-keratising and small cell 
types. Keratinising carcinomas are characterised by keratin spheres of infiltrating squamous 
epithelial cells with hyperchromatic pyknotic nuclei and infrequent mitoses. Large cell non-
keratinising carcinomas account for 75% of SCC and constitute  infiltrating sheets of 
undifferentiated polygonal cells forming masses with pushing borders, enlarged nuclei with 
granular chromatin and occasional keratisation of only single cells, with more frequent mitoses 
than keratinising types.  
 
1.4.1.4. Adenocarcinoma of the cervix 
Adenocarcinoma, arising from the endocervical epithelium, accounts for 15% of all invasive 
carcinomas and is associated with HPV (Young and Scully 1990; Duggan, McGregor et al. 
1995). It is usually well differentiated and may produce mucin, consisting of columnar cells with 
gland-like spaces. Subtypes of adenocarcinoma account for 30% glandular cancers and include 
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endometriod, clear cell, papillary villoglandular, papillary serous and mesonephric. This form of 
cervical cancer is difficult to diagnose with few early stage symptoms meaning that it is 
frequently diagnosed at much later stage than that of SCC. Unlike SCC this tumour does not have 
strong correlation with sexual behaviour or smoking but show association with obesity. 
 
1.4.1.5. Causes of cervical cancer 
Multiple pregnancies, smoking, exposing to radiation and viral infection are risk factors for 
cervical cancer, with HPV infection being the most significant. Almost all cervical cancers are 
HPV positive , an involvement which was first hypothesised in the 1970s (Wheeler 2008). 
Despite the success of the screening programme, women with minor cytological abnormalities 
continue to be treated unnecessarily because light microscopy cannot distinguish those women 
who will progress to invasive cancer and those women in whom epithelial abnormalities will 
spontaneously regress. Therefore, there are compelling reasons for the identification of other 
predictors of disease progression. 
 
1.4.1.5.1. HPV and cervical cancer 
Human papillomavirus (HPV) is a small double stranded DNA virus, of which there are over 130 
different types, 40 of these infecting the genital tract. Those most commonly associated with 
cervical intraepithelial neoplasia and invasive cancer and classified as high risk types are HPV 16 
and HPV 18, followed by other oncogenic types HPV 31, 33, 35, 52, 58, 39, 45, 59, 56, 66 and 
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51. HPV 16 and HPV 18 together are responsible for the development of approximately 80% of 
the cervical carcinomas worldwide, with HPV 16 shown to dominate with increasing grade of 
CIN (Bosch, Manos et al. 1995; Walboomers, Jacobs et al. 1999). HPV 33 and HPV 35 are 
classified as moderate risk types and low risk HPV 6 and HPV 11 are present in 90% genital 
warts and do not generally progress toward cancer. Other types of HPV are known to cause 
cancers at other sites such as head and neck. HPV is present in 99.7% biopsies of invasive 
carcinoma of cervix with 90% of CIN III positive for high risk HPV types (Walboomers, Jacobs 
et al. 1999). 
 
The HPV DNA genome is enclosed in a capsid comprised of 2 proteins, L1 and L2; infecting 
most women under the age of 25 shortly after they become sexually active. However, as a result 
of cell-mediated immunity, infection of the genital tract with HPV is usually transient, frequently 
showing viral clearance within a year of detection (Evander, Edlund et al. 1995; Ho, Bierman et 
al. 1998; Ho, Kadish et al. 1998; Woodman, Collins et al. 2001; Sellors, Karwalajtys et al. 2003). 
Infection does appear to show a second incidence peak in middle-aged women, when cervical 
cancer incidence is maximal, which may be due to reactivation of the latent virus. HPV is a 
necessary but not sufficient cause of cervical neoplasia and only a very small minority of women 
infected with these types will progress to invasive disease. Progressive disease follows the 
accumulation of genetic abnormalities, which may be dependent upon HPV integration status or 
infecting HPV type.  
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Adenocarcinoma of the cervix is most highly correlated with HPV 18 infection and HPV 16 
followed by 18 most frequently detected in SCC; however unlike HPV 16, HPV 18 is rarely 
detected at the time of diagnosis of high grade CIN (Zehbe and Wilander 1997). HPV 16 can be 
found in both episomal and integrated forms whereas HPV 18 is always integrated in malignant 
tissue and women with HPV 18 positive SCC have poorer survival than those who are HPV 16 
positive. When in a purely integrated population HPV 16 has worse prognosis than episomal 
forms or combination of episomal and integrated. This is suggestive of disease progression being 
determined by the integration status of the infecting HPV type (Pett and Coleman 2007).  
 
Oncogenic genital HPV encodes 2 potent oncogenes, E6 and E7, that disable cell cycle control 
mediated by inactivation of p53 and retinoblastoma tumour suppressors, allowing high-level 
amplification of the viral genome (Doorbar 2006). A bivalent (HPV 16, 18) and quadravalent 
(HPV 6, 11, 16, 18) prophylactic HPV vaccine has now been approved for use and offers great 
promise in prevention of cervical cancers when used in combination with successful cervical 
screening programmes. High-risk HPV types also show 25% associated with head and neck 
carcinomas and so the vaccine may also show promise at other sites. 
 
1.4.1.5.2. Other viruses and cervical cancer 
Genital herpes is primarily caused by HSV 2 infection and it has been shown that patients with 
cervical cancer have elevated HSV 2 levels. An interaction has been postulated between HSV and 
HPV 16/18 along with alteration of p53, with Herpes virus infection accelerating the viral 
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replication of HPV and increases its integration (Haverkos, Rohrer et al. 2000; Haverkos 2005). 
EBV is most commonly associated with Hodgkin’s and Burkitt lymphoma and lymphomas 
derived from immuno-compromised individuals with an established association with 
nasopharyngeal and gastric cancers. There have been a number of studies suggesting an  
association with cervical carcinoma, with an absence of EBV in normal cervix and CIN I and 8% 
of CIN II and III and 43% invasive carcinomas being EBV positive (Landers, O'Leary et al. 
1993). Studies have also shown that EBV latent genes EBNA2, LMP1 and EBER1 to be elevated 
in CIN and invasive carcinoma when compared with normal cervix.  It has been suggested that 
EBV-infected tumour infiltrating lymphocytes might contribute to cervical carcinogenesis (Al-
Daraji and Smith 2009).  
 
It has been shown that in the presence or absence of viral infection that immunosuppressed HIV-
positive females have higher incidence of cervical cancer. The HIV specific Tat protein up-
regulates HPV E6 and E7 oncogenes and enhances their oncogenetic transformation efficacy. The 
disease is more advanced in HIV-positive women with an increased incidence of relapse post 
treatment (Al-Daraji and Smith 2009). A negative correlation has been shown between Adeno-
associated viruses (AAV) and incidence of cervical cancer, with AAV displaying anti-oncogenic 
activity, inhibiting the oncogenic properties of HPV (Al-Daraji and Smith 2009).  Prior infection 
with Chlamydia has been correlated with increased progression to CIN III and invasive disease 
(Koskela, Anttila et al. 2000; Luostarinen, Lehtinen et al. 2004).   
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1.4.1.5.3. Smoking and cervical cancer 
Smoking has been shown to double the risk of cervical cancer, as it results in exposure to many 
harmful substances that are absorbed by the lungs and carried in the bloodstream throughout the 
body. Tobacco by-products have been found in the cervical mucus of women who smoke and it 
has been suggested that this results in DNA damage, contribute to the progression of cervical 
cancer (DeMarini 1983; DeMarini 2004).  
 
1.4.1.5.4. Epigenetic component of cervical cancer 
The presence of epigenetically inactivated TSGs in cervical smears or tissue is potentially a 
useful predictor of the natural history of the disease, as epigenetic changes are time dependent 
and heterogeneous. Aberrant methylation of CpG islands in the promoter regions of TSGs has 
already been reported in cervical intraepithelial neoplasia (CIN) (Virmani, Muller et al. 2001; 
Steenbergen, Kramer et al. 2004; Singh, Indra et al. 2007; Terra, Murta et al. 2007; Overmeer, 
Henken et al. 2008). However, it is unknown if these epigenetic changes are necessary or 
sufficient for the initiation or progression of disease.  
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1.4.2. Oral carcinoma 
Carcinoma of the oral cavity is the eighth most common cancer worldwide, with 274 000 new 
cases in 2002 (Parkin 2006) accounting for 4% cancers and 2% cancer deaths and possessing a 
higher death rate than carcinoma of the cervix, brain, liver, testes, kidney and skin  due to its 
diagnosis at late stage (World Health Organization (WHO) cancer database, 2000). 
Approximately two-thirds of cases occur in men, with an overall incidence rate in the UK of 4.5 
in 100 000 (Blot, Devesa et al. 1994). Cancer of the oral cavity is rare in people under 40 years 
old, with peak incidence at 60 years of age. 10-30% patients go on to develop second tumours of 
the aero digestive tract (Day and Blot 1992). Prior to development of a metastatic phenotype, 
cells undergo a number of genetic and phenotypic changes, with patients presenting mouth ulcers, 
warty nodules, pigmented lesions, enlarged neck nodes and difficulty swallowing, which 
provides a window of opportunity for intervention before the development of malignancy. 
Current treatment is surgery in combination with chemotherapy and radiotherapy (Arora, Matta et 
al. 2005).  
 
1.4.2.1. Histology of oral carcinoma 
Oral cancer can be classified as spindle-cell carcinoma, papillary squamous cell carcinomas, 
adenosquamous carcinoma, acantholytic squamous cell carcinomas and carcinoma cuniculatum, 
with 90% of malignant lesions being SCC (Johnson, Ranasinghe et al. 1993; Johnson and 
Warnakulasuriya 1993). Classification and staging includes the size of the tumour primary site, 
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spread of the tumour to regional lymph nodes and whether the tumour has spread or metastasized 
to distant sites such as the lung, brain or liver.  
 
1.4.2.1.1. Oral squamous cell carcinoma 
Clinically, SCC can present as a minor nodule and can extend in severity to a chronic ulcer. The 
degree of keratinisation, cellular and nuclear pleomorphism and mitotic activity provides a basis 
for the grading of SCC as grade 1 which is well differentiated, grade 2 being moderately 
differentiated and poorly differentiated carcinomas termed grade 3 (Pindborg, Reibel et al. 1985). 
Smoking and alcohol consumption are well established risk factors and abnormalities in the p53 
gene have been suggested to be early events in the development of oral SCC. The involvement of 
HPV is well defined in head and neck cancers and is suggestive of HPV 16 involvement in SCC 
development. Basaloid squamous cell carcinoma (BSCC) is a rare and aggressive form of SCC 
that presents as an aggressive, ulcerated, exophylic firm mass (Wain, Kier et al. 1986). It has a 
worse prognosis than conventional SCC with early disease recurrence rates and decreased 
survival rates. 
 
1.4.2.1.2. Oral verrucous carcinoma 
Oral verrucous carcinoma is a much less aggressive and well differentiated form of SCC, also 
known as Ackerman’s tumour, with excellent prognosis due to its slow cauliflower-like 
exophylic growth and low rate of metastasis (Indudharan, Das et al. 1996). Tumours occurring in 
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the lower lip and hard palate are warty with a greyish surface and erythematous areas and 
treatable by excision. Pathogenesis has been associated with tobacco chewing and an association 
has been suggested with HPV (Lubbe, Kormann et al. 1996).  
 
1.4.2.2. Causes of oral carcinoma 
Compared with other sites, the oral cavity is easy to access for examination and sampling yet 
despite the progress in therapeutic procedures, the five-year survival rate for oral cancer patients 
remains unchanged. Identification and characterisation of risk factors for the disease is crucial to 
both prevention and development of improved treatment regimes. A number of genetic and 
environmental/lifestyle factors have been shown to have prognostic significance. Poor oral heath 
and hygiene have been shown to contribute to disease with dental plaques interacting with saliva 
and potential being mutagenic. A synergistic and dose dependent effect of smoking and alcohol 
consumption upon oral cancer rates has been shown in Europe and South Africa, and a further 
risk of chewing of betel quid (which can activate NF-kB) has been demonstrated in Asia and 
Melanesia (Graham, Dayal et al. 1977; Elwood, Pearson et al. 1984; Somers 1985; Blot, 
McLaughlin et al. 1988; La Vecchia, Tavani et al. 1997). 75% of patients are smokers with heavy 
smokers, as compared with non-smokers, having a 6-fold increase in disease (Cawson 1969). 
Other physical factors such as accumulative expose to x-rays and UV radiation have been 
demonstrated in lip cancer and several head and neck cancers. The fact that some patients who 
have not been exposed to such risk factors still develop carcinomas would suggest a genetic and 
viral component to pathogenesis. 
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1.4.2.2.1. HPV and oral carcinoma 
Human Papillomavirus (HPV) infects the skin and mucosas and is associated with the formation 
of benign and malignant tumours. 25 of the 130 established types of HPV have shown association 
with oral carcinoma; HPV 1, 2, 3, 4, 6, 7, 10, 11, 13, 16, 18, 31, 32, 33, 35, 40, 45, 52, 55, 57, 58, 
59, 69, 72 and 73, with oral warts being most commonly positive for HPV 2 and HPV 57. Latent 
infection has also been demonstrated in normal oral mucosa for HPV 6 and HPV 11. Oral 
squamous cell carcinoma shows high prevalence of  HPV 13 and 32, and HPV 16, with detection 
of at least one of these in around 30% tumours (Saffer, Wahed et al. 2002; Syrjanen 2003; Castro 
and Bussoloti Filho 2006; Abdul-Rahman, Lim et al. 2007; Anaya-Saavedra, Ramirez-Amador et 
al. 2008). 
 
1.4.2.2.2. Genetic components of oral carcinoma causation 
Oral carcinogenesis is a multi-step process and can be the result of the progressive alteration in 
genes that regulate cell proliferation, apoptosis, genome stability, angiogenesis, invasion and 
metastasis (Hanahan and Weinberg 2000). Oral cancer has been linked with a down regulation of 
the tumour suppressors p53, p16, retinoblastoma (RB1), cyclin dependent kinase inhibitors and 
adenomatous polyposis coli (APC) (Somoza-Martin, Garcia-Garcia et al. 2005) and an over 
expression of oncogenes such as cyclin family members, epidermal growth factor receptor and 
Ras. Of these, perhaps one of the most significant is p53 that is a G1/S block in the cell cycle and 
is involved in DNA damage repair and apoptosis (Williams 2000). p53 mutation in head and neck 
cancer has been linked with smoking and its restoration in vitro and in vivo has been shown to 
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reverse the malignant phenotype (Langdon and Partridge 1992; Brennan, Boyle et al. 1995; 
Schantz 1995).  
 
Allelic loss has been demonstrated in oral cancer at 3p, 9p and 17p which are though to be early 
markers of carcinogenesis due to their common occurrence in dysplastic regions and at 13q and 
8p in later stage carcinogenesis (Braakhuis, Leemans et al. 2004; Braakhuis, Snijders et al. 2004). 
LOH has also been reported at the APC locus by a number of groups (Largey, Meltzer et al. 
1994; Huang, Chiang et al. 1997). Chromosomal gain has been demonstrated at 3q26 and 11q13 
(Forastiere, Koch et al. 2001; Gollin 2001). Stat3 has been demonstrated to up-regulate vascular 
endothelial growth factor (VEGF) and promote angiogenesis which gives rise to a poor prognosis 
phenotype. Pre-existing oral inflammatory disease and lichen planus have also been shown to 
predispose patients to development or oral cancer. 
 
1.4.2.2.3. Epigenetics component of oral carcinoma 
Hypermethylation of circulating DNA has shown promise as a tumour marker in oral cancer and 
with recent development in techniques used to detect methylation, such as pyrosequencing, the 
sensitivity and specificity are high and can be used in a non-invasive manner, e.g., on blood 
specimens (Shaw 2006). Methylation of a number of tumour suppressor genes has been reported 
in oral cancer pathogenesis including E-cadherin, CDH1, MGMT and DAPK1 (Wu, Roz et al. 
1999; Ha and Califano 2006; Shaw 2006)  
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1.4.3. Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma arising from the epithelial cells 
that line the nasopharynx, usually developing around the ostium of the Eustachian tube in the 
lateral wall. NPC differs from other head and neck cancers in terms of its geographic distribution, 
pathology and etiology including genetic susceptibility, carcinogen exposure and prior viral 
infection with Epstein Barr Virus (EBV) (Chang and Adami 2006; Agulnik and Epstein 2008). 
Close association with EBV makes NPC unique from other head and neck cancers. NPC is rare 
yet it is endemic in a few well defined populations, presenting with swelling of the neck, nasal 
obstruction and epistaxis; with tradition assessment by transnasal biopsy and fine needle 
aspiration biopsy. Tumours have a characteristic lymphoid infiltrate, with expression of 
inflammatory cytokines in malignant and infiltrating cells. Infiltrating lymphocytes have been 
suggested to play a role in disease pathogenesis, however there is no efficient immune response 
against the tumour. The size of primary tumour, lymph node involvement, skull base 
erosion/invasion and cranial nerve involvement can be used to predict the probable final outcome 
of NPC patients (Liu, Hsieh et al. 2003).  
 
During tumour growth, breach of the basement membrane and interaction with stroma causes a 
reaction involving recruitment of a variety of cell types, including fibroblasts, dendritic cells and 
a range of leukocytes, which in turn secrete a variety of chemokines, enzymes and growth factors 
(Le Bitoux and Stamenkovic 2008). This leads to a process which is similar to tissue injury, 
causing inflammation and surrounding tissue damage through processes such as mast cell 
 Introduction 
 
 35 
activation of the complement cascade, release of reactive oxygen species (ROS) by neutrophils, 
and release of matrix metalloproteinases (MMPs) by macrophages that contribute to extracellular 
matrix (ECM) breakdown. Virus induced transformation is also known to particularly stimulate 
immune responses – for example, EBV creates a strong cytotoxic T cell response which may 
contribute to breakdown of surrounding tissues (Comoli, De Palma et al. 2004; Yip, Abdullah et 
al. 2009). Tumours progression can often be restricted by an associated immune response 
characterized by the presence of tumour infiltrating lymphocytes (TILs). Control of tumour 
growth by TILs is often cytotoxic; this involves the production of cytokines which potentiate an 
immune response, characterized by high numbers of CD4 and CD8 positive T cells. High levels 
of TILs have been associated with a good prognosis in patients with cancer of the colon (Murray, 
Hreno et al. 1975).  
 
NPC shows a first peak in occurrence at 15–25 years and peaks again at 40-60 years of age, and 
has a 2 to 3 fold higher incidence in men compared with women. NPC, usually type III, accounts 
for around 50% of nasopharyngeal malignancies in children. In the United Kingdom the 
incidence of NPC is rare, around 1 in 100,000, and in North America it accounts for around 0.2% 
of all malignancies. The incidence of NPC is highest in southern China and southeast Asia, with a 
peak incidence of 20-30 cases per 100,000 (Yu 1991; Tse, Yu et al. 2006). There is a 50-fold 
regional variation in incidence across China, generally increasing from northern China, including 
Beijing and Tianjin, to southern China, such as in Hong Kong. In 2002, NPC was found to be the 
23rd most common new cancer in the world and the fourth in Hong Kong, with a 24-fold higher 
incidence in Hong Kong Chinese males than US males. Emigrants of a Chinese decent still have 
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an elevated incidence of NPC, but one that is lower than China if they are born in North America 
(Lung, Chang et al. 1994). 
 
1.4.3.1. Histology of NPC 
Two major systems of classification for NPC have been put forward by the American Joint 
Committee on Cancer (AJCC) and the World Health Organization (WHO). AJCC classification is 
clinically orientated, based on the status of the primary tumour, the status of the regional lymph 
nodes and the presence or absence of distant metastasis. This classification method is concerned 
with the stage of the tumour, not the histological tumour type, and is given a category code 
known as TNM staging; where T is the size or extent of the primary tumor, N is degree of spread 
to regional lymph nodes and M is the presence of distant metastasis (Kalogera-Fountzila, 
Karanikolas et al. 2006). Each of these categories is given a number ranging from 0 to 4 relating 
to the stage of each, with 4 being the most advanced. For example, a 1cm breast cancer that has 
not spread to the lymph nodes can be categorised as T1, N0, M0. 
 
Alternatively, the WHO classification is based on morphological characterization which 
incorporates the viral load of EBV in NPC. Keratinising squamous cell carcinoma, type I, is 
characterised well differentiated cells that produce keratin. Non-keratinising squamous 
carcinoma, type II, varies in cell differentiation but does not produce keratin. Type III is also non-
keratinising but less differentiated with highly variable cell types such as clear cell, spindle cell 
and anaplatic carcinoma. Type II  and type III NPC are invariably EBV positive (Liu and Yeh 
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1998), while type I and normal nasopharyngeal mucosal cells rarely harbour EBV (Baumforth, 
Young et al. 1999). Types II & III NPC have a better prognosis than type I. In high incidence 
areas 95% NPC are type III, with the majority of the rest being type II and in low-incidence 
regions type I is predominant.  
 
1.4.3.2. Causes of NPC 
Epidemiological evidence, such as that of Chinese emigrants, suggests that the pathogenesis of 
NPC can be attributed to genetic susceptibility and environmental factors  (Zheng, Yan et al. 
1994; Young and Rickinson 2004). Exposure to nitrosamines in salted fish and pickled foods (a 
staple food in endemic areas), smoking, frequent dust exposure, herbal medicines, formaldehyde 
and wood fires used for cooking have all been associated with a 2-6 fold increased risk of NPC. 
Eating lots of fresh fruit and vegetables on a regular basis, particularly in childhood, has been 
suggested to reduce the risk of NPC. Genetic susceptibility from the inheritance of mutated 
alleles or genes also increases the risk of NPC, such as polymorphisms in a subset of human 
leukocyte antigen types. A number of tumour suppressor genes have been reported to be down-
regulated in NPC compared with normal nasopharyngeal epithelium; RARRES1, FHIT, IGSF4, 
ZMYND10, CDKN2A and BRD7 (Lo, Kwong et al. 2001; Lo and Huang 2002). Equally, a large 
number of oncogenes and proto-oncogenes have been shown to be up-regulated in the 
pathogenesis of NPC; CSE 1L, MYB, KIT, LAMC2, MYC, HRAS, MST1R, CCND2, BCL2, 
CTTN, CXCL5, EGFR, PTGS2, FOSL, ID1, MDM2, PIK3CA and TNFRNSF5 (Chou, Lin et al. 
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2008). A number of pathways, such as the Wnt pathway, have been also been shown to be de-
regulated in NPC. 
 
1.4.3.2.1. EBV and NPC 
EBV infection is thought to be one of the main causative factors in the pathogenesis of NPC and 
it is the association with EBV that makes NPC distinct from other head and neck cancers. EBV 
transmission occurs mainly through saliva and targets the B lymphocytes. 90% of the population 
worldwide are thought to be EBV positive with infection being asymptomatic and life long as the 
virus is harmless until the balance between host and virus is altered. The fact that the majority of 
adults are EBV positive and only a small number develop NPC highlights that EBV alone is not a 
sufficient cause of disease and requires the contribution of environmental and genetic cofactors. 
Other diseases associated with EBV include those of lymphocytic origin such as infectious 
mononucleosis, Hodgkin’s disease, Burkitt’s lymphoma and those of epithelial origin, such as 
oral hairy leukoplakia and undifferentiated gastric carcinoma. 95% NPC tumours are correlated 
with EBV infection with the highest EBV titers being in undifferentiated carcinomas (Young and 
Murray 2003; Young and Rickinson 2004).  
 
EBV is a gamma-herpes virus carrying a 172kbp double-stranded DNA genome that enters the 
nucleus of infected cells to form a circular episome. EBV displays three patterns of latency based 
on the expression of its latent genes. In latency I, occurring in Burkitt’s Lymphoma, only the 
EBERS and EBNA1 are expressed; Latency II such as in Hodgkin’s Lymphoma, expresses the 
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EBERS, EBNA1, LMP1 and LMP2; whereas in infectious mononucleosis and 
immunosuppressed-lymphoproliferative disease a latency III pattern of expression is displayed 
and all the latent genes are expressed (Niller, Wolf et al. 2008). NPC has a latency II pattern of 
gene expression of the EBNA1 nuclear antigen, the latent membrane proteins, LMP2A and 
LMP2B, and the BamH1A transcripts. 80% of NPC tumours also express the oncogenic LMP1 
protein which is essential for cell immortalisation (Dawson, Rickinson et al. 1990). The 
monoclonality of the EBV genome would imply that its infection of the host occurs prior to 
clonal expansion of a malignant cell clone (Raab-Traub and Flynn 1986).  
 
1.4.3.2.2. Epigenetic component of NPC 
Recent findings suggest that epigenetic inactivation of a number of tumour suppressor genes 
plays an important role in the tumourigenesis of NPC, with these epigenetic changes influencing 
cellular pathways including apoptosis, cell cycle control and DNA repair in NPC cells (Lo and 
Huang 2002).  TSGs found to be methylated in NPC include CDKN2A, CDKN2B, RASF1A, 
MGMT and ARF. 
 
1.4.3.3. Detection and treatment of NPC 
In situ hybridisation techniques for EBERs are employed to detect EBV (Yamamoto, Nakamura 
et al. 1999; Kimura, Miyake et al. 2009) and since increased EBV-specific antibody titers have 
been shown in high-incidence areas antibodies against EBV capsid antigen are used in 
 Introduction 
 
 40 
combination with anti-EBV DNase antibodies (Li, Tan et al. 1985; Zeng, Zhang et al. 1985). 
NPC patients initially undergo flexible endoscopy, CT and MRI and patients with advanced 
disease are screened for distant metastasis by thoracic and abdominal CT and bone scan. NPC is a 
treatable disease, however it is usually diagnosed at late and advanced stage when there is a 5-
year survival rate of only 38% (Chen, Liu et al. 2008). NPC is usually treated by radiotherapy 
and recent studies have shown increased survival rates with chemotherapy, such as cisplatin and 
5-fluorouracil, administered prior to irradiation of the tumour. Unlike other malignancies of the 
head and neck, NPC is highly sensitive to radiation and chemotherapy when diagnosed at stage I 
or II disease. Less toxic compounds such as taxanes and cetuximab may prove useful when use in 
combination with current treatment regimes for advanced disease. Clinical trials are now 
investigating the use of demethylating agents such as 5-Aza-2’-deoxycitidine which de- repress 
lytic latent genes. Other potential targets are currently being explored such as Wnt antagonists in 
HNSCC and COX2 inhibitors which have been shown to reduce the growth of NPC.  
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1.5. Candidate tumour suppressor genes  
Several other candidate TSGs were identified in cervical cancer which had relevant function and 
expression patterns identified. However, the results of further investigation into each of these 
persuaded me not to take them forward and to exclude them from this investigation. 
 
1.5.1. DKK3 
DKK3, located on chromosome 11p15.2, is a secretary glycoprotein and member of the Dickkopf 
gene family, which are antagonists of Wnt, a member of the Wnt pathway. It inhibits Wnt 
signalling, leading to the suppression of cell growth and differentiation, development and cancer 
(Niehrs 2006). DKK3 specifically negatively modulates Wnt7A signalling, and tumour-specific 
DNA hypermethylation of DKK3 has been identified in prostate cancer, breast cancer and acute 
lymphoblastic leukaemia (Roman-Gomez, Jimenez-Velasco et al. 2004; Lodygin, Epanchintsev 
et al. 2005; Veeck, Bektas et al. 2008). It has been suggested that DKK3-induced apoptosis in 
prostate cancer cells is a consequence of JNK phosphorylation (Kashiwakura, Ochiai et al. 2008; 
Kawasaki, Watanabe et al. 2009). In addition DKK3 has been shown to have a TSG role in 
certain cancers, with its introduction into cell lines where it is silenced resulting in reduced 
colony formation and a slowing of growth attributed to an increased rate of apoptosis, notably in 
cervical cancer and hepatocellular carcinoma cell lines (Hsieh, Hsieh et al. 2004). DKK3 was 
identified as a candidate tumour suppressor gene in cervical cancer as it was up-regulated in our 
array following demethylation of HeLa and SiHa cervical cancer cell lines. Since the time of this 
study it has been demonstrated by Lee et al that DKK3 is down-regulated in cervical cancer and 
is a negative regulator of β-catenin, with the down-regulation of DKK3 in cancer contributing to 
the activation of  β-catenin signaling pathway (Lee, Jo et al. 2009).  In contrast, in head and neck 
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cancer LOH of DKK3 has recently been shown to increase cancer patient survival rates 
associated with lower lymph node metastasis (Katase, Gunduz et al. 2008).  
 
1.5.2. KLF4  
KLF4 was identified as a candidate tumour suppressor gene in cervical cancer as it was up-
regulated in our array following demethylation of CaSki and SiHa cervical cancer cell lines. 
KLF4, located on 9q31, is a member of a family of zinc-finger containing transcription factors 
that is highly expressed in epithelial tissues (Zhang, Geiman et al. 2000; Bieker 2001). KLF4 is 
an inhibitor of the cell cycle, blocking G1/S progression and suppressing cell proliferation 
through p21 (Shields, Christy et al. 1996; Chen, Johns et al. 2001). Expression of KLF4 is 
increased following DNA damage and is thought to mediate p53 G1/S checkpoint function 
(Yoon, Chen et al. 2003).  LOH has been demonstrated in colorectal cancer and in gastric cancer 
KLF4 is down-regulated as a consequence of hypermethylation of its promoter and LOH (Wei, 
Gong et al. 2005). These evidence suggests that KLF4 may be a TSG, however there are a small 
number of studies that identify it as on oncogene, being frequently over-expressed in squamous 
cell carcinoma, with over expression in 70% of primary breast cancers (Foster et al., 1999) 
(Foster et al, 2000). It has been suggested that these conflicting roles may be dependent on p21 
status, with loss of p21 function seemingly causing a switch from KLF4 inhibiting cellular 
proliferation to promoting proliferation (Rowland and Peeper 2006).  
 
1.5.3. RNASET2   
RNASET2, located on 6q27, is a 27 kDa T2-Rnase gylcoprotein that is able to bind actin in vitro 
(Smirnoff, Roiz et al. 2006). Deletion at this locus has been demonstrated in a number of 
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malignancies, including ovarian (Cooke, Shelling et al. 1996; Lin and Morin 2001), breast 
(Devilee, van den Broek et al. 1991; Devilee, van Vliet et al. 1991), stomach (Queimado, Seruca 
et al. 1995), uterine (Chappell, Lydon et al. 1997), kidney (Morita, Ishikawa et al. 1991), colon 
(Honchel, McDonnell et al. 1996) and liver (De Souza et al., 1995). Expression of RNASET2 has 
been demonstrated to be significantly reduced in both ovarian tumours and lines (Lin and Morin 
2001). RNASET2 was identified as a candidate tumour suppressor gene in cervical cancer as it 
was upregulated in our array following demethylation of the HeLa cervical cancer cell line. 
 
1.5.4. TIMP1   
TIMP1, xp11.3-p11.23, is an inhibitor of matrix metalloproteinases (MMPs) that has variable X-
chromosome inactivation in females, which has been  suggested to be regulated by acetylation of 
histone H3 (Anderson et al., 2005). An important balance is maintained between MMPs, which 
degrade extracellular matrix, and the TIMP family of proteins in order to control matrix turnover 
rate (Gomez, Alonso et al. 1997). A number of diseases have been associated with a disruption in 
this balance with upregulation of MMPs and downregulation of TIMP1 in Crohn’s disease and a 
number of sites of cancer (Lukashev and Werb 1998; Sykes, Bhogal et al. 1999). TIMP1 was 
identified as a candidate tumour suppressor gene in cervical cancer as it was upregulated in our 
array following demethylation of the HeLa cell line.  
 
1.5.5. AKAP12  
AKAP12, located on chromosome 6q24-25.2, is an anchoring protein controlling cell signalling, 
adhesion and differentiation (Gelman, Lee et al. 1998; Lin, Nelson et al. 2000). This locus is the 
site of LOH at a number of sites of cancer (Tibiletti, Sessa et al. 2000), with downregulation of 
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AKAP12 in cancers of the breast, prostate, ovary and colon (Yildirim, Paydas et al. 2007). 
AKAP12 has not previously been reported to be methylated in cervical tissue but methylated 
forms have been reported in colorectal and gastric cancers (Xia, Unger et al. 2001; Choi, Jong et 
al. 2004; Mori, Cai et al. 2006). AKAP12 was identified as a candidate tumour suppressor gene 
in cervical cancer as it was upregulated in our array following demethylation of HeLa, C33a and 
SiHa cervical cancer cell lines. 
 
1.5.6. CADM1  
CADM1, 11q23, encodes an immunoglobulin superfamily cell adhesion molecule involved in 
cell to cell interactions (Gomyo, Arai et al. 1999). It has been shown to be inactivated by 
promoter methylation and LOH in non-small cell lung cancer and other sites (Murakami 2005; 
Murakami 2005). It has been shown by other groups that CADM1 gene silencing via promoter 
hypermethylation is a frequent event in the progression from high-risk HPV-containing, high-
grade CIN lesions to invasive cervical cancer (Steenbergen, Kramer et al. 2004; Overmeer, 
Henken et al. 2008). Deletion of 11q is a frequent event in the pathogenesis of NPC and silencing 
of CADM1 by promoter hypermethylation has been observed in 36% primary NPC tumours and 
60% NPC cell lines (Hui, Lo et al. 2002). CADM1 was added to this list despite not being 
present on the array because it had recently been reported to be epigenetically silenced in cervical 
cancer (Steenbergen, Kramer et al. 2004). 
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1.6. Clusterin 
Located on 8p21-12 Clusterin (CLU) is coded by a single gene spanning 17kb with a single 
promoter, N-terminal hydrophobic leader sequence, 9 exons and 8 introns coding. The gene 
encodes 3 CLU isoforms, and differences in subcellular localisation dictate their function (Pajak 
and Orzechowski 2006). CLU is a multifunctional and widely expressed glycoprotein found in a 
diverse range of tissues, such as breast, prostate and kidney (Shannan, Seifert et al. 2006). Such 
an expression pattern is suggestive of a central role in cellular homeostasis, and the protein is 
known to have both pro-apoptotic and anti-apoptotic functions. This functional dichotomy may 
be related to the different isoforms, two of which are translated into a secreted, cytoplasmic and 
anti-apoptotic clusterin protein (sCLU), and one of which is alternately spliced and translated 
into a nuclear and pro-apoptotic clusterin protein (nCLU).  
 
1.6.1. Clusterin isoforms  
Databases such as the National Center for Biotechnology Information (NCBI) reference sequence 
database shows two N terminal differing cytoprotective isoforms of CLU to be expressed in 
humans and chimpanzees designated Isoform 1 (NM_001831) being translated from the first 
exon and Isoform 2 (NM_203339) being translated from exon II. Of these only isoform 1 is able 
to produce the third CLU protein, nCLU, through alternative splicing and exclusion of exon II 
(Cochrane, Wang et al. 2007). This classification has lead to much confusion as in the literature 
because CLU isoforms are referred to as sCLU and nCLU and in public databases they are 
referred to as isoform 1 and isoform 2. To clarify at this stage, both the publicly available 
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sequences designated isoform 1 and 2 are anti-apoptotic and code for sCLU. The sequence for 
nCLU is not available in the public database, however from the literature we know that is 
produced alternative splicing of isoform 1 and is pro-apoptotic.  
 
1.6.1.1. Cytoplasmic and secreted CLU 
Translation from the first ATG codon generates a full length 60kDa CLU transcript (449 amino 
acids) that is targeted to the endoplasmic reticulum by the 22mer leader peptide. Once in the ER 
this precursor protein is glycosylated and cleaved to generate α- and β-chains, held together by 
five disulfide bonds. This mature protein can also be secreted from the cell as a 70-80 kDa 
heterodimeric glycoprotein which has chaperone activity. The mature protein contains a nuclear 
localisation signal which is not utilised under normal homeostatic conditions (O'Sullivan, Whyte 
et al. 2003).  
 
There is a variety of evidence that both the mature 80kDa glycosylated CLU protein secreted 
from the cell and the unglcosylated 60kDa cytoplasmic precursor are anti-apoptotic (Hara, 
Miyake et al. 2001; You, Ji et al. 2003).  These anti-apoptotic effects prevail even when induced 
by BAX (Zhang, Kim et al. 2005), H2O2 (Miyake, Hara et al. 2004), TNF alpha (Sensibar, 
Sutkowski et al. 1995; Sintich, Steinberg et al. 1999; Zhang, Zhou et al. 2006), 1,25(OH)2D3 
(Shannan, Seifert et al. 2007), lethal heat shock dose (Wu, Park et al. 2002) and ionising radiation 
(Zellweger, Chi et al. 2002). It has also been reported to contribute to resistance to Fas-mediated 
apoptosis (Miyake, Hara et al. 2001). 
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There is also evidence that the secreted clusterin protein has anti-proliferative effects. Transient 
transfection of full length rat CLU in PNT2 a non-tumourigenic immortalised prostate cell line 
expressing very low levels of CLU led to an inhibition of proliferation (Bettuzzi, Scorcioni et al. 
2002). In the PC-3 androgen independent human prostate cancer cell line expressing low or 
undetectable levels of CLU over-expression of intracellular CLU increased cell death and 
decreased proliferation (Scaltriti, Santamaria et al. 2004) Reduced proliferation was also 
observed with over-expression of full length CLU (Scaltriti, Bettuzzi et al. 2004) and nCLU in 
which there was also reduced motility and disruption of actin cytoskeleton (Moretti, Marelli et al. 
2007). Conversely, the same authors showed that over-expression of sCLU had no effect on cell 
proliferation, mobility, or the actin cytoskeleton. 
 
1.6.1.2. Nuclear CLU 
Alternative splicing generates an N-terminal truncated pro-apoptotic 45kDa CLU, synthesised 
from the second in-frame AUG codon eliminating exon II. This isoform of CLU does not have 
the protein export sequence in the leader peptide and so the protein does not enter the ER, and 
therefore does not undergo glycosylation and α/β cleavage (Leskov, Klokov et al. 2003).  
 
The precursor protein resides in cytoplasm and translocates to the nucleus in response to pro-
apoptotic signals to induce apoptosis.  Evidence for this comes from a variety of model cell lines 
– in the PC-3 androgen independent human prostate cancer cell line, which expresses low or 
undetectable levels of CLU, stable transfection of full length or intracellular CLU results in 
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nuclear localisation of the protein and gives rise to reduced proliferation and increase in cell 
death (Scaltriti, Bettuzzi et al. 2004). The same authors showed that a non-tumourigenic 
immortalised prostate cell line, PNT1A, stably transfected with full length CLU also had the 
same localization and effect. In PC-3 prostate cancer cells nCLU activity is associated with 
decreased motility and disassembly of the actin cytoskeleton. nCLU  binds to alpha-actinin in the 
cytoplasm causing disassembly of the cytoskeleton and an explanation for nCLU-induced cell 
death (Moretti, Marelli et al. 2007). When LNCaP androgen independent human prostate cancer 
cell line expressing low or undetectable levels of CLU was stably transfected with full-length 
CLU without leader sequence, the nuclear isoform could be identified in cytoplasm and nucleus, 
which increased sensitivity to TNF alpha-induced apoptosis in vitro and in vivo (Zhang, Zhou et 
al. 2006). 
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A 
B 
Figure 1.2. Alternative splicing of the clusterin gene produces two different 
forms of the protein.  
A. Secreted clusterin is translated from the first ATG codon to generate a 60kDa 
CLU transcript. B. In the case of nuclear clusterin, alternative splicing generates an 
N-terminal truncated pro-apoptotic 45kDa CLU, synthesised from the second in-
frame AUG codon eliminating exon 2. [Modified from Savkovic et al 2007, 
Biochem Biophys Res Comm 356, 431-437] 
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1.6.2. A role for clusterin in carcinogenesis? 
Over the past several years, significant data has been generated on the expression and activity of 
clusterin and its role in malignant disease – CLU expression has been associated with 
tumourigenesis and the progression of various malignancies. However, much of the available 
data remains conflicting at present, with evidence of overexpression of CLU in some cancers 
indicating an oncogenic role, while its repression in other cancers conversely indicates that some 
aspects of its activity may have a tumour suppressor role. 
 
1.6.2.1. Evidence for clusterin as an oncogene 
There is a variety of evidence using animal models of disease progression, transfection studies in 
cell lines and expression studies in disease and normal tissues which has highlighted a significant 
over-expression of CLU in tumourigenesis and provides strong evidence that it may be an 
oncogene. Furthermore, not only is its overexpression associated with cancer rather than normal 
tissue, but increased expression correlates with disease severity in a number of cases. 
 
In colon, hepatocellular, breast, ovarian, endometrial, melanoma and follicular dendritic cell 
tumours cytoplasmic CLU over-expression was associated with an increased histological grade 
(Chen, Halberg et al. 2003; Xie, Sham et al. 2005) (Xie, Lau et al. 2005); (Abdul-Rahman, Lim et 
al. 2007); (Hoeller, Pratscher et al. 2005); (Grogg, Macon et al. 2005); however this was not 
necessarily predictive of prognosis or disease reoccurrence (So, Sinnemann et al. 2005; Zhang, 
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Zhang et al. 2006; Kruger, Ola et al. 2007); (Kang, Hong et al. 2004); (Hsieh, Chen et al. 2005). 
In bladder cancer overexpression of CLU was found to be significantly associated with 
recurrence-free survival (Miyake, Gleave et al. 2002); (Kruger, Mahnken et al. 2006), with one 
contradicting study showing that recurrence-free survival of patients with overexpression of CLU 
was significantly shorter (Luo, Xie et al. 2005). In renal cancer multivariate analyses revealed 
that strong expression of clusterin was an independent predictor of tumour recurrence and overall 
survival (Miyake, Hara et al. 2002). In hepatocellular carcinoma univariate analysis showed 
recurrence-free survival was significantly lower in patients with strong clusterin expression 
(Kurahashi, Muramaki et al. 2005).  
 
In various human cancers the tumour suppressor gene PTEN is one of the most commonly 
mutated/deleted genes and its alteration is strongly implicated in prostate cancer development. 
Disease progression in humans can be demonstrated in the murine Pten prostate cancer model 
which progresses from hyperplasia to prostatic intraepithelial neoplasia (PIN), to invasive 
adenocarcinoma, followed by metastasis. CLU is up-regulated in Pten null prostate cancers and is 
thought to be regulated by a Pten-controlled signalling pathway contributing to initiation and 
progression of disease (Wang, Gao et al. 2003). This up-regulation of CLU is accompanied by 
down-regulation of Nkx3.1, which is interestingly also located on 8p21. In prostate cancer 
patients who had not received androgen ablation CLU staining intensity correlated with Gleason 
score, corresponding to disease severity but not predictive of disease reoccurrence (Steinberg, 
Oyasu et al. 1997); (Zhou, Yang et al. 2003); (Ronquist, Carlsson et al. 2006) (Zhang, Kim et al. 
2005) (Miyake, Muramaki et al. 2006). Over-expression of clusterin reduces proliferation and 
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motility and cause disruption of the actin cytoskeleton in androgen independent prostate cancer 
cell lines (Bettuzzi, Scorcioni et al. 2002; Zhou, Janulis et al. 2002; Scaltriti, Bettuzzi et al. 2004; 
Scaltriti, Santamaria et al. 2004; Moretti, Marelli et al. 2007).  
 
Clusterin expression and regulation has not been reported in nasopharyngeal or oral cancers, 
however two studies have looked at the expression of clusterin in cervical neoplasia and 
demonstrated its overexpression. CLU was expressed distinctly higher in cancers, with strong 
positive staining throughout each of the cervical cancer tissue samples (Park, Yeo et al. 2006). In 
a recent study of invasive cervical cancer specimens from patients who underwent radical 
hysterectomy and systematic lymphadenectomy, CLU positive patients showed significantly 
worse prognosis than those who did not express CLU (Watari, Ohta et al. 2008).  
 
1.6.2.2. Evidence for clusterin as a TSG 
Although there is a significant amount of evidence for overexpression of CLU in a wide range of 
human cancers, cell lines and animal models, indicating that it may have an oncogenic role, there 
is also a notable body of evidence for its underexpression (i.e. repression) in a variety of animal 
models of disease progression and expression studies in disease and normal tissues. These studies 
have highlighted a significant down-regulation of CLU in tumourigenesis, and provide evidence 
that it may potentially act as a tumour suppressor gene. 
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In the colon, oesophagous, skin, AML and breast a down-regulation of CLU has been associated 
with malignancy (Chen, Turner et al. 2004); (Zhang, Ying et al. 2003); (Goufman, Moshkovskii 
et al. 2006); (Chung, Kwak et al. 2004).  Interestingly in a study of colon cancer there was loss of 
one CLU allele in 67% of cases (Andersen, Schepeler et al. 2007). Clusterin expression in skin is 
restricted to differentiating but not proliferating cell layers, suggesting a possible negative role in 
cell division, influencing the choice between proliferation and differentiation (Thomas-
Tikhonenko, Viard-Leveugle et al. 2004).  Clusterin-positive patients with pancreatic cancer 
survived significantly longer and hence down-regulation of CLU may be involved in the 
progression of pancreatic cancer (Xie, Motoo et al. 2002). However, many studies have found 
that expression may not necessarily be related to disease progression or tumour size (Grutzmann, 
Boriss et al. 2005; Jhala, Jhala et al. 2006; Mourra, Couvelard et al. 2007). 
 
Although it has been suggested that CLU is an oncogene in prostate cancer progression, CLU has 
been shown to be down-regulated in malignant tissue from patients undergoing radical 
prostectomy after androgen ablation (Bettuzzi, Davalli et al. 2000); (Scaltriti, Brausi et al. 2004). 
Studies in transgenic adenocarcinoma mouse prostate (TRAMP) mice that spontaneously develop 
prostate cancer provide a contradiction to the rest of the literature, indicating that CLU is down-
regulated during prostate cancer onset and progression, and therefore may have a possible role as 
a novel tumour-suppressor gene in the prostate (Caporali, Davalli et al. 2004). The authors have 
suggested that lack of CLU increases the susceptibility to tumourigenesis after carcinogenic 
challenge and hence is considered to be a tumour attenuator acting predominantly at early stages 
of neoplastic growth. The apparent contradiction in the literature concerning CLU regulation in 
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prostate cancer may be explained by the cellular localization of CLU and the recent study 
showing that in these models of prostate cancer CLU is hypermethylated (Rauhala, Porkka et al. 
2008). 
 
CLU expression has been reported in cervical cancer, with one study reporting down-regulation 
(Choi, Kim et al. 2007). This down-regulation is contradictory to two other studies of cervical 
cancer, which demonstrate its up-regulation (Park, Yeo et al. 2006). A further study also shows 
that there is no change in CLU expression in squamous and adenocarcinomas relative to disease 
free controls (Abdul-Rahman, Lim et al. 2007). 
 
It is probable that this down-regulation observed is of the nuclear isoform of the protein, as some 
studies discussed have indeed suggested. Therefore, in current treatment regimes for a number 
cancer types discussed it would be of great advantage to over-express the nuclear isoform as a 
means of reducing chemo- and radio-resistance. What is not known in these studies is whether 
the intracellular localization of the protein is cytoplasmic CLU or a pre-cursor for the nuclear 
isoform, not yet translocated to the nucleus. It would therefore be of great use if an antibody was 
developed to distinguish between the cytoplasmic and nuclear isoform of CLU to clarify the 
discrepancies in the literature of CLU being an oncogene and a tumour suppressor. These latter 
studies suggest caution in the current use of anti-sense oligonucleotides target to CLU until the 
isoforms responsible for its down-regulation and over-expression have been clarified. A biphasic 
action of CLU has been proposed; a tumour attenuator acting predominantly at early stages of 
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neoplastic growth and possibly as an enhancer of the malignant phenotype in full-fledged 
tumours (Thomas-Tikhonenko, Viard-Leveugle et al. 2004). 
 
Site of Cancer CLU expression
Breast ↑
HCC ↑
Pancreas ↓
Oesphageous ↓
Colon ↑↓
Cervix ↑↓
Ovary ↑
Endometrium ↑
Prostate ↑↓
Glioma ↑
Haemagioma ↑
Germ cell ↓
FDC ↑
ALCL ↑
VHL defective tumour ↓
Melanoma ↑
Larynx ↑
Lung ↑
Bladder ↑
Kidney ↑
 
 
Table 1.3. Summary of the expression of CLU observed in malignant tissue 
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1.6.2.3. The role of CLU isoforms in patterns of expression in malignant tissues 
As described previously, clusterin has two main isoforms – a nuclear isoform which is pro-
apoptotic and a cytoplasmic, secreted isoform which is anti-apoptotic. The expression of these 
two variants in malignant tissue may provide us with some insight into the potentially conflicting 
evidence for CLU both as a tumour suppressor gene and an oncogene, with overexpression of the 
cytoplasmic, secreted form conferring oncogenic effects while the nuclear form has TSG effects.  
 
1.6.2.3.1. Isoform expression providing evidence of CLU as an oncogene 
Tumour cell survival and progression has been shown to be correlated with an overexpression of 
cytoplasmic and secreted CLU, and a downregulation of nuclear CLU (Pucci, Bonanno et al. 
2004). For example, activation of the p53 TSG suppresses basal and stress-induced sCLU by 
repressing CLU promoter activity and transcription (Criswell, Klokov et al. 2003). In a study of 
patients with stage III serous ovarian adenocarcinomas cytoplasmic and secreted CLU, but not 
nuclear CLU, were more highly expressed in tumours from survivors than in those of deceased 
patients (Partheen, Levan et al. 2008). Over-expression of full length CLU in bladder cancer 
prolongs cell survival, resulting in enhanced metastatic potential in vivo (Miyake, Gleave et al. 
2002). The chemopreventive action of green tea catechins in lowering the incidence of 
malignancy in the disease progression transgenic adenocarcinoma mouse prostate (TRAMP) 
model was found to be coupled with clusterin over-expression and its nuclear localisation 
(Caporali, Davalli et al. 2004). This is in keeping with data showing that when CLU translocates 
from the nucleus to the cytoplasm in colon adenocarcinoma it promotes tumour progression.  
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1.6.2.3.2. Isoform expression providing evidence of CLU as a TSG 
Many reports in the literature correlate the nuclear localisation of CLU with a TSG role in cells. 
For example, transient transfection of full length CLU in HT29, a colon cancer cell line which 
does not express CLU and  MCF-7:WS8 oestrogen dependent led to nuclear localisation of the 
protein and directly induced apoptosis or enhanced chemotherapy-induced apoptosis (Chen, 
Turner et al. 2004). (Yang, Leskov et al. 2000). A recent study showed that loss of CLU in its 
nuclear localization was linked with initiation and advancement of spontaneous breast cancer in 
Tientsin albino 2 mice (Sun, Zhang et al. 2007). In colon cancer specimens CLU was found in the 
nucleus in healthy colonic mucosa but not in high-grade and metastatic carcinoma, where it 
appears in cytoplasm, indicating that CLU location and intensity of expression varies with 
disease status and its severity (Pucci, Bonanno et al. 2004).  This shift in localisation is an 
unusual finding given that clusterin is a marker of apoptosis and conflicts with the rest of the 
literature with regards to its role in tumourigenesis at other sites, where its localisation in normal 
tissue is predominantly cytoplasmic. However, the expression of nuclear CLU is normal colonic 
mucosa suggests that it is regulating cell cycle and apoptosis, especially given that a loss of 
nCLU and concurrent increase in sCLU has been associated with enhanced metastatic potential.  
 
CLU is translocated to nucleus in response to cytotoxic stimuli such as TGFbeta stimulation,  IR 
(Leskov, Klokov et al. 2003) and overexpression of full length CLU with nuclear localisation 
inhibited cell growth and  increased cell death (Yang, Leskov et al. 2000; Scaltriti, Bettuzzi et al. 
2004; Scaltriti, Santamaria et al. 2004; Trougakos, Lourda et al. 2005). Nuclear localisation of 
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CLU may have a possible impact on DSB repair by causing a decrease in Ku70/Ku80 DNA end 
binding activity with its overexpression reducing cell growth and colony-forming ability 
associated with increased G(1) cell cycle checkpoint arrest and increased cell death (Yang, Yeh et 
al. 1999; Yang, Leskov et al. 2000). Nuclear CLU is a pro-apoptotic protein, whose function may 
in part be due to its C terminal interaction with Ku70/Ku80. CLU initially binds to Ku70 to form 
the trimeric protein complex, without direct interaction between CLU and Ku80. This binding 
activity is thought to be responsible for loss of DNA repair in severely damaged cells (Yang, 
Leskov et al. 2000), and accumulation of damaged DNA may be directly responsible for 
apoptotic cell death. There has been much debate in previous years by groups such as Betuzzi as 
to whether nuclear localization of CLU was actually real or just an artefact of transfection. These 
studies demonstrate that CLU can be expressed in the nucleus with distinct phenotypic effects.  
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Figure 1.3. Generation of secreted CLU and nuclear CLU. 
A. The full length CLU transcript (60kDa) is targeted to the endoplasmic 
reticulum (ER) by its 22mer leader peptide. This precursor protein is 
glycosylated and cleaved in the ER to generate α- and β-chains, held together by 
disulfide bonds. This mature protein is then secreted from the cell. B. The 
truncated 45kDa CLU transcript does not contain the protein export sequence in 
the leader peptide and therefore the protein does not enter the ER for 
glycosylation and α/β cleavage. Instead, the precursor protein resides in 
cytoplasm and translocates to the nucleus in response to pro-apoptotic signals. 
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1.6.3. Regulation of clusterin expression 
As previously described, clusterin expression is found in a wide variety of normal tissues, as well 
as showing both overexpression and downregulation in cancerous tissue. CLU expression is 
responsive to a wide range of stimuli, both external and internal, and elucidation of how these 
pathways function and interact is clearly vital if the role of CLU in normal tissue and the 
carcinogenic process is to be fully understood. 
 
1.6.3.1. Regulation of clusterin expression at the genomic level 
There is a range of evidence that at a genomic level the regulation of CLU expression is likely to 
be affected through either epigenetic regulation or large-scale deletion of the gene.  
 
1.6.3.1.1 Epigenetic regulation 
Silencing of gene expression by CpG methylation of tumour suppressor genes is a frequent event 
in cancer (Esteller and Herman 2002; Worm and Guldberg 2002; Baylin 2005; Gronbaek, Hother 
et al. 2007; Palii and Robertson 2007; Esteller 2008). CLU is down regulated and 
hypermethylated within its promoter in a CpG island 14.5kb up-stream of the transcription start 
site after induction of oncogenic HRAS in immortalized rat fibroblasts (Lund, Weisshaupt et al. 
2006). Following treatment with the commonly used demethylating agent 5’-Aza-2’deoxycitine 
and a MEK1,2 inhibitor (as previously described, CLU is a MEK/ERC target gene) up-regulation 
of CLU was observed.  It is also possible that CLU is epigenetically regulated in tumour-
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conditioned endothelial cells, as CLU was re-expressed following administration of the 
demethylating agent 5’-Aza-2'-deoxycytidine and trichostatin A (Hellebrekers, Melotte et al. 
2007).  
 
1.6.3.1.2. Genomic alterations at the CLU locus 
Alteration of oncogene and tumour suppressor gene transcription has been examined in terms of 
loss of heterozygosity (LOH) and DNA copy number in microdissected colorectal cancers. 67% 
of the tumours showed both LOH and reduced DNA copy number, suggesting loss of one CLU 
allele (Andersen, Schepeler et al. 2007). 
 
1.6.3.2. Alteration of CLU expression in response to external stimuli 
Alteration of CLU expression is associated with a variety of cytotoxic and oncogenic stimuli, and 
is known to have a range of effects dependent upon the cellular environment it is altered in. 
 
1.6.3.2.1. Androgen ablation 
Androgens are known to stimulate prostate cancer cells to grow. Treatment for prostatic cancer 
has therefore included the use of drugs which reduce the levels of androgens (anti-androgens 
such as flutamide) and cause tumours to slow down their growth rate and shrink. The use of 
drugs, hormones or even castration to reduce levels of androgens has proved useful in the short 
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term to slow tumour growth; however it is not a cure as the tumour eventually finds a way to 
grow independent of androgens. The progression to androgen independence has been extensively 
studied using the androgen responsive mammary models. CLU was initially thought to be an 
androgen-repressed gene in the rat prostate, with a loss of apoptotic potential in the progression 
of an androgen-dependent tumour to an androgen-independent state (Bettuzzi, Hiipakka et al. 
1989).  
 
Shionogi Carcinoma 115 (SC115) is an androgen-sensitive transplantable mouse tumour. CLU 
expression is sensitive to androgen withdrawal in androgen-dependent and-independent Shionogi 
carcinomas and was up-regulated after androgen withdrawal in regressing SC115 (Rennie, 
Bruchovsky et al. 1990; Rennie, Bruchovsky et al. 1994; Akakura, Bruchovsky et al. 1996). 
Androgen withdrawal appears to send an apoptotic signal that causes the up-regulation of CLU in 
order for cells to adapt and survive this change. This would explain the difficulties in treating 
prostate cancer, which becomes androgen-independent following up-regulation of anti-apoptotic 
genes such as CLU (July, Akbari et al. 2002).  
 
Androgen withdrawal has been further investigated by a number of other groups who also saw 
the up-regulation of CLU after castration in mice bearing PC-82 xenografts (Kyprianou, English 
et al. 1990), Shionogi carcinomas (Rennie, Bruchovsky et al. 1988; Miyake, Nelson et al. 2000),  
Dunning R3327 PAP prostatic adenocarcinoma (Brandstrom, Westin et al. 1994) and in a rat 
tumour progression model (Asamoto, Hokaiwado et al. 2001). Increasing testosterone levels 
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caused a rise in CLU expression levels via increased basal reactive oxygen species levels; this 
effect was reversed by androgen withdrawal (Pinthus, Bryskin et al. 2007). These studies all 
highlight the anti-apoptotic nature of CLU that confers resistance to androgen ablation and 
thereby helps accelerate the progression to androgen independence. This is further strengthened 
by the observation that CLU isoform 1 (which can generate nCLU) is down regulated by 
androgens, while isoform 2 (which appears to be retained in the cytoplasm) increases as the 
LNCaP xenograft tumour progresses to androgen-independence (Cochrane, Wang et al. 2007). 
 
1.6.3.2.2. Oestrogen ablation 
Oestrogen stimulates the growth of breast cancer cells in pre-menopausal women with oestrogen 
receptor positive breast cancer which accounts for round 80% of breast cancers. Oestrogen 
ablation, be it by surgical removal of the ovaries, radiotherapy or hormone manipulation has been 
shown to improve pre-menopausal women’s chance of long-term survival (Cochrane et al, 
1998(2000). In healthy women, oestrogen is involved in regulation of the menstrual cycle and in 
particular the thickening of the endometrium and growth of the uterus. Anti-apoptotic CLU was 
found to be repressed by oestrogens in normal uterus (Wunsche, Tenniswood et al. 1998) and 
may be required for the shedding of the endometrium in the menstrual cycle. CLU has been 
shown to be up-regulated in DMBA-induced rat mammary carcinoma by the selective oestrogen 
receptor modulator Toremifene, opposing the effects of oestrogen (Huovinen, Warri et al. 1993) 
and by another selective oestrogen receptor modulator, tamoxifen in the absence of the oestrogen 
oestradiol in RUCA-1 cells in vitro and in vivo (Zierau, O'Sullivan et al. 2004). Tamoxifen was 
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found to increase the expression of CLU both at the RNA and protein level in both the primary 
tumours and lymph metastases in intact and ovariectomized animals, perhaps explaining why 
there is an increased incidence of endometrial cancer in post-menopausal patients treated with 
tamoxifen (Lhomme, Pautier et al. 2003). 
 
Anti-oestrogens such as vitamin D have been shown to inhibit breast cancer growth in vitro and 
in vivo through reduced proliferation and increased apoptosis, although the mechanism by which 
this occurs is unclear. CLU is modulated by treatment with 1,25(OH)2D3 in vitamin D-
responsive but not in vitamin D-resistant melanoma cell lines (Shannan, Seifert et al. 2006). Up-
regulation of CLU has been observed following oestrogen ablation in mice with MCF-7 tumours 
(Kyprianou, English et al. 1991) and following treatment with the anti-oestrogens 4-
hydroxytamoxifen (Welsh 1994), toremifene (Warri, Huovinen et al. 1993), 1,25(OH)2D3 
(James, Mackay et al. 1996; Simboli-Campbell, Narvaez et al. 1996; Simboli-Campbell, Narvaez 
et al. 1997), tamoxifen (Chen, Tritton et al. 1996) and paclitaxel (2005).  This is interesting given 
that up-regulation of secreted or cytoplasmic CLU has an anti-apoptotic effect. In these studies 
anti-oestrogens induced apoptosis and showed increased secretion of active TGF-beta. It is 
known that TGF-beta is able to stimulate translocation of CLU to the nucleus (Reddy, Jin et al. 
1996), which would explain the pro-apoptotic effect in these studies. Combination of current neo-
adjuvant therapy and screening for deregulated genes such as CLU that could be targeted to 
overcome resistance to treatment has promising potential as a new therapeutic strategy 
(Cappelletti, Gariboldi et al. 2008). 
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1.6.3.2.3. Human chorionic gonadotrophin 
The glycoprotein hormone human chorionic gonadotropin (hCG) inhibits mammary 
tumorigenesis through induction of differentiation and inhibition of proliferation of human breast 
epithelial cells in vitro. This inhibition may be a bystander effect or indeed mediated by CLU 
given that it is up regulated post treatment with hCG in Sprague-Dawley rats (Srivastava, Russo 
et al. 1997) and in MCF-10F, a normal human immortalized bronchial epithelial cell line 
(Srivastava, Russo et al. 1998). 
 
1.6.3.2.4. Chemotherapy 
Resistance to apoptosis caused by CLU overexpression leads to a variety of cellular phenotypes, 
including increased chemoresistance in response to a range of drugs including etopiside, 
camptothecin, paclitaxel, cisplatin and taxol (Miyake, Nelson et al. 2000; Hara, Miyake et al. 
2001; Hoeller, Pratscher et al. 2005; Zhang, Kim et al. 2005). 
 
A number of drugs commonly used in chemotherapy regimens to treat cancers such as prostate 
and breast have been shown to up-regulate cell survival genes such as CLU. This provides a 
means by which cancer cells are then able to resist death ligand-induced apoptosis by expressing 
anti-apoptotic proteins. Pre-treatment of breast cancer cell lines with the glucocorticoid 
dexamethasone has been shown to inhibit chemotherapy-induced cytotoxicity and is associated 
with CLU induction. Anti-sense oligonucleotides targeted to CLU reverses this effect, even in the 
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presence of glucocorticoids, and play a role in attenuation of the inflammatory response 
(Redondo, Tellez et al. 2007). Glucocorticoids have been shown to inhibit chemotherapy induced 
apoptosis by conferring protection from the pro-apoptotic signals of cytokines and tumour 
suppressors through modulation of survival genes such as NF-kB, Bcl-2 and Bcl-xL. This 
suggests a possible role for CLU in glucocorticoid-mediated survival. Given that glucocorticoids 
are frequently used prior to treatment with chemotherapy to prevent any adverse effects, it is 
possible that they might actually be hindering the effectiveness of chemotherapy (Wu, Chaudhuri 
et al. 2004). 
 
As described previously, androgen ablation leads to apoptosis in prostate cancer cells, but 
androgen-independent human prostate cancer cells may not show the same effects. Non-androgen 
ablative cytotoxic drugs such as 5-fluorodeoxyuridine have been used to induce proliferation-
dependent death. While androgen-independent human prostate cancer cells retain the ability to 
activate the apoptotic cascade, this is only achievable after treatment with cytotoxic compounds. 
CLU is up-regulated in androgen-independent Dunning R-3327 AT-3, PC-3 and DU-145 
prostatic cancer cells (Kyprianou and Isaacs 1989; Furuya and Isaacs 1994; Kyprianou, Bains et 
al. 1994) and mouse mammary tumour cells treated with 5-fluorodeoxyuridine (Furuya and 
Shimazaki 1996). CLU is also up-regulated in response to irinotecan in colon cancer cell lines 
(Chen, Turner et al. 2004). These studies suggest that CLU is associated with initiation of 
proliferation-dependent programmed cell death.  
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Cisplatin also has been observed to up regulate CLU in the human bladder cancer KoTCC-1 
model (Miyake, Hara et al. 2001), in the renal cell carcinoma cell line Caki-1 (Lee, Jin et al. 
2002) and in a cisplatin-sensitive parental human ovarian carcinoma cell line but not its cisplatin-
resistant variant (Deng, Parekh et al. 2002). However, this effect was only transient and down 
regulation of CLU actually increased the cytotoxic effect of cisplatin. This evidence therefore 
suggests that knockdown of CLU to counteract its up-regulation by cisplatin could be used to 
improve chemotherapy. This is of importance since CLU up-regulation has been seen after 
chemotherapy in primary peripheral blood leukemic cells (Chow, Nowak et al. 2006), by 
paclitaxel in the renal cell carcinoma cell line Caki-2 (Zellweger, Miyake et al. 2001), by 
glucocorticoids in an in vitro haemangioma model (Hasan, Tan et al. 2003) and post treatment of 
breast cancer cells with Trastuzumab, a HER2-targeted monoclonal antibody. Biroccio et al also 
investigated knockdown of CLU by anti-sense oligonucleotide in combination with Trastuzumab 
to counteract CLU up-regulation by the antibody and found a significantly enhanced sensitivity 
of cells to Trastuzumab (Biroccio, D'Angelo et al. 2005). 
 
Up-regulation of CLU by the ribonucleotide reductase inhibitor MDL 101,731 was observed in 
human prostate tumour xenografts (Wright, Cross-Doersen et al. 1996) and the prostate cancer 
cell line PC-3 but not in LNCaP cells after treatment with camptothecin (CPT), a topoisomerase I 
inhibitor (Mizutani, Matsumoto et al. 2006). Two groups demonstrated up-regulation of nuclear 
CLU by ethylenediaminetetraacetic acid in COLO 205 cells (Pajak and Orzechowski 2007) and 
significant up regulation in PC-3 cells after treatment with doxazosin accumulating first in 
cytoplasm, then in nucleus (Youm, Yang et al. 2007). Contrary to the rest of the literature, 
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Artwohl et al showed a down-regulation of CLU by levamisole in cultured human micro- and 
macrovascular endothelial cells and fibroblasts (Artwohl, Holzenbein et al. 2000).  
 
CLU is down regulated in both docetaxel resistant PC3 and DU145 prostate cancer cells by 
resveratrol, which functions as a tyrosine kinase inhibitor, sensitising tumour cells to tumour 
necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors. This effect is thought to be 
mediated through inhibition of Src and Jak kinases, resulting in loss of STAT1 activation 
essential for CLU transcription (Sallman, Chen et al. 2007).  
 
In conclusion, it can be seen that the effects of CLU expression on chemotherapy outcome is 
obstructive conferring chemoresistance in cancer cells that would otherwise undergo 
programmed cell death, an effect which is overcome by treatment of cells with anti-sense 
oligonucleotides to CLU in combination with current chemotherapeutic regimes. Recent 
publications have also suggested that CLU is able to directly bind to chemotherapeutic drugs 
such as paclitaxel to prevent their interaction with microtubules which would otherwise lead to 
apoptosis (Chi, Siu et al. 2008; Park, Yeo et al. 2008).  
 
1.6.3.2.5. Radiation 
Following exposure to ionizing radiation, DNA repair pathways are activated conferring delays in 
cell cycle checkpoints leading to either repair or cell death if cells are too badly damaged 
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(Leskov, Criswell et al. 2001). A number of IR-inducible proteins are also activated, such as 
protein-tyrosine kinases, which may affect cell fate of not just irradiated cells but may also have a 
bystander effect on nearby cells. A potential role for CLU has been suggested in low dose 
ionizing radiation (IR)-inducible adaptive response and genomic instability if damaged cells that 
would normally undergo apoptosis are allowed to survive and continue to proliferate. The 
potential mechanism is thought to be  that secreted CLU allows cells to escape growth arrest via 
binding to TGF-beta (Klokov, Criswell et al. 2004). 
 
Basal CLU expression increased in MCF-7 and RKO colon cancer cells after exposure to small 
non-toxic doses of irradiation and by can be increased by HPV E6; however expression was 
repressed by p53 in HCT116 colon cancer cell line (Criswell, Klokov et al. 2003). This 
repression of the sCLU protein may be important for the cascade of p53-mediated events leading 
to cell death after IR or other cytotoxic agent exposure. 
 
CLU up-regulation by ionizing radiation has been demonstrated in the prostate cancer cell lines 
DU-145 and PC-3 (Sklar, Eddy et al. 1993), in a dose dependent manner in PC-3 cells 
(Kyprianou and Rock 1998; Zellweger, Chi et al. 2002) and in MCF-7 breast cancer cells (Yang, 
Leskov et al. 2000). In vitro 8-12 Gy of radiation over 3 days led to an over-expression of CLU 
and increased cell survival with cells becoming less sensitive to radiation; this was also the case 
in vivo when radiation dose was increased up to 30 Gy. Irradiation of LNCaP tumours which do 
not express CLU resulted in small amount of CLU being expressed, presumably in a cell survival 
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response. When CLU was transfected into this cell line there was a more than a three-fold 
increase in its expression in response to radiation, with decreased radiosensitivity and a 54% 
reduction in cell cycle arrest and apoptosis (Zellweger, Kiyama et al. 2003). Knockdown of CLU 
in prostate cancer patients may therefore help reduce radioresistance with cells losing their 
protection from apoptosis. 
 
Criswell et al. showed that this up regulation of CLU by ionizing radiation is dependent on 
stress-induced activation of IGF-1R-Src-Mek-Erk-Egr-1 signalling (Criswell, Beman et al. 2005). 
Minutes after ionising radiation, MAPK signalling can be detected, with re-activation of 
Src/MAPK signalling 24–72 hours after radiation leading to up-regulation of insulin-like growth 
factor-1 (IGF-1) and phosphorylation-dependent activation of its receptor (IGF-1R). Activated 
IGF-1R then stimulates the downstream Src-Mek-Erk signal transduction cascade to finally 
transactivate the early growth response-1 (Egr-1) transcription factor, required for CLU promoter 
activation leading to sCLU expression. Activation of Erk1/2 is of importance given that it has 
been shown to cause EGFR activation, whose over-expression has been demonstrated at a 
number of tumour sites such as breast cancer may contribute to radio-resistance in various 
tumours, including breast cancer cells by activation of Erk1/2 (Zhou, Kim et al. 2004).  
 
CLU induction has been previously identified as a marker of apoptosis (CLU  induction 
correlates with internuceosomal DNA fragmentation), and overexpression of anti-apoptotic 
BCL2 after radiation is able to delay induction of CLU expression (Kyprianou, King et al. 1997). 
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In addition to this, nCLU is known to prevent DNA-PK-mediated end joining in DNA repair and 
therefore contribute to induction of apoptosis in response to IR (Leskov, Criswell et al. 2001). It 
is probable that the effect of sCLU is a late response to IR in providing an adaptive survival 
response. This further underlines the dichotomy of its role as both a pro-apoptotic and anti-
apoptotic protein. In summary, ionising radiation up-regulates CLU which leads to increased 
radioresistance in tumour cells, and to increased radiosensitivity in tumour cells. It would be 
worth exploring knockdown of CLU in combination with radiation therapy. 
 
1.6.3.2.6. Heat shock 
Clusterin has been described as a molecular chaperone given its ability to mimic the 
cytoprotective nature of heat shock proteins in binding to unfolded proteins (Humphreys, Carver 
et al. 1999). A number of groups have demonstrated the up-regulation of CLU by heat shock in 
the human epithelial carcinoma cell line, A431, specifically recognized by the heat shock 
transcription factor, HSF1 (Michel, Chatelain et al. 1997).  Rat primary culture hepatocytes also 
showed elevation of CLU levels by heat shock treatment (Kimura, Asami et al. 1997). CLU 
expression did not significantly increase in mouse Sertoli cells until 12 hours after the initial 
stimulus (Clark and Griswold 1997). In these cell types expression of the stress regulated gene 
HSP70 was induced 4 hours post heat shock, whereas CLU expression was increasingly elevated 
between 12 and 48 hours with sustained heat shock indicating that this was a late stress response 
with a cytoprotective effect. Other cellular stresses such as hydrogen peroxide, superoxide anion, 
 Introduction 
 
 72 
hyperoxia and UVA exposure also led to elevated levels of CLU in these cell types (Viard, 
Wehrli et al. 1999).   
 
CLU secretion in PC-3 prostate cells is inhibited by a sub-lethal heat shock leading to increased 
cytoplasmic CLU; however lethal heat stress caused accumulation of nCLU, degradation of 
HSP70 and caspase-3-dependent anoikis-death (Caccamo, Desenzani et al. 2006).  The 
degradation of HSP70 is important because over-expression of heat shock proteins acts as anti-
apoptotic signal in damaged cells, thereby increasing the tumourigenic potential of cancer cells 
(Garrido, Schmitt et al. 2003). This finding is mirrored by another study demonstrating that CLU 
is up regulated and then down-regulated by a lethal dose of heat shock in prostate cancer line, 
PC-3, and the bladder cancer line TSU-Pr1 (Wu, Park et al. 2002).  It therefore seems that in 
response to non-lethal heat shock, via the heat shock element in its promoter, sCLU is able to act 
as a molecular chaperone, preventing cells from undergoing apoptosis. Additionally, in response 
to sub-lethal heat shock secretion of the CLU protein is blocked resulting in its accumulation in 
the cytoplasm and correlating with cell survival. In protecting partly denatured protein from 
caspase 3 mediated apoptosis, cytoplasmic CLU acts as an intracellular chaperone, supporting 
HSP70. However, when cells receive a lethal dose of heat shock, CLU translocates to the nucleus 
to signal programmed cell death. Addition of exogenous nCLU might therefore increase the 
effectiveness of heat shock therapy in ablation of prostate cancer. 
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1.6.3.2.7.  Immunosuppressants and carcinogens 
Up-regulation of CLU has also been associated with immunosuppressants and carcinogens. 
Mycophenolic acid is an immunosuppressant drug used to prevent rejection in organ 
transplantation. In cancer cells it induces terminal differentiation by inhibiting inosine 5'-
monophosphate dehydrogenase, causing replication arrest and accumulation of  cells in the S-
phase of the cell cycle (Floryk and Huberman 2006). This can be explained given that CLU is up 
regulated following mycophenolic acid-induced differentiation in the androgen-independent 
prostate cancer cell line DU145 and is known to be anti-proliferative. Sprague-Dawley rats have 
shown an up-regulation of CLU by phenol II, a cystogenic chemical (Rosenberg, Manivel et al. 
1995), an effect which has also been observed in rat prostate following initiation with N-nitroso-
N-methylurea and promotion with testosterone propionate (Kadomatsu, Anzano et al. 1993). 
CLU expression increased as cysts developed, although this was reversible by withdrawal of the 
drugs. 
 
1.6.3.2.8. Serum deprivation 
Serum deprivation in vitro causes cell stress and leads to apoptosis. CLU has been shown to be 
up-regulated by serum deprivation in P19 embryonic carcinoma cells (Fratelli, Galli et al. 1996) 
and a study by Caccamo et al found that the 70-80 kDa precursor protein of sCLU was down-
regulated by serum deprivation and  the 45kDa nuclear isoform up regulated in PNT1a cells 
(Caccamo, Scaltriti et al. 2003). This is consistent with serum deprivation inducing CLU 
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translocation to the nucleus and resulted in anoikis. Therefore, serum deprivation induces 
expression of pro-apoptotic nuclear CLU as a stress response.  
 
1.6.3.2.9. Response to other external cellular stimuli    
Due to their anti-proliferative activity, retinoids have shown promise as anti-cancer agents. 
Bayon et al. demonstrated that CLU expression could be induced by retinoid antagonist MX781 
in PC-3 and DU-145 prostate cells via HSF1 and possibly AP-1 (Bayon, Ortiz et al. 2004). There 
was a significant increase in HSF-1 and to a lesser extent AP-1 DNA binding activity; mutation 
of the AP-1 site and the heat shock element site in the CLU promoter completely abolishes 
MX781-induced transcriptional activation in PC3 and DU145 prostate cancer cells. In response to 
retinoid antagonists HSF-1 participates in the regulation of anti-apoptotic CLU. 
 
Oxidative stress by photodynamic therapy is associated with the induction of apoptosis in many 
cancer cells in vitro and in vivo, which could be explained by an induction of nCLU in cancer 
cells (Kalka, Ahmad et al. 2000). TNF alpha has been shown to induce cell death in LNCaP cells 
via a transient increase in levels of pro-apoptotic nuclear CLU and a sustained decrease in the 
pro-survival secreted isoform (Sensibar, Sutkowski et al. 1995). LNCaP cells gain protection 
against the cytotoxic TNF-induced cell death following stable over-expression of sCLU.  
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Other factors such as anchorage, UVB irradiation and cAMP have all been shown to down-
regulate the expression of CLU. CLU is suppressed by anchorage, however anchorage-
independent growth is a characteristic of tumour cells and so could provide a means of preventing 
programmed cell death of MCF-7 cells by re-expression of the pro-survival protein CLU 
(Goldberg, Jin et al. 2001). CLU is reversibly down regulated by cyclic adenosine 3',5'-
monophosphate (cAMP) in testicular Leydig tumour cell lines through activation of the protein 
kinase A pathway (Pignataro, Feng et al. 1992). CLU has been found to be down-regulated 
following programmed cell death induced by UVB irradiation of human U937, HeLa, and A431 
cell lines and dexamethasone-induced cell death of the human lymphoblastoid cell line CEM-C7 
(French, Wohlwend et al. 1994). Furthermore, CLU expression was found to be up-regulated 
only in normal cells and led to their survival despite induction of programmed cell death 
pathways.  
 
CLU has been shown to be down-regulated in rapidly dividing human keratinocytes infected with 
a Myc-encoding adenovirus, with knockdown enhancing proliferation (Thomas-Tikhonenko, 
Viard-Leveugle et al. 2004). Following overexpression of CLU DNA replication was suppressed 
in keratinocytes and other cells of epithelial origin, suggesting that CLU is an inhibitor of cell 
proliferation in epithelial cells. This observation has been confirmed in vivo where squamous cell 
carcinomas were more differentiated with increased skin papillomas in CLU deficient mice.  
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In melanoma cell lines the down-regulation of secreted protein, acidic and rich in cysteines 
(SPARC) is associated with increased tumour aggression and resulted in reversible CLU down-
regulation and inhibition of melanoma growth in vivo (Sosa, Girotti et al. 2007). Interestingly 
decreased SPARC expression also resulted in decreased N-Cadherin and increased levels of 
HSP27, it has previously been demonstrated by Poon et al that CLU and HSP70 have a 
conflicting relationship., with CLU stabilizing stressed proteins in a state competent for refolding 
by heat shock protein 70 (Poon, Easterbrook-Smith et al. 2000). 
 
1.6.3.2.10. Regulation of nuclear clusterin expression by external stimuli 
The expression of pro-apoptotic nuclear CLU is inducible by Ca++ depletion (Caccamo, Scaltriti 
et al. 2005); (Pajak and Orzechowski 2007). CLU is localised to the nucleus following TGF-beta 
stimulation of two epithelial cell lines, HepG2 and CCL64 (Reddy, Jin et al. 1996). Nuclear 
expression of CLU increased in MCF-7 cells after initiation of apoptosis with anti-estrogens and 
TNF (O'Sullivan, Whyte et al. 2003). These studies indicate that it is possible to induce 
expression of the nuclear isoform of CLU in response to cellular stresses, which results in 
apoptosis. CLU isoforms may be modulated by somostatin, a cytostatic hormone in colon cancer 
where translocation of CLU from the nucleus to the cytoplasm is indicative of increased tumour 
aggressiveness, and where nCLU is predominantly expressed in normal cells (Pucci, Bonanno et 
al. 2004). 
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1.6.3.3. Regulation of clusterin expression in response to internal cellular signals 
Intracellular CLU has been shown to interact with Bax, inhibiting its oligomerization and the 
subsequent release of cytochrome c and caspase activation, which results in inhibition of 
apoptosis in cells (Zhang, Kim et al. 2005). This interaction also leads to inhibition of oncogenic 
c-Myc-mediated apoptosis, where CLU promotes c-Myc-mediated transformation in vitro and 
tumour progression in vivo. CLU expression has been associated with tumorigenesis and the 
progression of various malignancies, possibly through interfering with Bax pro-apoptotic 
activities. Indeed, there is a large range of evidence in the literature which describes CLU as a 
cell survival protein, however as previously described this is dependent on the cellular 
localisation of the protein.  
 
Cellular senescence and restricted proliferative ability in normal cells could potentially be 
explained by the up-regulation of cytoprotective CLU, which is found in normal rat embryonic 
fibroblasts and human osteoblasts cell cultures undergoing aging in vitro (Gonos, Derventzi et al. 
1998). A study by French et al found CLU to be down-regulated in in vitro aging of human 
peripheral blood neutrophils undergoing programmed cell death (French, Wohlwend et al. 1994). 
In undifferentiated Leydig cells expressing anti-apoptotic Bcl-2 and proapoptotic Bax in tumours 
nCLU, along with Bax, was up-regulated during regression of the tumourigenic rat Leydig cells, 
with subsequent elevation of Fas-R and Fas-L (Woolveridge, Taylor et al. 2001).  
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B-MYB is a universally expressed transcription factor, which like CLU is involved in the 
regulation of cell survival, proliferation, and differentiation. CLU expression is induced in 
mammalian cell lines following transient transfection of B-MYB by interaction with a MYB 
binding site in the CLU 5’ flanking region (Cervellera, Raschella et al. 2000). 
 
Cellular CLU overexpression is a common and permanent feature shared by all trefoil factor 1 
(TFF1) null antropyloric tumours, and it has be suggested that this deficiency causes the 
accumulation of misfolded proteins in the endoplasmic reticulum by TFF1 interacting with the 
ER machinery affecting protein folding and secretion (Torres, Karam et al. 2002). Mutations in 
the von Hippel-Lindau (VHL) tumour suppressor gene are known to predispose people to cancer. 
In tumours it is able to target the transcription factor hypoxia induced factor (HIF) for destruction 
by polyubiquitination and in doing so down-regulates CLU and its secretion (Nakamura, Abreu-
e-Lima et al. 2006). CLU has been shown to be up regulated by STAT1 up-regulation by 
docetaxel in docetaxel-resistant prostate tumour cells (Patterson, Wei et al. 2006). Inhibition of 
STAT1 leading to inhibition of CLU led to re-sensitisation of DU145-DR prostate cancer cells to 
docetaxel. Combined therapies targeting the STAT1 pathway could therefore reduce chemo-
resistance through down-regulation of CLU.  
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1.6.4.  Clusterin regulation of NF-ĸB  
The regulation of transcriptional targets of CLU can also give us insight into its role in normal 
and malignant tissue. One particularly pertinent example of this is its regulation of NF-kB. With 
about 300 genes under its control, NF-ĸB is a key regulator of the transcription of stress proteins 
as well as the control of apoptosis (Karin 2006; Papa, Bubici et al. 2006; Basak and Hoffmann 
2008). NF-ĸB function is regulated through its interaction with inhibitory molecules, IkBs, which 
are able to suppress its activity by keeping it in an inactive state. Phosphorylation and 
ubiquitination of IkBs by kinases (IKK) abolishes IkBs allowing for the release and translocation 
to the nucleus of an active NF-ĸB (Karin 2006). The up-regulation of NF-ĸB is a common trigger 
mechanism for the cell propagation essential for their transformation and tumourigenesis, with its 
expression contributing significantly to the pathogenesis of inflammatory disease (Grossmann, 
Nakamura et al. 1999; Chen, Castranova et al. 2001; Ghosh and Hayden 2008). 
 
In 2003 Santilli et al. proposed an explanation for the pro-apoptotic activity of CLU through an 
involvement in the regulation of NF-ĸB activity. Transfection of CLU into both normal and 
tumourigenic cells caused a stabilisation of inhibitors of NF-kB and consequently inhibition of 
NF-ĸB activity. CLU has been shown to modulate both signal dependent and independent IkB 
turnover downstream of IKK kinase (Santilli, Aronow et al. 2003). Later studies revealed that 
CLU interacted with phosphorylated IkBa to prevent E3 ubiquitin ligase binding which induced 
IkBa stabilisation and prevented NF-kB translocation to the nucleus (Devauchelle, Essabbani et 
al. 2006). NF-ĸB is important for cell invasive properties and CLU inhibition of it may therefore 
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suppress cell invasion and result in increased responsiveness of cancer cells to apoptotic stimuli. 
Deletion of the CLU export signal in the N-terminus of the protein did not affect CLU ability to 
down-regulate NF-ĸB which would suggest that intracellular CLU, be it cytoplasmic or nuclear, 
is involved in this regulation, and not the secreted form of the protein (Pajak and Orzechowski 
2006).  
 
Conversely, down-regulation of CLU results in loss of IkB stability and a TNF dependent 
increase in NF-ĸB activity, with a consequential effect on NF-kB target genes (Savkovic, Gantzer 
et al. 2007). siRNA knockdown of CLU promoted the production of cytokines IL6 and IL8, of 
which NF-ĸB is a key transcriptional regulator (Devauchelle, Essabbani et al. 2006). The anti-
apoptotic function of CLU may perhaps be explained by reduced NF-ĸB activation and 
subsequent reduced expression of pro-apoptotic cytokines such a TNFα. It is possible that CLU is 
part of an NF-ĸB feedback mechanism regulating stress response mechanisms (Savkovic, 
Gantzer et al. 2007). When cells get stressed NF-ĸB is activated which then activates NF-ĸB 
target genes including pro-inflammatory and pro-apoptotic cytokines such as TNFα, resulting in 
cell death.  CLU is an NF-ĸB target gene which when activated translocates to the nucleus, 
reducing the levels of NF-ĸB. It therefore acts as a pro-survival protein to limit the effects of pro-
apoptotic cytokines. 
 
Having already demonstrated that CLU down regulates NF-ĸB and IL-6, Zhang et al. 
investigated this further in cells over-expressing phospholipase A2 (PLA2)-activating protein 
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(PLAA), which has been shown to regulate the production of prostaglandins (PGE2) and tumour 
necrosis factor (TNF)-α (Ribardo, Kuhl et al. 2002). In these cells there is an induction in NF-ĸB 
activation and in the production of IL-6, with a concurrent reduction in CLU expression. 
Transfection of CLU into these cells reduced TNF- α dependent production of the pro-
inflammatory lipid PGE2 (Zhang, Sha et al. 2008). It is thought that by inhibiting NF-ĸB that 
CLU is able to reduce inflammation by limiting expression of pro-inflammatory cytokines. 
 
By exposing cells to high serum concentrations, similar to those in disease states, it is possible to 
induce apoptosis in cell culture. In response to BSA induced apoptosis ERK and AP1 are 
activated, which have been linked with NF-ĸB activation (Hsu, Young et al. 2000; Lombardi, 
Cantini et al. 2008) CLU is also induced by BSA which serves as a negative feedback loop 
stabilising IkBα and in doing so prevents continued NF-ĸB activation and its production of anti-
apoptotic Bcl-xL, thus switching from inflammation to AP-1 induced apoptosis (Takase, Marumo 
et al. 2008; Takase, Minto et al. 2008). These findings are in line with the data produced by other 
groups who have already shown that CLU significantly suppresses NF-ĸB but not AP1 dependent 
transactivation (Santilli, Aronow et al. 2003).  
 
These data suggest that CLU could be a tumour suppressor gene that is essential for controlling 
NF-ĸB pathway derived signals and that loss of CLU in cells that depend on NF-ĸB activity for 
chemoresistance, proliferation, or invasion could lead to tumour progression. A conflicting paper 
by Nuutinen et al. suggested that CLU induction is NF-ĸB independent and unrelated to the 
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inflammatory response in N9 microglia (Nuutinen, Suuronen et al. 2005). A possible reason for 
this may be that in the murine microglial cell line there does not appear to be any non-
glycosylated nCLU by Western blot analysis. It is therefore possible that it is indeed nuclear CLU 
that interacts with NF-ĸB and has a role in its regulation. This finding is mirrored in a very recent 
study showing that over-expression of the sCLU does not interfere with IkB stability or NF-ĸB 
activity (Ammar and Closset 2008). 
 
1.6.5. Clusterin knockdown: a potential therapeutic strategy in cancer 
A phosphorothioate antisense oligonucleotide, OXG-011, targeted to the first ATG codon 
attenuates full length CLU expression with unknown effect on nCLU is currently being validated 
in phase II clinical trials at a number of sites of cancer including breast and prostate. It has been 
shown to strongly inhibit clusterin expression in in vitro and in vivo laboratory models, with an 
increase in apoptosis. This possibly suggests that there is an up-regulation of pro-apoptotic nCLU 
given that OGX-011 inhibits translation of full-length secreted clusterin but not the alternatively 
spliced nuclear clusterin. 
 
CLU repression by antisense oligonucleotides is presently in early stage clinical trials for prostate 
cancer given that it causes sensitization of cancer cells to chemotherapeutic drug-mediated 
apoptosis. One of the most commonly used treatments for prostate cancer is docetaxel and it has 
been found that in blocking CLU expression the phytoalexin resveratrol is able sensitise the 
docetaxel-resistant tumour cells PC-3 and DU145 to TRAIL mediated apoptosis (Sallman, Chen 
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et al. 2007). In the prostate cancer cell line PC-3M siRNA targeted to CLU rendered cells 
sensitive to apoptosis and promoted Bax oligomerization, and subsequent caspase activation 
(Zhang, Kim et al. 2005). Since the anti-apoptotic genes Bcl-2 and Bcl-xL have been implicated 
in chemo-resistance and tumour progression a Bcl-2/Bcl-xL bispecific ASO has been used in 
combination with CLU siRNA in LNCaP cells, which resulted in chemo-sensitisation and the up-
regulation of Bax (Yamanaka, Rocchi et al. 2006). 
 
Treatment of prostate cancer cells with CLU ASO enhanced their chemo-sensitivity to paclitaxel, 
mitoxantrone and docetaxel in vitro and vivo, resulting in induced tumour regression and a 
reduction in mean tumour volume.(Miyake, Chi et al. 2000; Gleave, Miyake et al. 2001; 
Zellweger, Miyake et al. 2001; Miyake, Hara et al. 2003; Springate, Jackson et al. 2005). Since 
CLU mediates radioresistance through the inhibition of apoptosis, inactivation of clusterin using 
ASO technology might offer an innovative line of attack to increase the efficacy of radiation 
therapy for prostate cancer patients. CLU antisense oligodeoxynucleotide has also been shown to 
enhance the efficacy of adenoviral-mediated p53 gene transfer in the treatment of orthoptic PC-3 
tumours. (Zellweger, Chi et al. 2002; Yamanaka, Gleave et al. 2005) 
 
Clusterin offers a protection to PC-3 cells against heat shock and plays an important role in the 
cascade of events initiated by heat shock. Prostate cancer cells treated with CLU ASO lose their 
protection against heat shock and thus have an increase in apoptosis, which can be reversed by 
addition of exogenous CLU (Sensibar, Sutkowski et al. 1995; Wu, Park et al. 2002).  
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siRNA knockdown of CLU in breast cancer cell lines resulted in a decrease in cell survival after 
doxorubicin treatment and a 3-fold increase in IR-induced lethality (Mallory, Crudden et al. 
2005; Sutton, Kim et al. 2006). CLU ASO enhanced the sensitivity of breast cancer cells to a 
HER2-targeted monoclonal antibody and increases chemotherapy-induced cytotoxicity, even in 
the presence of glucocorticoids which regulate cell survival signalling in breast cancer (Biroccio 
et al., 2005; Redondo et al., 2007). ASO treatment in vivo enhanced paclitaxel induced delay of 
MCF-7 tumour growth (Biroccio, D'Angelo et al. 2005; So, Sinnemann et al. 2005; Redondo, 
Tellez et al. 2007). Therefore, therapies which combine CLU ASO or perhaps antibodies to CLU 
with current chemotherapy regimens could provide a means of inhibiting breast cancer 
progression.  
 
In bladder cancer CLU ASO in combination with cisplatin or gemcitabine decreased KoTCC-1 
tumour volume and enhanced radiation sensitivity and chemosensitivity of bladder cancer cells to 
cisplatin (Miyake, Hara et al. 2001; Chung, Kwak et al. 2004; Miyake, Eto et al. 2004; 
Yamanaka, Gleave et al. 2005). Combined treatment with ASO, adenoviral-mediated p53 gene 
transfer and cisplatin eradicated KoTCC-1 tumours and lymph node metastases in 60% and 100% 
of mice, respectively (Miyake, Yamanaka et al. 2005). In cervical cancer cell lines, the 
expression of CLU was concurrent with paclitaxel resistance. Post siRNA treatment of HeLa cell 
line, chemosensitivity to paclitaxel was significantly reduced, suggesting that CLU may indeed 
cause paclitaxel resistance in cervical cancer cells (Park, Yeo et al. 2006). 
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The effectiveness of antisense oligonucleotides targeted to CLU has also been shown in number 
of other cancer cell lines. For example, in a lung cancer cell line treated with the ASO showed 
enhanced chemosensitivity to paclitaxel in vitro and in vivo and decreased cell survival in H460 
xenografts treated with OGX-011 plus radiotherapy (July, Beraldi et al. 2004; Cao, Shinohara et 
al. 2005). Treatment of the renal cancer cell lines Caki-1 and Caki-2 with CLU ASO enhanced 
chemosensitivity to paclitaxel in vitro and delayed tumour growth in vivo with an increase in 
chemosensitivity lost 48 hours after cisplatin treatment (Zellweger, Miyake et al. 2001; Lee, Jin 
et al. 2002). Chemosensitisation has also been observed in Melanoma cell lines which show high 
levels of CLU expression post treatment with CLU ASO. This finding was also replicated in vivo 
in CLU ASO treated SCID-mouse/human-melanoma xenotransplantation model, showing 
improved tumour response to the chemotherapy drug dacarbazine (Hoeller, Pratscher et al. 2005). 
ASO treatment of HT29, HCT116, HT29 APC led to decreased chemotherapy or APC induced 
apoptosis (Chen, Turner et al. 2004). ASO treated A431 cells showed increased proliferation 
(Thomas-Tikhonenko, Viard-Leveugle et al. 2004). 
 
CLU provides a cytoprotective function in osteosarcoma cell lines, where its knockdown has 
been shown to reduce cell growth and induce endogenous apoptosis. Cells were sensitized to 
genotoxic and oxidative stress aggravated by chemotherapeutic drugs and H2O2 (Trougakos, So et 
al. 2004). CLU ASO strongly inhibited angiogenesis and caused a significant apoptotic response 
in the endothelial cell line HUVEC (Jackson, Gleave et al. 2005). This is of particular interest 
given that the use of anti-angiogenic ASOs is progressing well in cancer clinical trials. The anti-
proliferative effect of CLU has also be shown to be eradicated post treatment of the human 
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epidermoid line A431 with CLU ASO leading to increased proliferation (Thomas-Tikhonenko, 
Viard-Leveugle et al. 2004). In colon cancer cell lines nuclear CLU has been shown to be 
affected by CLU ASO and was found to be highly dependent on p21 but not p53 expression, 
resulting in decreased chemotherapeutic or APC induced apoptosis (Chen, Turner et al. 2004). 
 
In conclusion the use of antisense oligonucleotides targeted to full length cyoplasmic and 
secreted CLU show very promising results in trials so far. However, at sites of cancer where CLU 
has been demonstrated to be down-regulated it would be of use to introduce the nuclear isoform 
of CLU to increase the sensitivity of cancer cells to chemo- and radio-therapies and result in 
programmed cell death of cancer cells. 
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Aims and objectives 
 
1. To define the pattern of expression of CLU in cervical, oral and nasopharyngeal cancer 
compared with normal epithelium 
2. To determine the contribution of epigenetic regulation, in terms of DNA methylation,  to 
the transcriptional control of CLU 
3. To determine the phenotypic consequences of re-expression of CLU in an NPC cell line 
model 
4. To investigate the contribution of CLU to the regulation of NF-kB activity 
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2.1. Search for candidate genes 
I used several sources of information to identify candidate tumour suppressor genes which may 
be inactivated by promoter methylation. The first, based on the results of a demethylation 
experiment, utilised 4 cervical cell lines, 2 of which are infected with HPV16, one with HPV18 
and one HPV negative cell line, which were treated with 5-Aza,2-deoxycytidine and Trichostatin 
A. Gene expression profiles were compared before and after demethylation treatment. Genes 
which were found to be up-regulated following treatment were matched against a list of tumour 
suppressor genes identified from a literature review.  This exercise revealed that a number of 
tumour suppressor genes not previously associated with cervical cancer had been up-regulated 
following demethylation. Secondly, the literature was reviewed to identify those studies which 
reported changes in gene expression in cervical keratinocyte cell lines in response to transfection 
with the viral oncogenes E6 & E7. I included in this review one study which described changes in 
gene expression following integration of HPV16 in the W12 cell line since it has been suggested 
that viral integration may play a role in expression of tumour suppressor genes such as p16INK4a 
(Wentzensen, Vinokurova et al. 2004; Vinokurova, Wentzensen et al. 2005).  
 
2.2.  Natural history cohorts 
Sections were taken under Bolton cohort study ethical committee reference number 28/93/9. The 
study population for this investigation is drawn from a randomised controlled trial completed 
some years ago. All women referred for evaluation of cytological abnormality to the colposcopy 
clinics in the Birmingham and Midlands Hospital for Women were included in the trial if: (a) the 
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colposcopist considered them suitable for out-patient laser vaporisation and (b) histological 
examination of a colpscopically directed punch biopsy revealed changes consistent with cervical 
HPV infection, either alone or in association with CIN 1 or CIN 2. Eligible women were 
randomised into treatment and non-treatment groups. Untreated patients were monitored by 
regular cytological and colposcopic examination at intervals of four months and further 
histological samples removed when the cytological or colposcopic findings suggested 
progression of disease. Progression was defined as histological evidence of a change from HPV 
infection alone to CIN, or an increase in grade of CIN. All patients were assessed in a dedicated 
research clinic by one observer, but histological material removed during the course of the trial 
was processed in one of two laboratories, dependent on the consultant to whom the patient had 
been initially referred. One laboratory routinely fixed specimens in formal saline and the other in 
Bouin’s fluid, which has been shown to inhibit the detection of HPV DNA sequences; these cases 
have been discarded from this investigation. Baseline material from the remaining 93 cases has 
previously been tested for the presence of HPV 16 and HPV 18 DNA. Seven women progressed 
to CIN 1, 9 to CIN 2 and 25 to CIN3 after a median follow-up of 36 months (range 4-84); the 
relative risk of progression associated with the presence of HPV 16 or HPV 18 DNA sequences 
was 2.3 (95% CI 1.23 to 4.27).   
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2.3.  CELL LINES AND TISSUES 
2.3.1.  Growth media and supplements for cell culture 
All cell lines used were anchorage dependent and subclones of the parental cell lines were grown 
in complete growth media which consisted of RPMI 1640 (GIBICO, Invitrogen, US) media 
supplied ready supplemented with L-glutamine (0.2M) and adjusted to pH 7. This was further 
supplemented with 10% foetal calf serum (GIBCO), 1% penicillin-streptomycin solution (Sigma-
Aldrich Ltd, Gillingham, Dorset, UK-Aldrich, US) and 200mg/ml ciproxin (GIBCO); which was 
stored at 4C for up to 1 month. Genticin G418 (GIBCO) was used to supplement the growth 
media of cells transfected with neomycin resistance genes, this was added to media at 1mg/ml. 
 
2.3.2. Cultivation of cell lines 
All cell lines were maintained in incubators at 37C supplied with 5% CO2. Cells were grown in 
a variety of tissue culture plasticware depending on the nature of the experiment. Cell stocks 
were maintained in 75cm
2
 tissue culture flasks (IWAKI, Japan) and fed twice weekly. When the 
cell lines reached 90% confluency cells were washed with PBS and then incubated for ~5 
minutes at 37C with 3-4mls of 1x trypsin solution (GIBCO). When cells became separated from 
the flask they were recovered in access media supplemented with 5% foetal calf serum, pelleted 
at 1500rpm for 5 minutes and then resuspended in fresh complete media. Cells were then plated 
out in new culture flasks for further cultivation. 
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Cell line Cell origin Basal Media Supplemented with
Plate Coating / drug 
selection
NHFK
Normal human foreskin 
Keratinocytes
Defined keratinocyte 
SFM 
Defined keratinocyte SFM growth supplement Gelatin coated plates
NHCK
Normal human cervical 
Keratinocytes
Defined keratinocyte 
SFM 
Defined keratinocyte SFM growth supplement Gelatin coated plates
HeLa HPV18 cervical cancer RPMI 10% FCS, 2% L-glutamine, 2% pen/strep
CaSki HPV16 cervical cancer RPMI 10% FCS, 2% L-glutamine, 2% pen/strep
SiHa HPV16 cervical cancer DMEM 10% FCS, 2% L-glutamine, 2% pen/strep
C33a HPV negative cervical cancer DMEM 10% FCS, 2% L-glutamine, 2% pen/strep
W12
Low grade cervical intraepithelial 
neoplasia
DMEM 10% FCS, 2% L-glutamine, 2% pen/strep 3T3 feeder layer
HEK293 Human embryonic kidney DMEM 10% FCS, 2% L-glutamine, 2% pen/strep
H103 Oral squamous cell carcinoma DMEM/F12 (1:1)
5% FCS, 2% L-glutamine, 1% pen/strep, 0.5% 
Ciproxin
H157 Oral squamous cell carcinoma DMEM/F12 (1:1)
5% FCS, 2% L-glutamine, 1% pen/strep, 0.5% 
Ciproxin
H376 Oral squamous cell carcinoma DMEM/F12 (1:1)
5% FCS, 2% L-glutamine, 1% pen/strep, 0.5% 
Ciproxin
SCC4 Oral squamous cell carcinoma DMEM/F12 (1:1)
5% FCS, 2% L-glutamine, 1% pen/strep, 0.5% 
Ciproxin
SCC9 Oral squamous cell carcinoma DMEM/F12 (1:1)
5% FCS, 2% L-glutamine, 1% pen/strep, 0.5% 
Ciproxin
SCC15 Oral squamous cell carcinoma DMEM/F12 (1:1)
5% FCS, 2% L-glutamine, 1% pen/strep, 0.5% 
Ciproxin
SCC27 Oral squamous cell carcinoma DMEM/F12 (1:1)
5% FCS, 2% L-glutamine, 1% pen/strep, 0.5% 
Ciproxin
NP69
SV40 immortilised nasopharyngeal 
cells
DMEM/F12 (1:1)
5% FCS, 2% L-glutamine, 1% pen/strep, 0.5% 
Ciproxin
C666-1
EBV positive undifferentiated 
nasopharyngeal carcinoma
RPMI
10% B cell serum, 2% L-glutamine, 2% 
pen/strep, 0.5% ciproxin 
1mg/ml fibronectin 
coated plates
Ad-AH parental
EBV negative nasopharyngeal 
carcinoma
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep
Ad-AH neo
EBV negative nasopharyngeal 
carcinoma + neomycin resistance 
cassette
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep Geneticin G418
Ad-AH EBV
Nasopharyngeal carcinoma 
infected with recombinant EBV
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep Geneticin G418
Ad-AH -LMP2A
Nasopharyngeal carcinoma 
infected with mutant rEBV in 
which LMP2A is deleted
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep Geneticin G418
Ad-AH EBNA1
Nasopharyngeal carcinoma 
transfected with EBNA1
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep Geneticin G418
Ad-AH LMP2A
Nasopharyngeal carcinoma 
transfected withLMP2A
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep Geneticin G418
Ad-AH LMP2B
Nasopharyngeal carcinoma 
transfected withLMP2B
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep Geneticin G418
Ad-AH LMP1
Nasopharyngeal carcinoma 
transfected with LMP1
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep Geneticin G418
NPC TWO 1
EBV negative nasopharyngeal 
carcinoma
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep
NPC TWO 4
EBV negative nasopharyngeal 
carcinoma
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep
HONE1
Nasopharyngeal carcinoma latency 
infected with EBV
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep
CNE 1
EBV negative nasopharyngeal 
carcinoma
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep
CNE 2
EBV negative nasopharyngeal 
carcinoma
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep
SUNE1
EBV negative nasopharyngeal 
carcinoma
RPMI 10% FCS, 2% L-glutamine, 2% pen/strep
AGS Gastric adenocarcinoma RPMI 10% FCS, 2% L-glutamine, 2% pen/strep  
   Table 2.1: Growth media for cell lines used in this thesis (GIBCO) 
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2.3.3.  Cell counting 
Many experiments require a set number of cells so it is important to have a method of 
determining cell numbers. After harvesting cells in the same manner as for subculture a sample of 
cell suspension was drawn into the main square on a haemocytometer grid (Sigma-Aldrich Ltd, 
Gillingham, Dorset, UK-Aldrich Ltd, Gillingham, Dorset, UK) overlain with a cover slip. The 
volume that can be contained in a large grid is 10
-4
ml. Light microscopy was used to count the 
number of cells in four large grids on the haemocytometer, and the number divided by four to 
give an average number per 10
4
ml. This number is them multiplied by the total volume (mls) of 
the cell suspension to give the overall number of cells present.  
 
2.3.4.  Preparation for mycoplasma testing 
Mycoplasma infections are a common problem with cultured cells that can affect cell behaviour 
and obscure results. All cell lines were periodically tested for the presence of mycoplasma, using 
the MycoAlert mycoplasma Detection Kit (Lonza, Switzerland) according to the manufacturer’s 
protocol, and were found to be consistently negative for mycoplasma. 
 
2.3.5.  Cryopreservation 
The day prior to cryopreservation cells were washed in complete media by centrifugation at 
1500rpm for 5 minutes and then resuspened at a density of 5x10
5
 cells/ml of complete media and 
cultivated in tissue culture flask. On the day of cyropreservation cells were pelleted as described 
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previously. Typically, 5x10
6
 cells were re-suspended in 1ml ampoules of freezing media 
containing 10% DMSO and transferred to cryotubes (Nunc, Denmark). These were placed in 
cyropreservation boxes (Mr Frosty, Nalgene, US) and stored for 24hrs at -80C. The cells were 
then transferred from the cyropreseravtion boxes to liquid nitrogen freezers (-140C) for long-
term storage. Frozen cells were recovered by warming rapidly in a 37C water bath and then 
transferring to a 15ml tube (Falcon). 5ml of pre-warmed complete media (37C) was then added 
to the cells drop-wise, and the cells were then pelleted at 4530rcf for 5 minutes. The supernatant 
was subsequently discarded and the cells resuspended in 8ml complete media and transferred to a 
25cm
2
 culture flask (IWAKI). 
 
2.3.6.  Tissue section preparation 
2.3.6.1.  Section preparation for immunohistochemistry 
Parffin-embedded tissues from the cervix, oral cavity and nasopharynx were cut at 5m on to 
adhesive-coated slides (Vectorbond reagent, Novocastra Laboratories Ltd, UK) using a rotary 
microtome. Slides were incubated at 37C overnight and stored at room temperature prior to 
staining. Immediately prior to immunhistochemical (IHC) staining, paraffin embedded tissue 
sections were de-waxed by incubating in xylene (2-times 5 min) and then industrial methylated 
spirits (IMS) (2-times 5 min). A standard cryostat was used to prepare frozen sections at 5m. 
Sections were fixed in formal-saline, washed in PBS (pH 7.6), dried at room temperature and 
then individually wrapped in aluminium foil prior to storage at -20C. 
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2.3.6.2.  Section preparation for quantitative-reverse transcriptase-PCR and cell lysis 
A standard cryostat was used to cut 20-30 frozen 5m sections directly in to a pre-chilled sterile 
1.5ml eppendorf. The tube was then sealed and placed immediately into liquid nitrogen for 
storage prior to protein or RNA extraction.  
 
2.3.7.  Cytospin preparation for immunohistochemistry and immunofluorescent staining 
Between 10
5
-10
6
 cells were washed in warm PBS by centrifuging at 1500rpm 3-times. After the 
final wash the pellet was resuspended in 5-15ml of warm PBS. 1-3 drops of cell suspension was 
loaded on to an adhesive-coated slide (Novocastra) through a cytospin funnel. The cells were 
then centrifuged on the slide using a standard Cytospin at 4530rcf for 5 minutes. Slides were then 
fixed in formal-saline (for IHC) or 4% paraformaldehyde (for IF staining) for 20 minutes, washed 
in PBS for 5 minutes, water for 5 minutes, air-dried and stored at room temperature (RT) prior to 
staining. 
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2.4.  TRANSFECTION OF PLASMID DNA INTO MAMMALIAN CELLS 
2.4.1.  Transient transfection of cells 
The lipid-based transfection reagent, Lipofectamine (Invitrogen) was used in conjunction with 
Plus reagent (Invitrogen) to transfect cells. The day prior to transfection 1x10
6
 cells were seeded 
in 60mm tissue culture plates (IWAKI) with 2ml of complete RMPI media and cultivated 
overnight. To transfect the cells complete RPMI media was aspirated from the cells and they 
were washed by gently over-laying with serum-free Optimem media (GIBCO). This was done to 
remove serum, which would otherwise reduce the transfection efficiency. 2ml of fresh Optimem 
media was then added to the cells and the Plus reagent mastermix prepared (6µl Plus reagent, 
133µl Optimem media, 1µg DNA), gently mixed and incubated in the dark for 15 minutes. The 
Lipofectamine mastermix was then prepared (4µl Lipofectamine, 133µl Optimem media) with 
gently mixing by pipette. The two master mixes were then combined and mixed by pipetting, and 
the solution incubated for a further 15 minutes in the dark. Following this, 276l of the combined 
mastermix was added drop-wise to the cells. After 8hrs incubation with the combined mastermix 
2ml of complete RPMI media was added to the cells. 24hrs post-transfection all media was 
aspirated from the cells and replaced with 2ml fresh complete RPMI media. The transfected cells 
were harvested 48hrs-post transfection. 
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2.4.2.  Small interfering RNA (siRNA) transfection 
RNA interference describes a phenomenon that occurs naturally in cells in which the expression 
of individual genes is inhibited by interference of the mRNA being transcribed. When double 
stranded RNAs are made, the enzyme Dicer can snip them to form short interfering RNAs 
(siRNAs). The short siRNA sections unwind into single stranded RNAs which then combine with 
proteins to form a complex called RNA-Induced Silencing Complex (RISC). The RISC complex 
captures a native mRNA molecule complementary to the short siRNA sequence and digests it 
into RNA fragments which are not translated. By using synthetic 21bp siRNA duplexes this 
process can be mimicked to achieve specific gene knock-down at the transcriptional level in 
mammalian cells during culture. Small interfering RNA (siRNA) and scrambles siRNA were 
designed according to the criteria determined by (Reynolds, Anderson et al. 2006), to the coding 
region of human CLU, with no homology to any known human sequence. The siRNA duplexes 
were made to working stocks of 20 μM in RNase-free water. 
 
For transfecting HeLa/293 cells in 6 well plates, 2x10
5
 cells were seeded one day before 
transfection. The following day, the transfection mix was prepared by mixing 20μM of siRNA or 
scrambled siRNA with 167.5μl of optiMEM. In a separate tube, 3μl of lipofectamine RNAiMAX 
(Invitrogen) was diluted in 27μl of optiMEM (0.3%). After mixing gently, both mixtures were 
incubated at room temperature for 10 minutes. Then the two mixtures were combined, gently 
flicked and incubated for a further 10 minutes at room temperature. Meanwhile, the cells were 
washed twice with phosphate-buffered saline (PBS) before adding 800µl optiMEM to the 6 well 
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dishes. The final transfection mix was then added to the plate and tilted to ensure even 
distribution. Mock cells were transfected using the method above but with no siRNA included. 
After 4 hours of incubation at 37 °C with 5% CO2, the transfection mix was replaced with normal 
RPMI media containing no antibiotics. Cells were assayed 24 and 48 hours after the transfection 
and knockdown assessed by RT-PCR, real-time PCR and Western blot. 
 
Gene Strand Sequence application
sense 5'-AGG AAG AAC CCU AAA UUU A99-3'
anti-sense 5'-UAA AUU UAG GGU UCU UCC U99-3'
sense 5'-GGU UUA UAU GAU CUU CAU A99-3'
anti-sense 5'-UAU GAA GAU CAU AUA AAC C99-3'
CLU
siRNA
SCRAMBLE
CLU
 
Table 2.2. siRNA duplexes used for knockdown of CLU in vitro 
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2.5.  PROTEIN ANALYSIS 
2.5.1.  Protein extraction 
The day prior to harvesting, cultured cells were fed with new complete media and seeded at a 
density of 5x10
5
cells/ml. Usually,  ~5x10
6
 cells (roughly 10ml of cell suspension) were harvested 
and washed three times in 10ml of cold PBS, centrifuging for 5 minutes at 1500rpm and 4C. The 
final wash was carried out in a 1.5ml eppendorf. After the last wash all supernatant was aspirated 
on ice. The cell pellet was then either snap-frozen in liquid nitrogen and stored at -80C for future 
use or lysed in between 50-500l of lysis buffer (9M urea, 50mM Tris pH7.5, 15mM -
mercaptoethanol), unless otherwise stated. Following addition of lysis buffer samples were 
vortexed vigorously for 1 minute and then clarified by centrifugation at 15000rpm for 20 
minutes. The supernatant was transferred to a new 1.5ml eppendorf and stored at -20C.  
 
Protein concentration was determined using the Dc protein assay (Bio-Rad, Hercules, CA). Five 
standards were prepared by solublising bovine serum albumin (BSA) in a 1:10 lysis buffer/water 
solution (BSA standards at 2mg/ml, 1mg/ml, 0.5mg/ml, 0.2mg/ml and 0.1mg/ml). These were 
used to generate a standard curve to quantify test samples by. 5l of each standard was added in 
triplicate to a 96 well flat-bottomed plate (Falcon). An aliquot of each sample was then diluted 
1:10 in water and 5l added in triplicate to the plate. 50l of Reagent A (Bio-rad) was added to 
each well and the plate gently agitated. Then 200l of reagent B was added and the plate gently 
agitated for a further 5 minutes at RT before the absorbance at 630nm was read on a spectrometer 
plate reader and the protein concentrations calculated. 
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2.5.2. Immunoblotting 
2.5.2.1 Solutions 
4x Laemmli loading buffer    Running Buffer 
250mM   Tris pH6.8     0.25M Tris base  
40%     Glycerol     1.92M Glycine  
5%     SDS      1%  SDS  
0.005%    Bromophenol blue            water 
     Water        
10% -mercaptoethanol added prior to use. 
 
Blocking buffer     Transfer Buffer 
5%  non-fat milk powder    25mM Tris base 
0.01%  Tween 20     0.2M Glycine 
  PBS      20% Methanol 
        water 
Stripping Buffer 
62.5mM   Tris-HCl (pH6.8) 
2%      SDS 
      Water 
0.1M  -mercaptoethanol added prior to use. 
 
2.5.2.2.  SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Typically 30g of protein lysate was separated by SDS-PAGE using 10% gradient pre-cast 
polyacrylamide gels (PAG) (Invitrogen). Laemmli loading buffer was added to each sample and 
then samples were heated at 95C for 10 minutes, cooled on ice and briefly pulsed before loading 
onto the gel. Weight markers were prepared and run alongside the protein samples (Kaleidoscope 
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marker, Bio-Rad). Gels were run (in running buffer) at 90mV for the first 20 minutes and then 
125mV for a further 90 minutes, or until the gel front had migrated to the bottom of the gel. 
Proteins were transferred (in transfer buffer) to a nitrocellulose membrane (Invitrogen) at 28mV 
for 2.5 hrs using the Novex immunoblotting apparatus. During transfer the transfer tank was 
packed with ice to prevent heat disruption of the gel or membrane.  
 
2.5.2.3.  Immunoblotting 
Following blotting the membrane was washed in 0.1% Tween-20 PBS with gentle agitation for 
10 minutes. It was then stained for 1 minute with poncaeu S (Sigma-Aldrich Ltd, Gillingham, 
Dorset, UK-Aldrich) to confirm successful protein transfer. The membrane was then washed a 
further three times for 5 minutes in 0.1% Tween-20 PBS. The final wash was replaced with 
blocking buffer and the membrane incubated for 1hr at RT with gently agitation. Membranes 
were then probed overnight with primary antibody, diluted to the appropriate concentration with 
blocking buffer. The following day membranes were washed in 0.1% Tween-20 PBS for 1hr; 
washes were changed at regular intervals. Secondary peroxidase-labelled antibody diluted in 
blocking solution was used to incubate the membranes in for 1hr. Following further washing for 
1hr, proteins were visualised with the enhanced chemiluminescence technique (ECL) 
(Amersham, UK) as per manufacture’s instructions. 
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Gene Species Supplier Epitope Applications Dilution
CLU Mouse monoclonal Vector 7D1 IHC 1:200
CLU Mouse monoclonal Upstate 41D WB, IHC, IF 1:1000
CLU Mouse monoclonal Santa Cruz B-5 WB, IHC, IF 1:1000
DKK3 Goat polyclonal Santa Cruz C19 IHC 1:600
DKK3 Goat polyclonal Santa Cruz N17 IHC 1:600
AKAP12 Mouse monoclonal abcam JP74 IHC 1:500
TIMP1 Mouse monoclonal Chemicon 8E8.2 IHC 1:25
 
Table 2.3. Primary antibodies used for Western blotting, Immunohistochemistry and 
Immunofluorescence 
 
2.5.2.4.  Stripping membranes for re-probing 
To facilitate re-probing of membranes with different primary antibodies, previous blotting 
reagents were removed. Initially membranes were washed in 0.1% Tween-20 PBS for 30 
minutes, followed by 20 minute incubation in stripping buffer. The membranes were then washed 
in 0.1% Tween-20 PBS for a period of 4hrs, with wash buffer being exchanged every 30 minutes. 
Following stripping membranes was re-probed as described in section 2.5.2.3. 
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2.5.3.  Immunohistochemistry 
2.5.3.1.  Solutions 
Antigen retrieval buffer   Tris buffered saline (TBS) pH 7.6 
1mM EDTA     6.05g Tris 
0.1% Tween-20    8.76g NaCl 
Water      1L Water 
      pH adjust to pH 7.6 with 1M HCl. 
 
2.5.3.2.  Immunohistochemical staining with low temperature antigen retrieval 
All slides were incubated for 10 minutes in 0.3% hydrogen peroxide in methanol to block 
endogenous peroxidase activity and then washed in running tap water. Sections were incubated in 
antigen retrieval buffer on a hotplate stirrer at 600rpm, 65C for 16hrs. Immunostaining was 
carried out in the Shandon Sequenza Immunostaining Station (Thermo Electron Corp. US) to 
ensure consistent staining. Slides were mounted in to coverplates (Thermo Electron) and washed 
in TBS for 5 minutes. Next, 100l of primary antibody was applied at the appropriate dilution in 
TBS and incubated at RT for 1hr. The antibody solution was then removed and the slide washed 
in 0.1% Tween-20 TBS for 5 minutes. 2 drops of Dakochemate Envision Secondary (Dako) was 
then placed on each section and incubated for 30 minutes. However, for rat primary antibodies a 
rabbit anti-rat secondary antibody (Dako) was used diluted 1:200 in TBS. Slides were then 
washed with 0.1% Tween-20 TBS for 5 minutes. The coverplate was then removed from the slide 
and the slide placed on to a staining rack. Slides were then rinsed with TBS. Staining was 
visualised by incubating with chromagen (DAB, Dako) for 5 minutes or Novared (Dako) for 
30secs. Following visualisation, slides were placed in a coplin jar and washed in water. The 
 Materials and Methods 
 
 
104 
slides were then counterstained in haematoxylin (Sigma-Aldrich Ltd, Gillingham, Dorset, UK-
Aldrich) for 30secs and rinsed in hot water for 2 minutes, followed by cold for 5 minutes. The 
slides were then dehydrated by sequential incubation for 5 minutes in IMS and xylene. Following 
dehydration, after the xylene had evaporated from the slides, coverslips were applied with DPX 
mountant (BDH chemicals, Merck, US).  
 
2.5.3.4.  Haematoxylin and Eosin (H&E) staining 
H&E staining of sections was carried out by the Queen Elizabeth Hospital’s Department of 
Pathology. The department’s automated system was used to ensure consistency of staining. 
 
2.5.3.5.  Scoring of staining 
Immunohistochemical staining was evaluated subjectively using light microscopy blinded to the 
data on at least 2 separate occasions by both an observer and a pathologist, either Dr Terry 
Rollason or Dr Maizaton Abdullah. In the event of intra-observer or inter-observer error a 
consensus score was decided on after examination by both observers at a multi-headed 
microscope. Staining was assessed semi-quantitatively in terms of candidate gene expression  on 
a scale of 0 to 3+ according to the intensity of staining, where;   
-  denotes a complete absence of staining   1+  denotes weak staining intensity 
+/-  denotes faint/equivocal staining   2+  denotes moderate staining intensity 
3+  denotes a strong staining intensity 
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2.5.4.  Immunofluorescent (IF) staining 
Cytospins were subjected to heat-activated antigen retrieval prior to IF staining. Slides were 
submerged in 1L of citric acid buffer pH 6.0 (0.1M citric acid, 0.1M sodium citrate) and 
microwaved at full power for 20 minutes. After microwaving slides were air-cooled for 5mins 
then rinsed under a running tap for 10 minutes. Following that the slides were washed in 1% 
tween-20 PBS for 5 minutes. Cytospins were permeablised in 0.5% Triton X-100 for 5 minutes 
and then rinsed with 1% tween-20 PBS. The cells were then blocked with 100l of 20% HINGS 
for 1hr. The blocking solution was then removed and the cells incubated for 1.5hrs with 50l of 
primary antibody diluted in 20% HINGS at 1:100. Following this cells were washed by 
repeatedly passing 1% tween-20 PBS over the slides (6 passes in total). Excess PBS was then 
removed from the cells and replaced with 50l of fluorophore-conjugated secondary antibody 
diluted in 20% HINGS at 1:1000 (Alexa Fluor 594 anti-mouse, Molecular Probes). Slides were 
then incubated in the dark for 1.5hrs and washed as described previously. DAPI nucleic acid stain 
(Molecular Probes, Invitrogen) was used to counterstain the cell nuclei. 150nM of DAPI diluted 
in PBS was applied to the cytospin for 1 minute and then washed in 1% tween-20 PBS for 10 
minutes. Slides were then mounted with coverslides using the ProLong Antifade kit (Molecular 
Probes, Invitrogen) and viewed using a fluorescence microscope.  
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2.6.  RNA ANALYSIS 
2.6.1.  RNA Extraction 
RNA was extracted from cells using the RNA Easy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. The concentration and quality of RNA was assessed using the 
Nanodrop spectrometer (NanoDrop Technologies, US). The A260/280 of RNA samples was 
required to be between 1.9 and 2.1. RNA stocks were diluted to 1mg/ml for routine use. All RNA 
samples were stored at -80C. 
 
2.6.2.  cDNA synthesis 
cDNA synthesis was carried out under RNase-free conditions, on ice unless otherwise stated. 1l 
of Random Primers (Promega, 20g vial) and 1l dNTPs (Invitrogen, 10mM) were added to 
500ng of RNA in 0.5ml thin walled PCR tubes (Eppendorf) and the volume made up to 13l with 
DEPC-treated water. The samples were then incubated at 65C for 5 minutes and cooled rapidly 
on ice to denature RNA and prohibit re-annealing. cDNA mastermix was prepared (Table 2.4) 
and 7l added to each RNA sample. Reaction mixtures were then subject to incubation at 25C 
for 5 mins (annealing step), 50C for 60 mins (extension step), 70C for 15 mins 
(inactivation/denaturation step) and then held at 4C or kept at -20C for longer term storage. 
Incubations carried out in a Thermal Cycler. 
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Reagent Volume (l) Supplier 
5x First strand buffer 4 
Invitrogen 
 DTT (0.1M) 1 
Superscript III reverse transcriptase 1 
RNase Out 1 
     
     Table 2.4. cDNA mastermix 
 
2.6.3 Semi-quantitative-reverse transcriptase polymerase chain reaction 
1g of cDNA was then amplified by addition of 12.5l of 2x PCR mastermix (Promega) and 5l 
of a 2.5pmole/l mix of 5’sense primers and 3’anti-sense (1:1 ratio). Reaction mixes were then 
subject to appropriate thermal cycling in a Thermal Cycler. In semi-Q-RT-PCR 5 reaction 
mixtures were prepared for each sample, and these were subjected to either 15, 20, 25, 30 or 35 
thermal cycles. 
Step number Cycle step Time (mins) Temperature (C) 
1 Initial denaturing 5 95 
2 Denaturing 0.75 95 
3 Annealing 1 x 
4 Extension 2 72 
5 Final extension 5 72 
6 Hold/terminate HOLD 4 
      
     Table 2.5. RT-PCR thermal cycle program 
     Annealing temperatures (x) and cycles are given in table 2.6. 
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Gene Strand Sequence application
Annealing 
temperature (°C)
cycles Product size (bp)
sense 5'-TTC ATC CAG CAG TGT TGC TC-3'
anti-sense 5'-GGT GTG GGG TAG TGG AGA GA-3'
sense 5'-CCC ACA CAG GTG AGA AAC CT-3'
anti-sense 5'-ATG TGT AAG GCG AGG TGG TC-3'
sense 5'-ATT CAC TCG TTT CCC AAT CG'3'
anti-sense 5'-TAC TCT GGC AAG GGC ATC TT-3'
sense 5’-CCC CAG CCT GTG ATG GTA A-3’
anti-sense 5’-GGA TAG TTG TGG GGG GAT CGT A-3’
sense 5'-GTA GCT GAG CAA GAT GAG CTC-3'
anti-sense 5'-CCG CTG ACT TAG TAG CCA TCT-3'
sense 5'-AAT TCC GAC CTC GTC ATC AG-3'
anti-sense 5'-TGC AGT TTT CCA GCA ATG AG-3'
sense 5'-GCG AGC AGA GCG CTA TAA AT-3'
anti-sense 5'-CCC TGA TTG GAC ATT TCC TG-3'
sense 5'-AGA TGG ATT CGG TGT GAA GG-3'
anti-sense 5'-CCC TGA TTG GAC ATT TCC TG-3'
sense 5’-CCA CCC ATG GCA ATT CCA TGG CA-3’
anti-sense 5’-TCT AGA CGG CAG GTC AGG TCC AC-3’
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
CLU V2 60 35 203
GAPDH RT-PCR 60 25 187
30
28
35
198
191
232CLU V1
297
28
25
33
25
43
60
44
60
DKK3 
KLF4 
RNASET2 
CADM1 
AKAP12 
TIMP1 
238
169
225
60
60
60
 
Table 2.6. Primers used for RT-PCR 
All primers supplied by Alta Bioscience, UK. Stocks prepared at 100pM by dilution in RNase-
free water and stored at -20C. Where possible oligonucleotides for RT-PCR were designed to 
span an exon junction, have a GC content of between 40-60%, 3’-end content of <40%, low self 
or cross annealing potential and minimal hairpin structure. 
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2.6.4.  Agarose gel electrophoresis  
Agarose gel electrophoresis is commonly used to separate both DNA and RNA molecules on the 
basis of size. DNA and RNA molecules are negatively charged so migrate through gels towards 
the cathode. Agarose gels generally have relatively large pore sizes compared to other gel 
matrixes so are suitable for large molecules such as DNA or RNA. To some degree pore size can 
be determined by agarose concentration, with low concentrations of agarose providing better 
separation of large molecules than high concentrations and vice versa. A 0.8% gel will show 
good separation (resolution) of large DNA fragments (1–10kb) and a 2% gel will show good 
resolution for small fragments (0.2–1kb). In order to visualise DNA/RNA molecules once 
separated, ethidium bromide is incorporated into the gel matrix as this intercalates with the 
DNA/RNA molecules. Under ultraviolet illumination (UV light) the intercalated ethidium 
bromide emits light showing the position of the RNA/DNA molecules on the gel, and the use of a 
marker containing fragments on known size, allows estimations of band size to be made. 
 
2.6.4.1.  Solutions 
Tris-boric acid-EDTA (TBE) buffer   6x Gel loading dye 
108g Tris base     25mg bromophenol blue 
55g Boric acid     25mg xylene cyanol FF 
9.3g EDTA      3ml glycerol 
1L water      Water to a final volume 10ml 
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2.6.4.2.  Agarose gel electrophoresis of amplified products 
Agarose gels were prepared by dissolving agarose powder (Invitrogen, Paisley, UK) in 1xTBE 
(Sigma-Aldrich Ltd, Gillingham, Dorset, UK) by heating in a microwave on medium power for 
2-5 minutes. As described above the percentage agarose used depended on the application, 
molecules below 1kb were analysed on 2% (w/v) gels and molecules above 1kb were visualised 
on 0.8% (w/v) gels. Once cooled ethidium bromide was added at a final concentration of 1g/ml 
(Sigma-Aldrich Ltd, Gillingham, Dorset, UK-Aldrich). The solution was then poured into a 
prepared gel tray and an appropriate sample comb inserted. Once set, the comb and tray barriers 
were removed and the gel and tray placed into the electrophoresis tank previously filled with 1x 
TBE buffer. Bromophenol blue loading dye was added to each PCR sample at a 1:5 dilution. 
Samples were then loaded into the gel and run at 90V using a Powerpac (Bio-rad laboratories 
Inc., Hercules, California, USA), until the dye front had migrated ~2cm from the end of the gel. 
A molecular weight marker (100bp ladder, Promega) was run alongside the samples. Intercalated 
DNA was visualised under UV light using a transilluminator (Bio-rad laboratories Inc., Hercules, 
California, USA).  
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2.6.5.  Quantitative-RT-PCR (Q-RT-PCR) 
Q-RT-PCR uses a fluorogenic probe to enable the detection of a specific PCR. As in standard 
PCR, Q-RT-PCR amplifies a specific region of DNA located between two primers. A probe, 
which is specific to a sequence in the region flanked by the two PCR primers and that is labelled 
at the 5’-end with a fluorophore (FAM or VIC) and at the 3’-end with a quencher (TAMRA or 
MGB), is also included in the reaction. The Taq polymerase used possesses a 5’-3’ exonucleases 
activity. Thus, amplification of the target DNA sequence results in digestion of the fluorogenic 
probe and in turn release of the fluorophore from the quencher. Consequently, the amount of 
fluorescence is directly proportional to the amount of DNA amplification. The accumulation of 
fluorophores is monitored digitally at every thermal cycle. Relative quantitation is enabled by 
monitoring at which thermal cycle each different sample reaches a specific level of fluorescence; 
the cycle threshold (Ct).   
 
RNA was extracted for Q-RT-PCR as described in section 2.6.1 and cDNA generated as 
described in section 2.6.2. Prior to proceeding all equipment to be used was irradiated under UV 
light to remove any DNA contaminations. PCR reactions were performed in 96-well reaction 
plates (Applied Biosystems, US) and set-up on ice. All samples were run in triplicate to allow 
analysis using the delta CT method. 50ng of cDNA were used per well (1l). In addition 19l of 
mastermix was added to each well (Table 2.20). Pre-mixed primer sets and probe (Assays-on-
demand, Applied Biosystems) were used to amplify endogenous control and target gene (Table 
2.21). All primer sets amplify a region crossing an exon junction. 
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Reagent Volume (l) Supplier 
Taqman universal mastermix 10 
Applied Biosystems 
 
20x GAPDH endogenous control 1 
20x (target gene) primer and probe mix 1 
DEPC-treated water 7 Ambion 
      
       Table 2.7. Q-RT-PCR Mastermix 
 
Target 
gene 
Probe 
fluorescent 
reporter dye 
Product details 
CLU FAM Hs00156548_m1 
CADM1 FAM Hs00204937 
GAPDH VIC Human endogenous control 4352934E (VIC/TAMRA) 
B2M VIC Human endogenous control 4333766T (VIC/MGB) 
PGK1 VIC Human endogenous control 4333765T (VIC/MGB) 
18S VIC Human endogenous control 4310879E (VIC/TAMRA) 
      
     Table 2.8. Q-RT-PCR TaqMan® primer and probe kits (Applied Biosystems) 
 
After the mastermix was added to all samples the wells were sealed with optically clear caps 
(Applied Biosystems) and the 96 well plate centrifuged at 1200rpm for 5 minutes at 4C to 
remove air bubbles.  The plate was then placed in the ABI Prism 7700 Sequence Detection 
System (Applied Biosystems) and subjected to 40 thermal cycles.  
Step number Cycle step Time (secs) Temperature (C) 
1 Enzyme activation 120 50 
2 Denature 600 95 
3* Denature 15 95 
4* Anneal/extend 60 60 
 
       Table 2.9. Q-RT-PCR thermal cycle program 
      *Steps 3 and 4 were sequentially repeated 40-times. 
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2.6.5.1 The comparative Ct method (ddCt) for relative quantitation of gene expression 
The delta-delta (dd)Ct method (Livak and Schmittgen, 2001)  enables relative quantitation of 
transcripts without the need for standard curves when looking at expression levels of a target 
gene relative to an endogenous control (e.g.GAPDH). The ddCt was used to calculate the n-fold 
change in the amount of target gene transcripts (CLU, CADM1) present in one cell type relative 
to another, for example the n-fold change in CLU mRNA transcripts in HeLa cells relative to the 
level of CLU mRNA transcripts in CaSki cells. In order to calculate this the difference (dCt) 
between the Ct values of the target gene and the endogenous gene was calculated for each sample 
studied (dCt = target Ct – endogenous Ct). The sample selected as the ‘baseline’ sample for 
expression of the target gene is referred to as reference sample. The difference between each of 
the samples dCT and the reference samples dCT was calculated, generating the ddCt value for 
each sample (ddCt = reference dCt – target dCt). The ddCt for each sample was then converted to 
an absolute value using the following equation:  n-fold change in expression level = 2 
–ddCt. 
The n-
fold change in expression of target genes studied by Q-RT-PCR was calculated in this way. 
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Figure 2.1: Calculation of relative gene expression using ddCt method with the ABI Prism 
7700 Sequence Detection System (Applied Biosystems) 
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2.7.  IN VITRO FUNCTIONAL STUDIES 
2.7.1.  Cell Viability 
Following cell culture media was removed and cells were washed with PBS, detached with 
trypsin–EDTA, neutralized with complete medium, centrifuged and re-suspended in PBS. An 
aliquot of cell suspension was diluted with 0.4% trypan blue (Sigma-Aldrich Ltd, Gillingham, 
Dorset, UK–Aldrich), pipetted onto a hemocytometer and counted under a microscope at 40x 
magnification. Live cells excluded the dye, whereas dead cells admitted the dye and consequently 
stained intensely with trypan blue. The number of viable cells for each experimental condition 
was recorded. Trypan blue was used as rapid initial screen to check if cells were viable for 
subsequent transfection and apoptosis studies. PI was used as part of the dual staining procedure 
to measure apoptosis with Annexin V post transfection quantitatively. 
 
2.7.2.  Apoptosis assay 
Multiple lipofectamine transfections (section 2.4.2.1) were performed to produce sufficient cells 
for the viability study. 24hrs post-transfection cells were pooled and washed 3-times by 
centrifugation at 1500rpm for 5 minutes in RPMI media supplemented with either 10% or 1% 
foetal calf serum depending on study requirements. Cells were then resuspended at 3x10
5
 cells/ml 
in RPMI media supplemented with the appropriate amount of foetal calf serum. In 48-well tissue 
culture plates 500l of cell suspension was added to 5 wells in triplicate for each time point to be 
studied (0, 24, 48, 72 and 96 hrs post-transfection). Cells were then cultivated as normal without 
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additional feeding. At each time point cells were harvested and viability and apoptosis studied by 
annexin-V FITC/PI staining. 
  
Loss of plasma membrane is one of the earliest features of apoptosis. Annexin V has a high 
affinity for phospholipid phosphatidylserine, which is exposed to the external cellular 
environment in apoptotic cells permitting binding. Annexin-V specifically binds to the 
fluorochrome FITC and is therefore used to stain for early stage apoptotic cells. Later stages of 
apoptosis and necrosis include the loss of membrane integrity and so Annexin V is used in 
combination with propidium iodide, which is a vitality dye that is only taken up by dead cells due 
to their increased membrane permeability. Therefore, cells which are Annexin V positive but PI 
negative are in the early stages of apoptosis with the cell membrane still intact, with an absence 
of necrosis. 
 
In order to measure cell viability and apoptosis cells were stained with FITC-labelled annexin-V 
and PI using the Annexin V-FITC apoptosis detection kit I (BD Biosciences) following 
manufacturers instructions. Cells were stained in a volume of 100 μl 1 x binding buffer which 
contained 5 μl Annexin V-FITC and propidium iodide at 50 ng/ml. Cells were stained in the dark 
for 15 minutes before being analysed by FACS-Becton Dickson FACS-Calibur to detect 
apoptosis. An aliquot of 10,000 cells were analysed per condition. Green fluorescence was 
detected using FL1 channel and red fluorescence was detected using FL3 channel. Cell Quest 
Software (version 3.1f) displayed the results as a bivariate dot plot of Annexin V (FL1) and PI 
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(FL3) fluorescence intensity. A two-dimensional dot plot was generated of annexin V-PE versus 
PI fluorescence allowing the differentiation of viable, apoptotic and necrotic cells. 
 
2.7.3.  Proliferation assay 
The MTS cell proliferation assay (Promega, Madison, WI) was used to measure cell growth over 
time according to the manufacturer’s instructions. The MTS dye, 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxymethoxyphenyl)-2-(4-sulfo-phenyl)-2H-tetrazolium, is converted to a 
formazan product that is soluble in tissue culture medium and quantified by its absorbance at 492 
nm. Cell numbers were counted after the desired incubation time using a Beckmann Coulter 
counter. The cell number was proportional to MTS dye conversion within the range used in these 
experiments.  
 
The day prior to the experiment cells were fed with new complete media and seeded at a density 
of 5x10
5
cells/ml. The following day, cells were washed three times in RPMI media supplemented 
with either 1% or 10% foetal calf serum, centrifuging for 5 minutes at 1500prm. Cells were then 
resuspended at 3x10
5
 cells/ml. A separate 96-well tissue culture plate was used for each time 
point (0, 24, 48 and 72hrs) and 300L of cell suspension (9x105 cells/well) was added to wells in 
triplicate. Cells were then cultivated as normal without feeding.  
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2.7.4 TNFα stimulation 
To establish whether expression of CLU in HeLa cells regulated NF-kB in a TNF-dependent or 
independent manner, cells were transfected with CLU siRNA or scrambled siRNA (section 
2.4.2).  At 24, 48 and 72 hours post-transfection the cells were stimulated with 20mg/ml TNFα 
for 3 hours. Subsequently luciferase reporter assays for NF-kB reporter activity were carried out 
(section 2.7.5).  
 
2.7.5.  Luciferase reporter assays 
The Dual-Luciferase
®
 Reporter (DLR™) Assay System provides an efficient means of 
performing two reporter assays. In the DLR™ Assay, the activities of firefly and Renilla 
luciferases are measured sequentially from a single sample. The firefly luciferase reporter is 
measured first by adding Luciferase Assay Reagent II (LAR II) to generate a luminescent signal 
lasting at least one minute. After quantifying the firefly luminescence, this reaction is quenched, 
and the Renilla luciferase reaction is initiated simultaneously by adding Stop & Glo
®
 Reagent to 
the same sample. Luciferase reporter assays for NF-ĸB activity were carried out according to the 
manufacturer’s instructions. 
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2.8.  DNA METHYLATION 
2.8.1.  DNA extraction 
Solutions 
DNA lysis buffer   Precipitating solution 
0.2 ml 10X PCR buffer  1 ml absolute ethanol 
1.8 ml D/R water   40 µl 3M sodium acetate (pH 5.2) 
10µl Tween 20   1 µl glycogen 
 
2ml of DNA lysis buffer was made up immediately prior to extractions. Pelleted cells were 
washed with 1xPBS and pelleted at 3000rpm for 5 minutes. The supernatant was discarded and 
cell pellets resuspended in 400ul of prepared lysis buffer with 13µl Proteinase K (Sigma-Aldrich 
Ltd, Gillingham, Dorset, UK Aldrich) and incubated overnight at 55°C. The following day 400µl 
phenol (Sigma-Aldrich Ltd, Gillingham, Dorset, UK Aldrich) was added to each sample and 
vortex mixed until the solution appeared milky. After centrifugation at 13000rpm for 5 minutes 
the upper phase was aspirated and transferred to a fresh tube containing 400µl phenol and 400µl 
chloroform (Sigma-Aldrich Ltd, Gillingham, Dorset, UK Aldrich). Samples were vortex mixed, 
centrifuged for 5 minutes at 13000rpm and the upper phase aspirated and transferred into a fresh 
tube containing 400µl chloroform. This was followed by a final vortex mix and centrifugation at 
13000rpm for 5 minutes. The upper phase was very carefully transferred into a fresh tube 
containing precipitating solution, ensuring that no lower phase was transferred. Samples were 
precipitated at -80°C for a minimum of 24 hours.   
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The following day samples were centrifuged at 13000rpm, 0°C for 20 minutes and the resulting 
supernatant discarded. 800µl of ice cold 70% ethanol was added, samples were vortex mixed and 
centrifuged at 13000rpm, 4°C for 20 minutes. The resulting supernatant was discarded and 400µl 
room temperature 70% ethanol added to pellets, proceeded by a vortex mix and centrifugation at 
13000rpm, 4°C for 10 minutes. After discarding the final supernatant samples were dried at 37°C 
for up to 30 minutes until all ethanol had evaporated. Finally, DNA pellets were reconstituted in 
30µl of pre-warmed Dnase/Rnase free water and stored at -20° C. 
 
2.8.2.  MSP primer design 
A source database search was carried for the gene of interest, e.g.CLU (http://genome-
www5.stanford.edu/cgi-bin/source/sourceResult). The upstream genomic sequence plus the first 
exon was retrieved and copied into the Methprimer design program 
(http://www.urogene.org/methprimer/index1.html). The desired characteristics of MSP primer 
sequences were a length of 15-30bp, G+C content of 40-60%, no stretches of sequence 
complementary within or between primers and a G or C base at the 3’ end. The options  'pick 
MSP primers' and 'use CpG island prediction' were selected to generate a graphical representation 
of the CpG island(s) and a list of suitable unmethylated and methylated primers given. Where 
possible primers were designed to meet these criteria and basic local alignment search tool 
(BLAST) searches (http://www.ncbi.nlm.nih.gov/BLAST/) were performed in all cases to ensure 
that primers were not complimentary to other regions of the genome and bound specifically to 
target sequences.  
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2.8.3.  Sodium Bisulphite modification of DNA 
In this procedure, all unmethylated cytosines are deaminated and sulfonated, converting them to 
uracils, while 5-methylcytosines are protected from this modification. Bisulphite conversion of 
DNA results in uncomplimentary single-stranded DNA molecules, and subsequent PCR analysis 
results in incorporation of thymines in the place of the converted uracils. 3M NaOH (Sigma-
Aldrich Ltd, Gillingham, Dorset, UK) was added to 1-10µg DNA and incubated at 37°C for 15 
minutes. During this incubation 3M NaOH was added to Sodium Bisulphite (Sigma-Aldrich Ltd, 
Gillingham, Dorset, UK) to give a 3.12M solution which was warmed to 37°C and kept in the 
dark. After 15 minutes pre-warmed hydroquinone (Sigma-Aldrich Ltd, Gillingham, Dorset, UK) 
was added to the sodium bisulphite and vortex mixed vigorously. 200 l of this was added to DNA 
samples, which were placed in a thermocycle and subject to 20 cycles of heating to 99°C for 15 
seconds followed by 50°C for 15 minutes and subsequently held at 20°C for a maximum of 16 
hours to avoid precipitation of the sodium bisulphite. Following this, samples were purified using 
the Wizard
®
 DNA Clean-Up System (Promega) according to the manufacturer’s protocol. 
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2.8.4.  Methylation Specific PCR 
10l of modified DNA was amplified by addition of 12.5l of 2x PCR mastermix (Promega) and 
5l of a 2.5pmole/l mix of 5’sense primers and 3’anti-sense (1:1 ratio). Reaction mixes were 
then subject to appropriate thermal cycling in a Thermal Cycler, with unmethylatd and 
methylated reactions carried out in parallel. Resulting amplified products were analysed by 
agarose gel electrophoresis a described in section 2.6.4.  
 
Step number Cycle step Time (mins) Temperature (C) 
1 Initial denaturing 5 95 
2 Denaturing 0.75 95 
3 Annealing 1 x 
4 Extension 2 72 
5 Final extension 5 72 
6 Hold/terminate HOLD 4 
      
     Table 2.10. MSP thermal cycle program 
     Annealing temperatures (x) and cycles are given in table 2.11. 
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Gene Strand Sequence Application
Annealing 
temperature (°C)
cycles Product size (bp)
sense 5'-TTT TGG TTT TTT TTT GTT TTT GGG-3'
anti-sense 5'-CCA AAC CAC TAC ATC TCC ACT-3'
sense 5'-CGG TTT TTT TTC GTT TTC GGG-3'
anti-sense 5'-CAA ACC GCT ACA TCT CCG CT-3'
sense 5'-GGT TAA TGG TTG GGT TGT GG-3'
anti-sense 5'-AAA ACC ACC AAA CTA CAA ATA CAA ATA-3'
sense 5'-TTG GTT AAT GGT AGG GTT GC-3'
anti-sense 5'-GCC GAA CTA CGA ATA CAA ATA CGA A-3'
sense 5'-ATT AGT TTG TAG TTT TGT GTT ATG-3'
anti-sense 5'-TCT TTA AAT TAA ATA TAA CTT AAA AAC ATC-3'
sense 5'-GAT TAG TTC GTA GTT TCG CGT TAC-3'
anti-sense 5'-AAA TTA AAT ATA ACT TAA AAA CGT-3'
sense 5'-GAA TTT AGG GAG TTG ATA ATG GTG G-3'
anti-sense 5'-ACA ACT AAC AAA ACT AAA ACC AAA CTA ACA-3'
sense 5-GAA TTT AGG GAG TCG ATA ATG GC-3'
anti-sense 5'-CTA ACG AAC TAA AAC CGA ACT AAC G-3'
sense 5'-GGT GTT TGT GTG GTG AAG GAA TGT AGT TGT T-3'
anti-sense 5'-TCC ACT ACA ACA ACA ACC ACC AAA TAC ACC C-3'
sense 5'-TTT GCG TGG CGA AGG AAC GTA GTC GTT-3'
anti-sense 5'-TAC AAC AAC GAC CAC CGA ATA CGC CCG-3'
sense 5'-TAT GAT TTT GAA GGG GAG TTT TGA-3'
anti-sense 5'-CCT ACT ACC CAA AAA AAA CTT CCA A-3'
sense 5'-GTA CGA TTT TGA AGG GGA GTT TC-3'
anti-sense 5'-CTA CCC GAA AAA AAC TTC CGA-3'
sense 5'-TAG GTT AGA TGT ATT TGG TGT GTG G-3'
anti-sense 5'-AAA TTC AAA TTT TAC TTT CCC CAA A-3'
sense 5'-GTT AGG TTA GAT GTA TTC GGT GTG C-3'
anti-sense 5'-ATT CGA ATT TTA CTT TCC CCG A-3'
sense 5'-TTG GGT TGT TTT TGT AGT TTT AGT TG-3'
anti-sense 5'-AAC CAA AAA CAC TAC AAC ACA CC-3'
sense 5'-GGG TCG TTT TCG TAG TTT TAG TCG-3'
anti-sense 5'-CAA AAA CGC TAC GAC GCG CC-3'
sense 5'-GGT GTA TTT TTT TTT GTT GGT TT-3'
anti-sense 5'-CTC TAA ACA CTA AAT CTA CAA CA-3'
sense 5-GTG TAT TTT TTT TCG TCG GTT C-3'
anti-sense 5'-CTA AAC GCT AAA TCT ACG ACG-3'
sense 5'-TTT ATT TAG TTT GGT TTG TGG-3'
anti-sense 5'-TTA ACA ATA AAT ATT TAA AAA ACA AT-3'
sense 5'-GTT TGT TTA TTT AGT TTG GTT TGC-3'
anti-sense 5'-TAA CGA TAA ATA TTT AAA AAA CGA T-3'
sense 5'-TGT TTT GGA TTG GGA TAG ATA GTT G-3'
anti-sense 5'-CTT TCT AAA AAC CAA AAA ATA AAA ACC A-3'
sense 5'-GTT TTG GAT TGG GAT AGA TAG TCG-3'
anti-sense 5'-TAA AAA CCG AAA AAT AAA AAC CGA T-3'
215
211
204
204
187
183
179
175
151
155
192
187
180
183
185
187
210
204
60
60
54.5
51.5
40
130
133
234
239
60
61.5
61
59
60
60
60
60
60
60
60
60
DKK3 
DKK3 
KLF4 
KLF4 
MSP
MSP
MSP
MSP
57
57
62
61
40
40
40
40
40
40
CLU 
40
40
40
40
40
40
40
40
40
RNASET2 
RNASET2 
CADM1 
AKAP12 
TIMP1 
TIMP1 
60
60
MSP
MSP
MSP
MSP
MSP
MSP
40
40
40
40
40
40
MSP
MSP
MSP
MSP
MSP
MSP
MSP
MSP
MSP
MSP
MSP
MSP
M
U
M
U
M
U
M
U
M
U
M
U
M
U
M
U
M
U
M
U
M
U
 
Table 2.11. Primers used for MSP 
All primers supplied by Alta Bioscience, UK. Stocks prepared at 100pM by dilution in RNase-
free water and stored at -20C 
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2.8.5.  Bisulphite genomic sequencing 
DNA was bisulphite modified as in section 2.8.3 and amplified as in section 2.8.4 using the 
primers and cycling conditions below. 
Gene Strand Sequence Application
Annealing 
temperature (°C)
Product size (bp)
sense 5'-GGA TAG TGA TTG TTT AAG TT-3'
anti-sense 5'-ACA CAA TCT CAC AAT TCC CTA ACC CTA C-3'
sense 5'-GTA GGG TTA GGG AAT TGT GAG ATT GTG T-3'
anti-sense 5'-TCT CTA CCT AAC TAC CAT CCC CTA C-3'
sense 5'-GTA GGG GAT GGT AGT TAG GTA GAG A-3'
anti-sense 5'-ACA AAT CTC CAA ATC TCA ATT TCC C-3'
sense 5'-GGG AAA TTG AGA TTT GGA GAT TTG T-3'
anti-sense 5'-CCT CTC CAA ACC TCA AAT TAT CAT CTA T-3'
sense 5'-TGT GTT TTG GAT TGG GAT AGA TAG T-3'
anti-sense 5'-CAC CCC CTT TAA AAC TAA CTA CAA AC-3'
sense 5'-GTT TGT AGT TAG TTT TAA AGG GGG TG-3'
anti-sense 5'-TCT CTA CCT AAC TAC CAT CCC CTA C-3'
sense 5'-TGT AGT TAG TTT TAA AGG GGG TGT G-3'
anti-sense 5'-CTC TAC CTA ACT ACC ATC CCC TAC C-3'
sense 5'-ATT GTG TTT TGG ATT GGG ATA GAT A-3'
anti-sense 5'-CAC ACC CCC TTT AAA ACT AAC TAC A-3'
sense 5'-CGC CAG GGT TTT CCC AGT CAC GAC-3'
anti-sense 5'-TCA CAC AGG AAA CAG CTA TGA C-3'
286
282
200
CLU 1
CLU 2
CLU 3
CLU 4
CLU promoter
CLU p3
CLU promoter A
317
483
254
367
282
204
60
60
60
60
60
BGS
BGS
BGS
BGS
BGS
BGS
BGS
CLU promoter B
M13
60
60
60
60
BGS
BGS
 
Table 2.12. Primers used for BGS 
All primers supplied by Alta Bioscience, UK. Stocks prepared at 100pM by dilution in   RNase-
free water and stored at -20C 
 
The resulting PCR products were subsequently cloned using the pGem T Easy Vector system II 
(Promega) according to the manufacturer’s guidelines. A minimum of 10 colonies were then 
amplified by PCR using cycling condition as in section 2.7.4 and 5µl analysed by agarose gel 
electrophoresis (section 2.6.4) to confirm inserts. The remaining amplified product was purified 
using the QIAquick PCR purification kit (Qiagen) according to the manufacturer’s instructions. 
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Sequencing was performed using the PE Applied Biosystems 3100 ABI prism
TM
 capillary 
sequencer. The labelling reactions were set up using 30-50ng of PCR product, made up to 11µl 
with sterile distilled water, 1µl (80ng) of primer, 2µl of Big-Dye
TM
 Terminator Cycle Sequencing 
Ready Reaction kit (PE Applied Biosystems) and 6µl of 2.5x sequencing buffer (200mM Tris 
HCl, 5mM MgCl2, pH9.0). The labelling PCR was run for 30 cycles at 95
o
C for 10s, 50
o
C for 5s 
and 60
o
C for 4 minutes. The labelled products were then precipitated with 50µl absolute ethanol 
and 2µl 3M sodium acetate (pH4.6) in 0.5ml eppendorfs at room temperature for 15 minutes. The 
samples were then micro-centrifuged at 20,000 x g for 20 minutes. The supernatant was removed 
and the pellet washed with 250µl of 70% (v/v) ethanol, mixed by gentle flicking and spun at 
20,000 x g for 5 minutes. The supernatant was then removed and pellets dried for at least 1hr. 
10µl of ‘Hi-DyeTM’ (Applied Biosystems) was then added to the dry tubes to dissolve the DNA 
pellet, and samples were denatured at 97
o
C for 5 minutes then put on ice immediately to prevent 
reduplexing. 
 
The buffer chambers of the 3100 capillary sequencer were filled with 2.5x EDTA buffer (PE 
Applied Biosystems) and the water chambers filled accordingly. 3100 POP6
TM
 Performance 
Optimised Polymer was used to fill the 50cm sequencer capillary array (PE Applied Biosystems). 
The 3100 data collection software version 1.0 was set for sequencing at: Dye Set, E; Mobility 
File, DT3100POP6(BD)v2.mob; BIOLIMS Project, 3100_Project 1; Run Module 1, 
StdSeq50_POP6DefaultModule and Analysis Module 1, BC-3100_SeqOff.saz. The samples were 
loaded into the appropriate 96 well plates and run for approximately 2.5hrs. Following the run, 
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the extracted data files were analysed using the ABI sequencing analysis programme version 
3.6.1. 
 
2.8.6.1.  Pyrosequencing primer design 
All primers were designed using Biotage PSQ primer design software. The genomic sequences 
were obtained from the UCSC genome browser (http://genome.ucsc.edu) and the sequences were 
then in silico bisulfite converted. The chosen sequence was used to generate both biotinylated and 
non- biotinylated primers under the allele quantification assay type settings. Primers were 
required to be no more than 200bp in length and between 18-24 bp in size. 4 sets of primers were 
designed to span the CLU promoter and after initial optimisation of the PCR reaction only set 1 
taken forward. 
Gene Strand Sequence Application
Annealing 
temperature (°C)
Cycles Product size (bp)
sense 5'-AGA TTG TGT TTT GGA TTG GG-3'
anti-sense 5'-CRC ATC ATC ACC ACR AAT AAC TAT AC-3'
Probe 5'-TGT TTT GGA TTG GGA T-3'
sense 5'-GGG TTT TTT TTG GAG TTA GTA TAG-3'
anti-sense 5'-CCA CAC ACC CCC TTT AAA-3'
Probe 5'-TTT TTT GGA GTT AGT ATA GT-3'
sense 5'-GGT ATT TTT TGG GAG TGA GTT ATG TAG GT-3'
anti-sense 5'-CCA ACT ATA TCA TCC CTC TCT ACC T-3'
Probe 5'-GTT TGT AGT TAG TTT TAA AG-3'
sense 5'-TAG GGG ATG GTA GTT AGG TAG AGA-3'
anti-sense 5'-CCA AAT CTC AAT TTC CCC ATC TTT A-3'
Probe 5'-TAC CCC CCC ACC ACA-3'
CLU 1
CLU 2
CLU 3
CLU 4
55
55
55
55
Pyrosequencing
Pyrosequencing
Pyrosequencing
Pyrosequencing
158
177
247
245
50
50
50
50
 
Table 2.13. Primers used for pyrosequencing 
All primers supplied by Alta Bioscience, UK. Stocks prepared at 100pM by dilution in   RNase-
free water and stored at -20C 
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2.8.6.2.  Pyrosequencing  
DNA was bisulphite modified for pyrosequencing using the EZ DNA methylation gold kit (Zymo 
research) according to the manufaturer’s instructions. DNA was subsequently amplified using 
25µl hotstart taq mastermix (Thermo Scientific), 5pmol biotinylated primer and 10pmol each of 
biotinylated primer and sequencing primer as in section 2.8.4 using the primers in table 2.13.  
Step number Cycle step Time (mins) Temperature (C) 
1 Initial denaturing 15 95 
2 Denaturing 0.25 95 
3 Annealing 0.5 55 
4 Extension 0.5 72 
5 Final extension 10 72 
6 Hold/terminate HOLD 4 
 
    Table 2.14. Pyrosequencing thermal cycle program 
    Steps 2-4 were repeated for 50 cycles of denaturation, annealing and extension. 
 
A Pyromark ID system (Biotage) was used for pyrosequencing reactions according to the 
manufacturer’s instructions. Briefly, 3 µl streptavidin beads (GE healthcare) in 37 µl of binding 
buffer (Biotage) had 40 µl of biotinylated PCR product added in a 96 well plate and were left 
shaking for 5 minutes at 1300 rpm. Next, 15 pmol sequencing primer and 38.5 µl annealing 
buffer were added to each well of a sequencing plate (Biotage). Beads were captured using a 
vacuum preparation tool, and lowered into each of the following solutions for 5 s: 70% ethanol, 
denaturation buffer (Biotage) and wash buffer (Biotage).  Following this, beads were released 
onto the sequencing plate, placed on a heat block at 80º C for 2 minutes and left in the machine to 
cool. The Pyrogold SQA reagents (Biotage) were loaded into the reagent cartridge and the plate 
run. 
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2.8.7.  5-aza-2-deoxycytidine cell treatment 
When cells were around 50% confluent 20µM of 5-Aza-2’-deoxycitidine (Sigma-Aldrich Ltd, 
Gillingham, Dorset, UK-Aldrich Ltd, Gillingham, Dorset, UK) was added to cell and incubated 
overnight at 37°C and 5% CO2. At 24 hour intervals for a period of 3 days both media and 5-Aza-
2’-deoxycitidine were replenished. On the 4th day media was removed and replaced with media 
containing 0.3mM Trichostatin A and cells incubated overnight at 37°C and 5% CO2. The 
following day cells were harvested as in section 2.3.2 and RNA extracted as in section 2.5.1, 
followed by cDNA synthesis (section 2.6.2), and analysis by RT-PCR (section 2.6.3).    
 
2.9.  Statistical analysis 
All statistical analyses carried out on data obtained for this research thesis (t-tests and ANOVAs) 
were performed using R and MS Excel functions. 
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3.1 Identification of candidate tumour suppressor genes in cervical neoplasia 
Promoter hypermethylation has emerged as an important mechanism for tumour suppressor gene 
inactivation. By inhibiting DNA methylation and/or HDAC activity in cells in culture, it is 
possible to reverse gene silencing and transcriptionally reactivate epigenetically silenced genes 
(Stresemann, Bokelmann et al. 2008; Stresemann and Lyko 2008). Identification of candidate 
TSG in cervical neoplasia had been previously initiated in our laboratory in an experiment in 
which the cervical cancer cell lines, HeLa, CaSki, SiHa and C33a had been treated with 5-Aza-
2’-deoxycitidine and Trichostatin A. Gene expression profiling of these cell lines subsequently 
showed that this treatment resulted in the up-regulation of 364 genes. A literature search 
confirmed that a number of these up-regulated genes were already known to be tumour 
suppressor genes at other sites of cancer. I assisted in this process of identifying candidate genes 
by searching published micro-array datasets for genes which were up-regulated by the viral 
oncogenes HPV E6/E7; or up-regulated following HPV integration; or up-regulated in invasive 
cancer compared with normal tissue (Nees 2001, Duffy 2003, Alawazi 2002). Following these 
searches, a short list of seven candidate genes was selected. Six of these genes (DKK3, KLF4, 
RNASET2, TIMP1, AKAP12, CLU) were found to be increased in a post-treatment sample 
compared to at least one pre-treatment sample, following demethylation of cervical cancer cell 
lines.  
 
DKK3 and AKAP12 had not previously been reported to be methylated in cervical tissue at the 
time of this study, but methylated forms have been reported at other sites (Jin, Hamilton et al. 
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2008; Lee, Jo et al. 2009); RNASET2 expression has been reported in cervical tissue but 
methylated forms have not been identified (Smirnoff, Roiz et al. 2006). A seventh gene, CADM1, 
was added to this list although it was not present on the array because it had recently been 
reported to be epigenetically silenced in cervical cancer (Steenbergen, 2004) 
 
3.2. Confirmation of candidate gene expression in cervical cell lines 
Before investigating whether candidate genes were up-regulated post-demethylation it was 
important to establish their baseline expression in cervical cell lines. Figure 3.1 shows, using RT-
PCR, the expression of candidate genes in the cervical cancer cell lines HeLa, CaSki, SiHa and 
C33a, compared with their expression in a primary cell line normal human foreskin keratinocytes 
(NHFK) as a positive control. GAPDH was used as a loading control for gene expression levels. 
Single discrete bands of the expected size of amplified products were detected for all genes in at 
least one of the cervical cancer cell lines.  
 
TIMP1 is equally expressed in all of the four cervical cell lines compared with NHFK.  KLF4 is 
expressed at a lower level in SiHa and C33a compared with NHFK, HeLa and CaSki, possibly 
suggesting its expression is associated with HPV infection. RNASET2 is expressed at 
comparable levels in NHFK, in the HPV 16 positive cell lines CaSki and SiHa, but expression is 
not detectable in the HPV 18 cell line HeLa and very high levels of expression were detected in 
the HPV negative cell line C33a. It expression has been previously reported in cervical tissue 
(Smirnoff, Roiz et al. 2006), however its expression was induced in HeLa post demethylation and 
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so these results are not surprising.  AKAP12 is expressed weakly but at a comparable level to that 
of NHFK in HeLa and SiHa, highly expressed in C33a and expression was not detectable in 
CaSki. It has been reported to be methylated at other sites (Jin, Hamilton et al. 2008) and so it is 
possible that it is epigenetically silenced in these HPV positive cell lines, but given that it is 
expressed in HPV 16 positive SiHa and weekly in HPV18 positive HeLa, but not in HPV 16 
positive CaSki, its expression is unlikely to be due to HPV infection. Given that its expression 
levels are comparable in NHFK, it expression in cell lines does not seem to be significant. 
 
DKK3 and CADM1 show expression in C33a comparable to that of NHFK and do not appear to 
be expressed in the three HPV positive cervical cell lines HeLa, CaSki and SiHa, which is 
consistent with the data suggesting that they are epigenetically silenced in HPV positive cervical 
cell lines (Steenbergen, Kramer et al. 2004; Lee, Jo et al. 2009), CLU on the other hand was 
expressed at a higher level in all of the cervical cell lines compared with NHFK, especially in 
C33a, which is suggested of an oncogene, not a tumour suppressor gene. Its expression is 
unlikely to be associated with HPV infection given that its expression was similar in HPV 18 
positive HeLa, HPV 16 positive CaSki and SiHa and HPV negative C33a. Variability in 
expression of all candidate genes in these cell lines might have a range of explanations, including 
the fact that different cell lines have unique origins, acquire different mutations during culture, 
and as mentioned have different infecting HPV types.  
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3.2.1. Screening of candidate gene expression pre and post demethylation of the HeLa cell 
line using RT-PCR 
Due to depletion of the RNA used in the initial demethylation experiment, and to confirm 
candidate genes, I repeated the demethylation experiment. I decided to restrict this experiment to 
the HeLa cell line because all of my candidate genes had been found to be up-regulated on the 
array in one or more of the treated replicates from this cell line.  
 
Semi-quantitative RT-PCR was used to investigate changes in the expression of candidate genes 
following demethylation of HeLa. Figure 3.2 compares the expression of the candidate genes 
under consideration in untreated HeLa cells and in HeLa cells treated with increasing 
concentrations of the demethylating agent 5-Aza-2’-deoxycitidine. The results show up-
regulation of DKK3, TIMP1, AKAP12, RNASET2, CADM1 and CLU post-demethylation. 
There is no evidence for the up-regulation of KLF4. These findings are consistent with the 
possibility that DKK3, TIMP1, AKAP12, CADM1 and CLU are epigenetically down-regulated 
in HeLa cells. The results also show that a concentration of 20µM of 5-Aza-2’-deoxycitidine is 
sufficient to increase the expression of these genes in HeLa cells. 
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3.2.2. Screening of candidate gene expression pre and post demethylation of HPV 18 
transfected cervical and foreskin keratinocyte cell lines using RT-PCR  
To establish whether epigenetic silencing of the candidate genes occurred in a wider panel of cell 
lines I extended these experiments to include the demethylation of untransformed cell lines. I 
examined the impact of demethylation on two human keratinocyte cell lines: one of these was a 
cervical keratinocyte cell line transfected with HPV 18; and the other, a foreskin keratinocyte cell 
line also transfected with HPV18. Figure 3.3 compares the expression of the candidate genes 
under consideration in untreated cells and in cells treated with 5-Aza-2’-deoxycitidine. The 
results show up-regulation of DKK3, TIMP1 and CADM1 following demethylation of both cell 
lines, and are consistent with these genes being epigenetically regulated. AKAP12 and CLU were 
up-regulated post demethylation of the HPV18 positive foreskin keratinocytes but not following 
demethylation of cervical keratinocytes. Furthermore, CLU was not expressed in pre or post 
treatment cervical keratinocytes. 
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 3.3. Investigation of the presence of methylated forms of candidate tumour suppressor 
genes in cervical cancer cell lines 
Methylation of epigenetically silenced genes often occurs at their promoters (Gronbaek, Hother et 
al. 2007). To establish the methylation status of the promoters of the candidate genes, I used 
methylation specific PCR (MSP) to determine the presence or absence of methylated and 
unmethylated DNA in the cervical cancer cell lines HeLa, CaSki and C33a (Figure 3.4). Single 
discrete bands of the expected size of amplified PCR products were detected for all primer sets 
and controls behaved as expected throughout. This is with the exception of the MSP for 
RNASET2 which infrequently produced a doublet of bands at the expected size of the amplified 
product. Where evidence of methylation was detected, results were repeated alongside 
unmethylated PCR reactions to confirm that the results were reproducible.  
 
DKK3 appears almost entirely as methylated forms in HeLa and CaSki, with a weak 
unmethylated band also present in CaSki, whereas in C33a the presence of both  methylated and 
unmethylated forms can be detected. TIMP1 and CADM1 are methylated in all three cell lines, 
but for KLF4 and RNASET2 only unmethylated forms can be detected. AKAP12 is 
unmethylated in HeLa and C33a, with detection of both methylated and unmethylated forms in 
CaSki. CLU is methylated in CaSki compared with the detection of unmethylated and methylated 
forms in HeLa and C33a; interestingly it is very heavily methylated in the HPV negative cell line 
C33a. The presence of both unmethylated and methylated products could be due to a mixed cell 
population with some cells being methylated while others are not, or mixture of methylated and 
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unmethylated alleles within these cell types reflecting that the population as a whole is 
heterogeneous. Of the six genes which showed a change in expression following demethylation 
of HeLa, four were found to be methylated in this cell line (DKK3, TIMP1, CADM1 and CLU), 
and two were not (AKAP12 and RNASET2). It is possible that AKAP12 and RNASET2 are 
regulated by acetylation since they were not methylated in HeLa yet showed transcriptional up-
regulation post treatment with 5-Aza-2’-deoxycitidine and Trichostatin A. KLF4, which showed 
no change in expression following demethylation of HeLa, was found to be unmethylated in this 
cell line.  
 
With the exception of KLF4, no change in methylation status was detected by MSP for any of the 
candidate genes post demethylation of HeLa cells (Figure 3.5). We would have expected to see 
an increase in the amount of unmethylated form and a decrease in methylated. However, the 
technique of MSP is naturally biased towards the detection of methylated forms and the PCR for 
unmethylated forms is not as sensitive as that for the methylated. MSP is not a quantitative 
method and small changes in methylation status will be easily missed, thus further analysis using 
a quantitative method such as bisulphite genomic sequencing is required before conclusions can 
be drawn. Human male DNA was used as a methylated control, and human foetal DNA as an 
unmethylated control. Whereas methylated control DNA always tested positive for methylated 
forms, a satisfactory unmethylated control was difficult to obtain. Both the commercially 
available unmethylated controls, and PBMCs isolated from laboratory donors, did not always test 
positive for unmethylated product, and when they did, they often yielded both methylated and 
unmethylated product. Therefore, the presence of a weak unmethylated product from any of the 
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genes tested cannot be ruled out since MSP is known to be biased towards detecting methylated 
DNA even when only 0.1% of alleles are methylated (Herman, Graff et al. 1996; Liu and 
Maekawa 2003). 
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3.4. A longitudinal investigation of epigenetic and transcriptional changes in candidate 
genes using the W12 cell line disease-progression model 
The W12 cell line was originally generated from a woman with HPV 16 associated low-grade 
CIN (Stanley, Pett et al. 2007). At low passage, the cell line contains approximately 100 HPV 
episomes per cell and with serial passaging there is episomal loss and integrated clones emerge. 
Episomal W12 cells recapitulate the phenotypic characteristics of CIN I. When grown in 
organotypic raft culture, W12 cells have been shown to become progressively more dysplastic in 
successive passage. Therefore W12 cells can be used as an in vitro model for the longitudinal 
study of epigenetic changes contributing to disease progression.  
 
Using MSP, I investigated the methylation status of candidate gene promoters in passage 11 of 
the W12 cell line, where there are still some episomal clones and the integrated passage 22.  
Figure 3.6 compares the methylation status of the candidate genes under consideration in these 
passages. Methylated forms for KLF4, RNASET2 and AKAP12 cannot be detected in either the 
pre- or post-integration passage of W12. DKK3 is unmethylated in passage 11 and becomes 
methylated by passage 22. TIMP1, CLU and CADM1 are weakly methylated at passage 11 and 
become heavily methylated by passage 22 of W12.  This phenotype of progressive increase in 
methylation for DKK3, TIMP1, CADM1 and CLU was confirmed when the methylation status of 
these genes was examined in the intervening passages between 11 and 22 (Figure 3.7) However, 
these data are not quantitative, and changes in methylation status measured using pyrosequencing 
will be described in section 3.7. 
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Notwithstanding these changes in methylation status, there was no compelling evidence of 
transcriptional down-regulation on serial passage of W12 (Figure 3.8). However, there does 
appear to be some up-regulation of DKK3 and TIMP1 between passages 11 and 13 as there is 
episomal loss in W12. For other genes it is possible that transcriptional changes in any of the 
candidate genes are so slight that they cannot be detected by RT- PCR; this possibility is explored 
in a subsequent section by testing for transcriptional changes using Q RT-PCR (section 3.6) 
Alternatively, if the lack of transcriptional change is real, then it is possible that the increases in 
promoter methylation observed are insufficient to affect transcriptional change, or that 
methylation may precede transcriptional changes which will only become apparent in passages of 
the W12 beyond those tested here. 
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3.5. Re-evaluation of candidate genes  
At this stage, based on their expression and methylation status in cervical cancer cell lines and the 
W12 cell line model, the genes DKK3, TIMP1, CADM1, AKAP12 and CLU were taken forward 
for analysis in vivo. KLF4 was not pursued as methylated forms could not be detected in the 
cervical cancer cell line HeLa, CaSki and C33a or in the W12 model, nor was it transcriptionally 
up-regulated post demethylation. RNASET2 demonstrated transcriptional up-regulation post 
demethylation of HeLa and normal human foreskin keratinocytes transfected with HPV18 
(NHFK), however was unmethylated by MSP in cervical cancer cell lines. DKK3, TIMP1, 
CADM1, AKAP12 and CLU were all up-regulated at the RNA level post demethylation of 
HPV18 positive HeLa, NHCK and NHFK. In addition, methylated forms could be detected in the 
three cervical cell lines, HeLa, CaSki and C33a for DKK3, TIMP1, CADM1 and CLU, and in 
CaSki for AKAP12. With serial passage of the W12 cell line model all five of these genes 
showed an increase in promoter methylation, coinciding with loss of episomes and viral 
integration. It has been shown by other groups that CADM1 gene silencing via promoter 
hypermethylation is a frequent event in the progression from high-risk HPV-containing, high-
grade CIN lesions to invasive cervical cancer (Steenbergen, Kramer et al. 2004; Overmeer, 
Henken et al. 2008). 
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3.6. Pattern of candidate gene expression in cervical cancer, CIN and normal tissue 
 To evaluate the expression of the candidate genes DKK3, TIMP1, AKAP12, CADM1 and CLU 
in more detail, their expression at the RNA and protein level was investigated in cervical tissue.  
Two cohorts have been set up including one natural history cohort which included women who 
were referred for investigation of cytological abnormality; this cohort was be used for correlation 
of methylation of the CLU promoter to changes in CLU expression. A further study population 
included 37 paraffin fixed sections of cervical intraepithelial neoplasia, including CIN I, II and 
III, which were used to validate expression of candidate genes. Details of both cohorts are 
described in materials and methods chapter 2.2.  
 
3.6.1. RNA expression in CIN 
RT-PCR was used to investigate the pattern of expression of candidate genes in RNA extracted 
from fresh frozen biopsies taken from women with CIN as part of a cohort study (described 
above). Expression levels were compared with those seen in normal human foreskin 
keratinocytes (NHFK). The results show that all genes were expressed in NHFK (Figure 3.9). 
TIMP1 is expressed in all patients; DKK3 was weakly expressed in some samples, (patients 1, 2, 
4 and 5) but not in others (3, 6, 7, 8, and 9). CADM1, AKAP12 and CLU are not expressed in 
any of the patient samples tested. 
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3.6.2  Protein expression in cervical cancer, CIN and normal tissue 
The pattern of protein expression of candidate genes was investigated in a panel of 37 biopsies 
taken from women with cervical intraepithelial neoplasia (CIN) and compared to biopsies taken 
from normal cervical epithelium. The pattern of expression of each of the candidate genes was 
first assessed in control tissue. The AKAP12 antibody stains outside of the germinal centre and in 
blood vessels with very few positive cells in the germinal centre.   The DKK3 antibody stains 
kidney cells in the cytoplasm. TIMP1 is distinctly cytoplasmic in normal breast tissue. Strong 
clusterin expression in the germinal centre and a few positive staining in the mantle zone.  The 
CADM1 antibody available at the time of this investigation was poor quality, very occasionally 
staining in the germinal centres, but on the whole was largely negative.  
 
Prior to staining a panel of normal cervical epithelium and CIN, sections were stained with 
haematoxylin and eosin to examine the morphology of the cells and confirm their diagnosis 
(Figure 3.10). In normal squamous epithelium section shows normal keratinised squamous 
epithelium. In CIN I there are dysplastic squamous cells involving lower one third of the entire 
epithelium. The cells exhibit large hyperchromatic nuclei with abundant cytoplasm. In CIN II 
dysplastic squamous cells involving lower two third of the epithelium. The cells exhibit high 
nuclear-cytoplasmic ratio. In CIN III dysplastic cells involve the entire thickness of the squamous 
epithelium. Koilocytic changes are apparent. 
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Immunohistochemical staining of a panel of 37 cases of CIN compared with normal cervical 
tissue revealed an up-regulation of CLU and no difference in expression of DKK3, TIMP1 and 
AKAP12 between normal cervical epithelium and high grade CIN, as summarised in figure 3.11 
and in table 3.1. AKAP12 staining in CIN III shows hyperchromatic nuclei with cytoplasmic and 
weak nuclear staining; nuclear in areas of necrosis which are immunoreactive. CADM1 results 
could not be interpreted as the antibody available at the time of this study was of poor quality and 
unsuitable for immunohistochemistry. The most striking pattern of staining was that of CLU, 
which demonstrated only sparse, weak expression in CIN I and was strongly positive in CIN III 
and there was an absence of staining in invasive tissue. In CIN a regular basal layer and 
underlying stroma is evident, with the differentiated squamous epithelium showing strong 
cytoplasmic staining of CLU. In contrast, in adenocarcinoma and squamous carcinoma of the 
cervix there is a complete absence of CLU staining. Where CLU staining was present in cervical 
tissue it was always cytoplasmic in localisation, not nuclear, which is in agreement with 
published data using these CLU antibodies for staining of paraffin fixed tissues (Ha and Califano 
2006; Park, Yeo et al. 2006; He, Liu et al. 2009). Cytoplasmic expression of CLU is consistent 
with an anti-apoptotic function and since no necrotic tissue was present in these tissue sections of 
normal cervical epithelium and CIN no pro-apoptotic nuclear CLU was detected (Albert, 
Gonzalez et al. 2007).  
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Table 3.1: Immunohistochemical staining of normal cervical tissue and
cervical intraepithelial neoplasia (CIN).
AKAP12, DKK3 and TIMP1 show little or no expression in cervical sections,
however compared with normal cervical epithelium CLU is up-regulated in
CIN and down-regulated in invasive disease compared to CIN
Cervical sample Comment Diagnosis AKAP12 DKK3 TIMP1 CLU
3805 no squamous epithelium Normal 1+/- - -
1783-93 no squamous epithelium, endothelial glands +ve Normal no squamous no squamous -
1783 endothelial glands +ve Normal - no squamous -
6429-4-93 no squamous epithelium, endo Normal -
4066 squamous epithelium Normal 1+/- - - -
4401 squamous epithelium Normal - - - -
4546 HPV +ve koilocytes CIN I 1+/- - 1+
3671 HPV +ve koilocytes CIN I - - - 2+
6429 HPV +ve koilocytes CIN I - - - -
6429-A-93 HPV +ve koilocytes CIN I -
6476 HPV +ve koilocytes CIN I - - - 1+
5591 HPV +ve koilocytes CIN I - - - -
6379-2 HPV +ve koilocytes CIN I - - - -
6379-6 HPV +ve koilocytes CIN I - - -
6030 HPV +ve koilocytes, fragmented CIN I no squamous 1+/- no squamous 1+
0009-B8-93 HPV +ve koilocytes, little epithelium CIN I - - - -
5758-3-93 HPV +ve koilocytes CIN I/II - - - 2+/3+
2545 HPV +ve koilocytes CIN II - - - 2+
6550-B1-93 HPV +ve koilocytes, squamous CIN II - 2+
6152 HPV +ve koilocytes, endo cervical glands +ve CIN II - - - 1+
6821 HPV +ve koilocytes, endo cervical glands +ve CIN II 1+
6550 HPV +ve koilocytes, normal cells -ve, not squamous, dysplastic CIN III - 1+/- - 1+
6235 HPV +ve koilocytes CIN III - - - 3+
6373 HPV +ve koilocytes CIN III - - - -
6738 HPV +ve koilocytes CIN III - - - -
5952 HPV +ve koilocytes CIN III - - - 2+
5588 CIN III - - - 1+
6379-3 HPV +ve koilocytes CIN III - - - 1+
6378-5 HPV +ve koilocytes CIN III - 1+
6146 HPV +ve koilocytes, endo cervical glands +ve CIN III - - - 1+/-
6011 HPV +ve koilocytes, endo cervical glands +ve CIN III - - - 2+
6276 HPV +ve koilocytes, endo cervical glands +ve CIN III - - - 1+
5669 HPV +ve koilocytes, endo cervical glands +ve CIN III - - - 1+/-
6829-93 HPV +ve koilocytes, endo cervical glands +ve CIN III - - - 2+
6267-93 CIN III - - - 2+
6233 staining at periphery of tissue CIN III - - - 2+
6615 CIN III - - - 1+
6985 CIN III - - - -
6231 HPV +ve koilocytes CIN III - - - 1+
6750 HPV +ve koilocytes CIN III - - 1+/-
6150 CIN III - - - 1+/-
6218-2-93 patchy staining pattern CIN III - - - 2+
6211-2-93 HPV +ve koilocytes CIN III - - - 1+/-
6221-2-93 HPV +ve koilocytes CIN III - - - 1+/2+
15763 Adenocarcinoma - - - -
6293 Adenocarcinoma - - 2+ -
18091 Adenocarcinoma - - 1+/- -
1355 Squamous carcinoma - - - -
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3.7. Selection of a final candidate gene 
The validation of the 7 candidate genes was narrowed down to five genes for further validation in 
vivo. Although there was some down regulation of DKK3 at the RNA level in patient samples, 
this did not translate to the protein level with no difference detected between normal cervical 
epithelium and CIN, which could possibly be due to the poor quality of the antibody but a better 
commercial antibody was not  available at the time of this study. TIMP1 was expressed in all 
patient samples at the RNA level at a comparable level to its expression in normal human 
foreskin keratinocytes, with no evidence of down regulation. At the protein level there appeared 
to be little difference in expression between normal cervical epithelium and CIN, with some up-
regulation in 50% of invasive cancers. AKAP12 was down-regulated at the RNA level in patient 
samples compared with normal human foreskin keratinocytes but showed little difference in 
expression at the protein level between normal cervical epithelium and CIN. The antibody 
commercially available at the time of this study for CADM1 was of poor quality and not suitable 
for immunohistochemistry and so this gene could not be validated in vivo. Given the striking 
pattern of CLU expression in patient samples, being up-regulated in CIN and then down-
regulated in invasive cancer this is the gene I took forward for further in vitro and in vivo 
validation. 
 
To summarise at this stage, CLU was up-regulated in the initial demethylation experiment 
performed in my laboratory. Using MSP, the CLU promoter was found to be methylated in HeLa, 
Caski and C33a cell lines. Furthermore, when the demethylation experiment was repeated I was 
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able to confirm that CLU was up-regulated in the HeLa cell line following demethylation.  
Preliminary results, using MSP, also illustrated an increase in methylation of the CLU promoter 
in successive passage of the W12 cell line. However, I was not able to show a compelling change 
in CLU expression at the transcriptional level with increasing passage number.  
 
An up-regulation of clusterin at the protein level using immunohistochemical staining has been 
confirmed by Dr Maizaton Abdullah. In normal tissue, a regular basal layer and underlying 
stroma is evident, with the differentiated squamous epithelium showing strong cytoplasmic 
staining of CLU. In CIN there is an up-regulation of CLU, but a complete absence of CLU 
staining in invasive cancer. CLU was therefore investigated in a larger number of cervical 
samples (section 3.7.2). 
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3.8. Further investigation of clusterin as a candidate tumour suppressor gene 
Having identified CLU as potential tumour suppressor gene, it was necessary to confirm the 
results of previous RT-PCR using quantitative RT-PCR, confirm the changes in protein 
expression in a wider cohort of cervical samples and with different CLU antibodies, and to 
confirm MSP results using bisulphite genomic sequencing and pyrosequencing. 
 
3.8.1. Evaluation of changes in expression of CLU by Q RT-PCR 
Before CLU expression could be validated by Q RT-PCR this technique itself needed to be 
validated by making sure that multiplexing the reaction did not result in competitive 
amplification, by optimising the amount of input cDNA for exponential amplification and by 
finding an appropriate house keeping gene. 
 
3.8.1.1   Optimisation of CLU Q RT-PCR 
In multiplexing the reaction I needed to confirm that the two probes, one separate for the 
housekeeping gene and the other CLU, did not compete for amplification of the gene product and 
so not exhausting an entire reagent before the other has amplified. To address this issue, initial 
reactions were carried out in both singleplex and multiplex assays. Figure 3.12 shows no 
competitive amplification. Equally, ten-fold dilutions of cell line cDNA were used in titrations of 
1ug, 100ng, 10ng, 1ng, 100pg, 10pg, to determine the exponential region for amplification of 
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both target and endogenous control; which was found to be between 100ng and 10ng, thus 50ng 
of cell line cDNA was used in all experiments. 
 
It is essential to test a number of housekeeping genes to determine which one shows least 
variation in cell types or data sets. Four commonly used housekeeping genes, Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), Phosphoglycerate kinase 1 (PGK1), Beta-2 microglobulin 
(B2M) and 18S ribosomal RNA (18S) were validated as potential endogenous controls for 
expression of clusterin in cervical cell lines (Figures 3.13 and 3.14). Of the four housekeeping 
genes, B2M gave the most consistent amplification across all cell lines and figure 3.15 illustrates 
how variable the interpretation of gene expression data can be due to variation in housekeeping 
genes. There is a requirement to identify housekeeping type genes that show sample independent 
stability and studies have found that newly identified genes, that are not necessarily housekeeping 
genes, were more stably expressed in individual samples with similar ranges. Thus, statistical 
analysis of microarray data can be used to identify new candidate housekeeping genes showing 
consistent expression across tissues and diseases. 
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3.8.1.2. Q RT-PCR analysis of CLU expression in HeLa cell lines 
Q RT-PCR using the housekeeping gene B2M verified the pattern of expression of CLU using 
RNA from the HeLa demethylation experiment. Figure 3.16 compares the expression of CLU in 
untreated HeLa cells and in HeLa cells treated with increasing concentrations of 5-Aza-2’-
deoxycitidine. The results show up-regulation of CLU post demethylation and are consistent with 
those obtained using end point PCR (Figure 3.2).  
 
3.8.1.3. Q RT-PCR analysis of CLU expression in the W12 cell line model 
Transcriptional changes of CLU and CADM1 were validated in serial passage of the W12 cell 
line. CADM1 was included given that is a known tumour suppressor gene in cervical cancer, and 
hence was included for comparison in further validation of CLU. Figure 3.17 illustrates down 
regulation of CADM1 with serial passage as it becomes increasingly methylated. In contrast, 
CLU appeared not to be downregulated during serial passage of W12 cells. 
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3.8.2. Pattern of CLU protein expression in cervical tissue and cell lines 
Having demonstrated that CLU was up-regulated in CIN compared with normal cervix using a 
commercially available antibody from Vector, the same cohort was examined with two further 
CLU antibodies. Both of these other antibodies when assessed by 2 pathologists, Dr Terry 
Rollason and Dr Maizaton Abdullah, who were blinded to the previous data confirmed the data 
obtained from the previous antibody, showing increased staining for CLU in high grade CIN 
compared with normal cervical epithelium (Table 3.3). Similarly, examination of a wider cohort 
of adenocarcinomas and squamous cell carcinomas of the cervix with 3 CLU antibodies 
confirmed its downregulation in invasive cancer (Table 3.4). Immunohistochemistry showed an 
up-regulation of CLU at the protein level in HeLa, CaSki and SiHa compared with NHFK (Table 
3.5). With serial passage of the W12 cell line there was no apparent change in CLU protein 
expression. 
  
In order to validate the specificity of the CLU antibodies, the expression of CLU at the protein 
level in cell lines was investigated using western blotting. Figure 3.17 shows increased 
expression in HeLa, CaSki and SiHa when compared with C33a and normal human foreskin 
keratinocytes, as was seen in the cytospins. In HeLa and CaSki there is 45kDa band in addition to 
the 60kDa and 40kDa proteins observed in all the cell lines, which is the molecular weight 
corresponding to nuclear CLU. CLU transfected HEK 293 cell lysates were ran alongside as a 
positive control for CLU protein expression. Western blotting of W12 passage 15 and 56 cell 
lysates showed no change in CLU expression between the passages and confirmed results 
obtained by immunohistochemistry of cell lines. 
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3.8.3. Evaluation of the methylation status of the CLU promoter  
MSP is limited as it can only provide information on the CpG residues in the primers and not 
across the whole promoter and CpG island, so other techniques are required for a more detailed 
analysis of promoter methylation, such as bisulphite genomic sequencing. Figure 3.19A shows 
the two CLU transcripts and the predicted CpG island within the promoter region. Figure 3.19B 
illustrates the location of the MSP primers (blue underlined text) in the CLU promoter (pink), 
with the abundance of CpG dinucleotides highlighted in yellow.   
 
3.8.3.1. Methylation of CLU in HeLa and control DNA using bisulphite genomic sequencing 
Bisulphite genomic sequencing (BGS) was used to determine the pattern of promoter methylation 
across the entire CpG island in the promoter region of CLU in DNA extracted from HeLa. This 
confirmed the presence of the same methylated CpGs as detected by MSP analysis. However, as 
Figure 3.20 shows, less than 5% of HeLa cells show CLU methylation by BGS. This emphasises 
the bias and sensitivity of using MSP to detect methylation, which had previously given the false 
impression that HeLa cells were heavily methylated when in fact quantification by BGS has 
shown that only a small proportion of the CpGs are truly methylated. For comparison purposes, 
figure 3.21 shows an entirely unmethylated CLU promoter, with very low methylation of the 
adjacent CpG rich region in normal human cervical keratinocytes. Interestingly, BGS analysis 
shows that in positive methylated control DNA the CLU promoter is in fact unmethylated, but the 
adjacent CpG rich region is heavily methylated (figure 3.22).  After these data were obtained the 
University of California Santa Cruz (UCSC) website changed its prediction of the CLU promoter, 
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and gave a new prediction that matched up with the heavily methylated CpG rich region of CLU, 
thus reinforcing this conclusion. 
 
Methylation specific PCR is typically not very informative about methylation of CpG islands as it 
only provides methylation data for CpG di-nucleotides that are located where the primers lie. 
Figure 3.23 shows that the CpG di-nucleotides within the primers were heavily methylated, 
which explains my previous result which had shown a strong methylated band by MSP (section 
3.3); whilst the CpGs in-between are predominantly unmethylated. This led to a premature 
conclusion that in HeLa cells the CLU promoter was heavily methylated. The heavy methylation 
of the few CpG dinucleotides identified appears to have some regulation on CLU transcription, 
given that subsequent treatment of HeLa with 5-Aza-2’-deoxycitidine was sufficient to cause an 
increase in CLU expression. However, it is possible that this is an result of the acetylation by 
Trichostatin A and not a result of demethylation as no change in methylation status could be 
detected by MSP post treatment with 5-Aza-2’-deoxycitidine. Alternatively, this could be a non-
specific effect on CLU expression by the treatment itself. 
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3.8.3.2. Methylation of CLU in cervical cancer cell lines using pyrosequencing 
Pyrosequencing was used to confirm the pattern of promoter methylation of CLU in DNA 
extracted from cervical cancer cell lines and in the W12 cell line model. 4 sets of pyrosequencing 
primers were designed to span the entire CLU promoter and were tested initially on both the 
commercially available unmethylated and methylated controls. The set of primers that gave the 
most reproducible data with successive runs was taken forward for analysis in all DNA samples. 
Table 3.6 and figure 3.24 show methylation in 5 CpG dinucleotides of the CLU promoter and 
their means.  These 5 CpGs were selected as they were shown to be preferentially methylated by 
bisulphite genomic sequencing analysis. In HeLa cells the mean methylation was 12%, 62% in 
CaSki, 13% in SiHa and 64% in C33a, with unmethylated control DNA giving 5% methylation 
and methylated control DNA 91%. When HeLa cell were treated with 5-Aza-2’-deoxycitine there 
was no significant reduction in mean methylation from 15% to 14%, although there are slightly 
larger differences in the first two CpG dinucleotides showing a decrease from 16 % to 13% and 
22% to 17%  respectively. This provided further confirmation that in HeLa cells the CLU 
promoter is not regulated by DNA methylation. The high level of methylation in CaSki and C33a 
suggests that other cervical cell lines still may be epigenetically regulated by DNA methylation. 
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3.8.3.3. Methylation of CLU in primary human cervical keratinocytes and W12 using 
pyrosequencing 
NHFK showed a similar methylation to that of HeLa, a result consistent with that obtained by 
BGS. When NHCK were transfected with HPV18 there was a much higher level of methylation, 
with a mean CLU promoter methylation of 31%. W12 passages showed variation in methylation 
status, with methylation increasing from 8% to 16% from passage 9 to 11, decreasing to 3% in 
passage 12 and then increasing from passage 21, returning to a mean methylation of 14% in 
passage 58. These slight changes in methylation may be responsible for the variation seen in 
RNA expression in these passages (section 3.3). It is possible that the changes in methylation 
status between passages 9 and 11 may be related to the loss of episomes and HPV integration. 
 
3.8.3.4. Analysis of methylation of the CLU promoter in primary tissue by pyrosequencing 
As we have seen by immunohistochemical staining, CLU expression is increased in CIN and then 
down-regulated in invasive disease. In order to validate the relevance of any correlating 
epigenetic changes in vivo, a natural history cohort was used that included women who were 
referred for investigation of cytological abnormality, as described earlier. However, these women 
were not treated immediately, as usually happens, but instead they were kept on follow up to see 
if their disease spontaneously regressed. Women who progressed to high grade CIN were treated 
immediately. Therefore, we can compare the patterns of epigenetic change in those women who 
progressed and in those who did not. The risk of high grade CIN can potentially be related to the 
presence of epigenetic changes in baseline material taken at the time of study entry. 
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Table 3.7 shows the percentage methylation of 5 CpG dinucleotides within the CLU promoter in 
DNA extracted from cervical smears of 14 women with CIN. These cases are matched against 1, 
2 or 3 controls that showed either progression to higher grade abnormality or no change in CIN. 
These show both increases and decreases in the methylation status of the CLU promoter. Changes 
in methylation were small with both increases and decreases in methylation status associated with 
disease progression and no change in disease. However, overall an increase in methylation status 
correlated with disease progression from CIN I to CIN II and CIN III. If this is compared with 
expression of CLU at the protein level, there was a transient increase in CLU expression between 
normal cervical epithelium and high grade CIN and a down-regulation of CLU or loss of CLU in 
invasive disease. This down-regulation in invasive cancer preceded the overall increase in 
methylation of the CLU promoter and could be a consequence of CLU methylation. However, the 
fact that there were both increases and decreases in methylation of CLU means that no conclusion 
can be drawn from this subset and analysis is required in a wider cohort of patient samples.    
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 3.9. Summary of results 
Following a promising set of microarray results and a thorough literature review, I have 
investigated seven genes which I believed to be candidate tumour suppressor genes in cervical 
neoplasia. Although KLF4 and RNASET2 were up-regulated post-demethylation of the HeLa 
cell line, oddly methylation could not be detected in cervical cancer cell lines and so these genes 
were not pursued as candidates. AKAP12 showed variable methylation is cervical cancer cell 
lines, but no change in expression in CIN compared with normal cervical epithelium. Having 
found it to be hemi-methylated in HPV16 positive CaSki, the absence of any methylation in pre 
and post integration passages of W12 was unexpected. I might have expected to see methylation 
of AKAP12 in late but not early passages of W12, with methylation being associated with viral 
integration. This is because in CaSki cells methylation is accompanied by more than 600 
integrated HPV-16 copies present; however this was not the case in my results. DKK3, TIMP1, 
CLU and CADM1 were methylated in cervical cell lines and showed progressive increase in 
methylation with serial passage of the W12 cell line. Unfortunately, no convincing down-
regulation of these genes was seen with serial passage of W12; although it is possible that the 
methylation may precede transcriptional changes which will only become apparent in passages of 
the W12 beyond those tested. These four genes showed little or no expression in RNA extracted 
from cervical cancer patients, however these expression patterns were not substantiated at the 
protein level in the staining of cervical tissue, which showed no difference in expression between 
CIN and normal cervical samples.  
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The starting point of pursuing CLU as a candidate tumour suppressor gene in the pathogenesis of 
cervical neoplasia was the finding that CLU was up-regulated in the initial demethylation 
experiment performed in my laboratory. CLU was found to be methylated by MSP in cervical 
cancer cell lines and this was confirmed by pyrosequencing, with 50% of the cervical cell lines 
showing high levels of methylation of the CLU promoter. However, although 20 fold up-
regulation of CLU was seen post-treatment of the HeLa cell line with 5-Aza-2’-deoxycitidine and 
TSA, the cell line showed low levels of methylation between 5 and 15% by BGS and 
pyrosequencing. Additionally, when pyrosequencing was carried out on the demethylated HeLa, 
no significant change in methylation status was detected; this would suggest that the substantial 
up-regulation post-treatment of HeLa is more likely to be due to acetylation by the Trichostatin 
A.  In the W12 cell line model, there was variation in the methylation status of CLU with a 
distinct up-regulation of CLU between passages 9 and 11 proceeded by a significant decrease in 
methylation in passage 12; these changes in the methylation status of the CLU promoter may be 
related to the loss of episomes and viral integration. 
 
Methylation of CLU in cervical cancer was initially identified by Methylation Specific PCR, 
which is although is a very sensitive technique, it is biased towards the detection of even low 
levels of methylation, which could potential give false positive results. For example, in the HeLa 
cell line the CLU promoter was thought to be heavily methylated based on methylation detection 
by MSP, yet quantitative analysis by bisulphite genomic sequencing and pyrosequencing 
revealed only a small promotion of cells are methylated. Also, when this cell line were 
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demethylated in vitro it was also treated with the acetylating agent trichostatin A and so 
expression changes observed may not solely be due methylation, as discussed in chapter 6.16.1.  
 
When cohorts of women with CIN were analysed at the protein level, there was an up-regulation 
of CLU in high grade CIN compared with normal cervical epithelium, with a down-regulation or 
loss of CLU expression in squamous carcinoma and adenocarcinoma of the cervix. Q RT-PCR 
data is not entirely convincing given the inherent problems of housekeeping gene normalisation 
and is discussed in Chapter 6. Protein expression data is more reliable as it is not subject to the 
same sensitivity issues when comparing gene expression to housekeeping gene expression. 
 
In DNA extracted from cervical smears from women with CIN the majority showing an increase 
in methylation status correlating with disease progression from CIN I to CIN II and CIN III. All 
of the methylation frequencies seen in cervical smears were much lower than those in the cervical 
cell lines, with the exception of the HeLa cell line, suggesting that cell lines do not accurately 
represent the gene methylation frequencies observed in vivo, which is further discussed in chapter 
6.16.4. However, the methylation status of the CLU promoter was only examined in CIN and not 
in invasive disease, and had we examined invasive tumour samples the methylation frequencies 
could have been much higher, especially given the expression of CLU was very low level or lost 
in squamous and adeno-carcinoma samples examined. Alternatively, it is possible that high levels 
of methylation could be a feature of a small subset of cervical tumours.  
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Moreover, the story may not simply be confined to the cervix. For example, when Dr John 
Arrand used SNP analysis in the NPC cell line C666-1, this highlighted a possible deletion 
encompassing the clusterin locus on chromosome eight. Victor Lopes, a head and neck surgeon, 
has illustrated a possible deletion at this locus in oral cancer tissue samples. Gene expression 
profiling has also demonstrated that compared with disease free controls, a down-regulation of 
CLU is observed in the vast majority of oral cancers taken from patients in the UK and Sri Lanka. 
Microarray analysis has also shown that compared with disease free controls, a down-regulation 
of CLU in 18 of 25 NPC samples. There is therefore a compelling case for considering clusterin 
as a putative tumour suppressor gene in squamous cancer. 
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Investigation of the role of 
clusterin in oral and 
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Overview 
To further investigate the role of CLU in squamous cancer, I next set out to investigate the 
expression of CLU, and its regulation in oral and nasopharyngeal cancer. I first outline the 
reasons which led me to explore a possible tumour suppressor role for CLU in the pathogenesis 
of these cancers. Then, for each cancer in turn, I describe using cell lines and whole tissue how 
the expression of CLU varies at the RNA and protein level with disease state. I next report how 
methylation of the CLU promoter varies across these samples. In the section on nasopharyngeal 
cancer, I examine the possibility that CLU expression in the NPC cell line Ad-AH might be 
regulated by EBV or its latent genes. Finally, I focus in some detail on the NPC cell line C666-1 
which is a potential model for exploration of the consequences of restoring CLU expression, and 
its possible mechanism of action.  
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4.1. Reasons for investigating the expression of CLU, and its regulation in oral cancer 
The decision to investigate the expression and regulation of CLU in oral cancer was prompted by 
the results of a microarray experiment performed by Dr Victor Lopes, a PhD student in the 
Institute for Cancer Studies. The tissue samples included in this array were collected from oral 
cancer patients in the United Kingdom and in Sri Lanka (Kandy). Samples from each region were 
analysed separately in order to avoid potential confounding factors caused by different 
geographic localities, such as ethnicity, environment and diet, which can give rise to distinct 
origins in certain diseases. The analysis revealed the down-regulation of CLU in 21 out of 25 UK 
oral cancers and all 27 Kandy tumours when compared with tissue samples from 5 cancer-free 
controls (Figure 4.1). Down-regulation of CLU in 11 of 12 of these oral cancers was confirmed 
using Q RT-PCR by Ms P Gan, a BMedSci student attached to the Institute (Figure 4.2).  
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4.1.1. Expression of CLU at the RNA level in oral cancer cell lines 
The expression of CLU at the RNA and protein level was investigated in seven oral cancer cell 
lines (H103, H157, H376, SCC4, SCC9, SCC15, SCC27) provided by Dr Chris Dawson, and in 
neonatal foreskin keratinocytes provided by Dr Sally Roberts. Figure 4.3 shows the mRNA 
expression of CLU in seven oral cancer cell lines compared with that found in normal human 
foreskin keratinocytes by Q RT-PCR using two different housekeeping genes, GAPDH and B2M. 
Although B2M had been shown to be a more consistent house keeping gene in cervical cancer 
cell lines, the scenario might be different in other cancer cell lines and so 2 housekeeping genes 
were used for comparison in oral cancer cell lines. When expression was normalised against 
GAPDH, CLU was found to be down regulated compared with NHFK in one oral cancer cell line  
(H376), and up regulated in three (H103, SCC9 and SCC15). When expression was normalised 
against B2M, a somewhat different pattern emerged: CLU was found to be down regulated in 
H103, and up-regulated in SCC4. Because of this uncertainty I examined expression levels using 
semi-quantitative RT-PCR, which confirmed the results obtained using B2M as a housekeeping 
gene. 
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4.1.2. Expression of CLU at the protein level in oral cancer cell lines using Western blotting  
I investigated the expression of CLU using immunohistochemistry and Western blotting of the 
same 7 oral cancer cell lines. Figure 4.4 shows the expression of CLU using Western blotting and 
two commercially available antibodies. The 60kDa and 40kDa CLU proteins are present in all 
cell lines. CLU appears to be over-expressed at the protein level in SCC4 compared with normal 
keratinocytes and with the other oral cancer cell lines (H103, H157, H376, SCC9, SCC15, 
SCC27), with no evidence of down-regulation of CLU at the protein level in these cell lines. 
These results mirror those obtained at the RNA level when normalised to B2M, and are contrary 
expression levels in oral cancers by microarray and Q RT-PCR. This suggests that the NHFK 
control available at the time of this study may not have been a representative control for these 
samples or that these cell lines are not representative of tumour samples from patients. 
 
4.1.3. Expression of CLU at the protein level in oral cancer cell lines using 
immunohistochemistry 
I next used immunohistochemistry with two antibodies to examine the expression of CLU in 
cytospins prepared from the seven oral cancer cell lines (Figure 4.5 and 4.6). Compared with the 
other oral cancer cell lines, the staining appears to be more intense in SCC4 cells, and less intense 
in SCC27, H157 and H376 cell lines. Gradation of this staining shows that H103, SCC4, SCC9 
and SCC15 display very strong (3+) cytoplasmic staining;  H157, H376 and SCC27 show 
moderate (2+) to low (1+) cytoplasmic staining. These observations are consistent with those 
seen by western blot and Q RT-PCR results obtained following normalisation of expression 
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against B2M, but not with those obtained following normalisation against GAPDH, suggesting 
that B2M is a more representative and suitable house keeping gene for these samples (section 
4.2.1).  Both antibodies resulted in the same trend in staining pattern, however, staining intensity 
in SCC4, SCC9 and SCC15 was much greater using the Santa Cruz antibody than the Upstate 
antibody. This was also the case when staining a number of other tissues with the antibody, such 
as in cervix, suggesting it may have a greater binding affinity for its epitope. 
 
4.1.4. Expression of CLU at the protein level in oral cancers using immunohistochemistry  
I next used immunohistochemistry with two CLU antibodies to investigate the expression of 
CLU in 40 oral cancers (Figure 4.7 and Table 4.1). Only 2 out of 40 cancers showed expression 
of CLU, which was very weak (1+), whereas the remaining cancers did not express CLU. Where 
CLU expression was detected, it was the necrotic cells that stained positive for CLU, which is not 
surprising given the role of CLU in the regulation of apoptosis. 
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4.2.   Allelic loss and epigenetic regulation of CLU in oral cancer 
A contemporaneous in-house investigation using SNP analysis performed on whole tissue had 
revealed a possible deletion encompassing the CLU locus (8p21) in a number of oral cancers. 
This analysis was performed by Dr. J Arrand in the Institute for Cancer Studies, who 
subsequently confirmed using genomic PCR, loss of one CLU allele in oral cancers (Figure 
4.8). Although this region includes 11 genes which are reported to have a tumour suppressive 
function (BNIP3L, CLU, NKX3-1, PPP2R2A, RHOBTB2, TNFRSF10A and TNFRSF10B), 
only CLU was found to be down-regulated in the gene expression array. 
 
4.2.1.   Epigenetic regulation of CLU expression in oral cancers and cell lines 
As previously described (section 3.7), promoter methylation may have a strong influence on gene 
silencing. To evaluate whether this phenomenon governed CLU expression at other sites of 
cancer, the possible contribution of CpG island methylation to the loss of CLU expression in oral 
cancer cell lines and tissue was investigated using MSP and pyrosequencing. 
 
4.2.1.1. Frequency of methylation of the CLU promoter in oral cancer cell lines as 
determined by MSP 
MSP was used to determine the presence of methylated and unmethylated forms of CLU in six 
oral cancer cell lines, H103, H157, H376, SCC4, SCC9, SCC15 (Figure 4.9). Single discrete 
bands of the expected size of amplified PCR products were detected for all samples and controls 
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behaved as expected throughout. Where evidence of methylation was detected, results were 
repeated alongside unmethylated results to confirm that the results were reproducible. Methylated 
forms were detected in all cell lines, with four of the five also showing weak unmethylated bands 
(H157, SCC4, SCC9, SCC15). 
 
4.2.1.2. Frequency of CLU promoter methylation in oral cancer cell lines as determined by 
pyrosequencing 
Pyrosequencing was used to confirm the pattern of promoter methylation of CLU in DNA 
extracted from oral cancer cell lines. As in section 3.7.3.4, 4 sets of pyrosequencing primers were 
optimised on commercially available controls, the most reproducible set taken forward for 
analysis in all DNA samples. Table 4.2 shows methylation in 5 CpG dinucleotides of the CLU 
promoter and the mean of these. In H103 the mean methylation was 28%, 24% in H157, 22% in 
H376, 16% in SCC4, 17% in SCC9, 20% in SCC15 and 25% in SCC27. The controls behaved as 
expected throughout with unmethylated control DNA showing a mean methylation of 5% and 
methylated control DNA 83%. Interestingly, SCC4 which appeared to have the highest level of 
CLU expression at the RNA and protein level of all the cell lines (section 4.2) also had the lowest 
level of methylation of the 7 cell lines.   
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4.2.1.3.   Frequency of CLU promoter methylation in oral cancers as determined by MSP 
Again using MSP, I determined the presence of methylated and unmethylated forms of CLU in 4 
oral cancers and in oral tissue taken from a disease-free patient (Figure 4.10). Methylated and 
unmethylated forms were detected in all cancers and in the control patient, with no apparent 
difference between the disease-free control and the cancers. The presence of both unmethylated 
and methylated products, hemi-methylation, could be due to a mixed cell population with some 
cells being methylated while others are not, or mixture of methylated and unmethylated alleles 
within these tumours reflecting that the population as a whole is heterogeneous. It is also possible 
that in the tumour samples that adjacent normal cells may be contributing to the level of 
methylation detected and micro-dissected tumours would have provided a more accurate 
comparison. 
 
4.2.1.4. Frequency of methylation of the CLU promoter in oral cancers as determined by 
pyrosequencing 
10 randomly selected oral tumours from a cohort of 200 oral cancers were used to evaluate CLU 
promoter methylation frequency. Samples were randomly selected blinded to any clinical 
information about the tumour so as not to bias any subsequent data interpretation. Unfortunately, 
there was no remaining DNA from normal oral epithelium after MSP analysis and so this was 
unable to be validated by pyrosequencing.  Table 4.3 shows methylation in 5 CpG dinucleotides 
of the CLU promoter and the mean of these. The mean methylation across all 5 CpG 
dinucleotides for all 10 tumours is 13%, with a range from 7 to 20%.  CpG dinucleotides 1, 2 and 
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4 have consistently higher levels of methylation than CpGs 3 and 5 in all 10 of the oral cancers, 
and may be preferentially methylated in this subset of tumours. The controls behaved as expected 
throughout with unmethylated control DNA showing a mean methylation of 5% and methylated 
control DNA 83%.   
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4.3. Reasons for investigating the expression of CLU, and its regulation in nasopharyngeal 
cancer  
My interest in nasopharyngeal cancer (NPC) was prompted by the results of a microarray 
experiment which had been analysed in the Institute for Cancer Studies as part of an on-going 
collaboration with the Department of Oral and Dental Science, University of Bristol. The samples 
included in this array were collected from Malaysian patients by Dr. Lee-Fah Yap who was then 
a PhD student in Bristol. The analysis revealed the down-regulation of CLU in 19 (76%) of 25 
nasopharyngeal cancers when compared with tissue samples from 3 cancer-free controls (Figure 
4.11). A review of the literature also revealed down-regulation of CLU in two published arrays of 
primary NPC, one of which included whole tissue samples, the other, micro-dissected epithelium 
(Shi 2006, Sriuranpong 2004). 
 
4.3.1. Expression of CLU in nasopharyngeal cancer cell lines 
The expression of CLU at the RNA and protein level was investigated in the NPC cell lines 
C666-1, Ad-AH, CNE1, SUNE1, NPC TWO 1, NPC TWO 4, HONE 1. It was also measured in 
normal foreskin keratinocytes; in NP69, an SV40 immortalised normal nasopharyngeal line; and 
in HEK 293 cells, a human embryonic kidney cell line. 
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4.3.1.1. Expression of CLU at the RNA level in nasopharyngeal cancer cell lines 
Figure 4.12A and 4.12B show the mRNA expression of CLU in the seven NPC cell lines 
compared with that found in normal foreskin keratinocytes using Q RT-PCR. When expression 
was normalised against GAPDH, CLU was found to be down regulated in two NPC cancer cell 
lines (C666-1 and NPC TWO 4) compared with normal human foreskin keratinocytes, and up 
regulated in three (Ad-AH, SUNE 1 and NPC TWO 1). When expression was normalised against 
B2M, a somewhat different pattern emerged: CLU was found to be down regulated in only one 
cell line (C666-1), and up regulated in four others (CNE 1, SUNE 1, NPC TWO 1 and HONE 1). 
Because of this uncertainty I examined expression levels using semi-quantitative RT-PCR, which 
verified the results normalised to B2M. 
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4.3.1.2.   Expression of CLU at the protein level in nasopharyngeal cell lines using western 
blotting and immunohistochemistry 
I used Western blotting with two CLU antibodies to evaluate the expression of CLU in lysates 
prepared from NHFK, NP69, Ad-AH, C666-1, HONE1, CNE2, AGS and following infection of 
Ad-AH, HONE 1, CNE 2 and AGS with EBV (Figure 4.13). C666-1 does not express any of the 
CLU proteins and mirrors findings at the RNA level that CLU is not expressed in this cell line. 
The 60kDa and 40kDa CLU proteins are present in other all cell lines. Ad-AH, HONE 1 and 
CNE 2 show higher levels of CLU expression than NHFK and NP69, and post-infection of these 
cell lines with EBV there is a significant over-expression of the 60kDa CLU protein. HONE 1 
and CNE 2 additionally highly express a 45kDa CLU protein, as does Ad-AH, however this is at 
a much a lower level. This molecular weight corresponds to the size of nuclear CLU, but the 
antibodies used are not able to discriminate between CLU isoforms and so it is also possible that 
this is a precursor protein for cytoplasmic CLU. The gastric cancer cell line AGS displayed a 
similar profile of expression of the CLU protein as the NPC cell lines. The expression of CLU at 
the protein level was also examined by immunohistochemistry which confirmed that C666-1 did 
not express CLU. Ad-AH cells showed moderate (2+) to high (3+) levels of CLU which was 
predominantly nuclear in localisation using both Santa Cruz and Upstate antibodies (Figure 4.18 
and Table 4.5).   
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4.3.1.3. Expression of CLU at the protein level in nasopharyngeal cancers using 
immunohistochemistry  
Figure 4.14 shows using immunohistochemistry the expression of CLU in normal tonsillar 
epithelium, normal nasopharyngeal epithelium, and in malignant NPC cells. This pattern of 
expression was confirmed using two antibodies. CLU is strongly expressed in the follicular 
dendritic cells (FDCs) within the tonsil; there is weak staining in normal epithelium adjacent to 
tumour tissue and complete absence of staining in malignant cells. Similar down regulation of 
CLU was seen in 10/12 tumours as summarised in table 4.4.  
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4.4.   Impact of EBV and its latent genes on the expression of CLU in the Ad-AH cell line 
I next investigated the impact on CLU expression of the infection of the NPC cell line, Ad-AH, 
with EBV and its latent genes, EBNA1, LMP2A, LMP2B and LMP1. Ad-AH was also infected 
with a recombinant EBV in which the LMP2A gene had been deleted (∆LMP2A EBV, Stewart et 
al. PNAS). Infections were performed by Dr John O’Neil, a member of the NPC group in the 
Institute for Cancer Studies. 
 
4.4.1.   Impact of EBV and its latent genes on the expression of CLU at the RNA level in Ad-
AH cell line 
Figure 4.15 shows the RNA expression of CLU as determined by Q RT-PCR in the parental Ad-
AH line and following its infection with EBV and transfection with plasmids encoding individual 
latent genes or control plasmid containing a neomycin-resistance gene.  CLU was substantially 
and significantly up-regulated following infection with EBV and ∆LMP2A EBV; 6.6 fold and 3.3 
fold respectively when compared with the parental cell line. In the remaining comparisons, 
expression following infection with an EBV latent gene had been normalised against that 
observed following transfection with a vector containing a neomycin resistance gene under the 
same experimental conditions. Expression of the latent genes EBNA1, LMP2A, LMP2B and 
LMP1 in Ad-AH did not show any change in the expression of CLU at the RNA level compared 
with the parental cell line. 
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4.4.2   Impact of EBV and its latent genes on the expression of CLU at the protein level in 
Ad-AH cell line 
To evaluate whether changes in RNA expression were reflected in protein expression, I next 
investigated the impact of EBV infection and expression of its latent genes on the expression of 
CLU at the protein level in Ad-AH cells using a variety of techniques. 
 
4.4.2.1   Western blotting 
Figure 4.16 shows using Western blotting, the expression of CLU in the parental Ad-AH cell 
line, and following its infection with EBV, and transfection with EBV latent genes and a vector 
containing a neomycin-resistance gene. Compared with the parental cell line, the 60kDa CLU 
protein is over-expressed following infection with EBV and ∆LMP2A EBV, with the 40kDa α 
and β subunits also over-expressed post infection with EBV; these results confirm those observed 
at the RNA level (4.4.1). CLU is additionally up-regulated at the protein level post-transfection 
with LMP1 in Ad-AH cells compared to parental cells and its neo-counterpart. The 60kDa CLU 
protein appears to be down-regulated following transfection of Ad-AH cells with LMP2A and 
LMP2B, which was not seen at the RNA level. The 45kDa CLU protein seems to be very weakly 
expressed in these two cell lines, but not in the parental cell line or post-transfection any of the 
others. This is interesting given that the 60kDa protein seems to be down-regulated post 
transfection of Ad-AH with LMP2A or LMP2B and in these we also see the expression of a 
45kDa protein, corresponding to the molecular weight of nuclear CLU. 
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4.4.2.2   Immunofluorescence  
To explore the possible down-regulation of CLU in Ad-AH cells transfected with LMP2A or 
LMP2B I used immunofluorescence and three antibodies to stain methanol-fixed cells which 
were prepared from the Ad-AH cell line after stable transfection with LMP2A or neomycin 
control gene (Figure 4.17). Both nuclear and cytoplasmic staining are observed; and using the 
Vector antibody, staining of the Golgi apparatus can also be seen. However, there is no 
compelling evidence that following transfection with LMP2A alters either the intensity of 
staining or the cellular localisation of CLU in this cell line. Interestingly in both the cell lines 
nuclear CLU expression was observed in cells that appeared to be undergoing apoptosis. 
 
4.4.2.3   Immunohistochemistry 
The expression of CLU at the protein level was further examined by immunohistochemistry in 
the C666-1 cell line and in the Ad-AH parental cell line and following its infection with EBV, 
and transfection with EBV latent genes and a vector containing a neomycin-resistance gene. 
Figure 4.18 shows the expression of CLU in whole cell lysates prepared from parental Ad-AH 
and Ad-AH infected with EBV and shows up-regulation of CLU at the protein level post 
infection of this cell line with EBV. Immunohistochemical analysis also confirmed that C666-1 
did not express CLU, with Ad-AH cell lysates showing moderate (2+) to high (3+) levels of 
CLU, which was nuclear in localisation (Table 4.5). 
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Cytospin localisation Upstate Santa Cruz
Parental Nuclear 2+ 2+
LMP2A k/o Nuclear 3+ 2+
EBV Nuclear 2+ 3+
neo Nuclear 2+ 2+
EBNA1 Nuclear 2+ 2+
neo Nuclear 2+ 2+
LMP2A Nuclear 2+ 2+
LMP2B Nuclear 3+ 2+
neo Nuclear 2+ 2+
LMP1 Nuclear 2+ 2+
C666-1 - -
Table 4.5: Immunohistochemistry in Ad-AH cell line
and in C666-1 cell line
Immunohistochemical staining in the Ad-AH cell line and
following its infection with EBV and transfection with its
latent genes showed a strong nuclear stain in all cell lines.
Figure 4.18: Immunohistochemical staining for CLU
expression in the Ad-AH cell line.
Expression of CLU in cytospins prepared from the Ad-AH
parental and infected cell line. Compared with the parental
cell line, the staining pattern appears to be more intense in
the cytospins prepared from Ad-AH transfected with EBV.
Ad-AH parental                   Ad-AH EBV
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4.5.   Allelic loss and epigenetic regulation of CLU in the Ad-AH and C666-1 cell lines 
I decided to focus in more detail on the C666-1 nasopharyngeal cancer cell line because a 
contemporaneous in-house investigation using SNP analysis had revealed in this cell line, and in 
the Ad-AH cell line, a possible deletion encompassing the CLU locus (8p21). This analysis was 
performed by Dr. J Arrand in the Institute for Cancer Studies, who subsequently confirmed using 
genomic PCR, a 7.6mb deletion with loss of one CLU allele in C666-1 (Figure 4.19A and 
4.19B). Allelic loss having been demonstrated, I have investigated the methylation status of the 
CLU promoter in the remaining allele using bisulphite genomic sequencing and pyrosequencing. 
I have also examined using RT-PCR, changes in CLU expression following demethylation of this 
cell line with 5-aza, 2’-deoxycitidine. 
 
4.5.1.  Methylation status of the CLU promoter in Ad-AH and C666-1 as determined by 
MSP 
MSP was used to determine the presence of methylated and unmethylated forms of CLU in the 
Ad-AH and C666-1 cell lines (figure 4.20). Single discrete bands of the expected size of 
amplified PCR products were detected for all samples and controls behaved as expected 
throughout. Where evidence of methylation was detected, results were repeated alongside 
unmethylated results to confirm that the results were reproducible. Both methylated and 
unmethylated forms of CLU were detected in both cell lines, with the methylated band being 
predominant, especially in C666-1. The methylation status of the CLU promoter was also 
determined following infection of Ad-AH with EBV, EBV latent genes and a neomycin-
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resistance gene (figure 4.21). There appears to be a reduced level in methylation following 
infection of the parental line with EBV and its latent genes, however it is difficult to determine by 
MSP as it is not quantitative and requires further investigation by pyrosequencing (section 4.9). 
 
4.5.2. Transcriptional and epigenetic changes in CLU expression following demethylation of 
C666-1 
I investigated whether demethylation of C666-1 would be followed by the up-regulation of CLU. 
Figure 4.22 shows using RT-PCR up-regulation of CLU mRNA following treatment with the 
demethylating agent 5-Aza-2’-deoxycidine. Examination of the intensity of promoter methylation 
before and after treatment with 5-Aza, using MSP shows that drug treatment results in significant 
demethylation of the CLU promoter (Figure 4.23). This change was confirmed on 
pyrosequencing; which showed a decrease in the methylation of the CLU promoter from 77% to 
31% (section 4.5.4).  
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4.5.3. Analysis of the CLU promoter in C666-1 cells using bisulphite genomic sequencing 
Bisulphite genomic sequencing (BGS) was used to confirm the pattern of promoter methylation 
across the entire CpG island in the promoter region of CLU in DNA extracted from C666-1 cells. 
Figure 4.24 shows the distribution of methylated CpGs within the CLU promoter and the 
adjacent CpG rich region.  Approximately 85% of CpGs in the CLU promoter were found to be 
methylated by BGS in this cell line, and BGS confirming the methylation of CpG di-nucleotides 
covered by the MSP primers. Additionally, this analysis shows that the majority of CpG di-
nucleotides are frequently methylated. 
 
4.5.4. Frequency of methylation of the CLU promoter in NPC cell lines as determined by 
pyrosequencing 
Pyrosequencing was used to confirm the pattern of promoter methylation of CLU in DNA 
extracted from nasopharyngeal cancer cell lines. As in section 3.7.3.4, 4 sets of pyrosequencing 
primers were optimised on commercially available controls, the most reproducible set taken 
forward for analysis in all DNA samples. Table 4.6 shows methylation in 5 CpG dinucleotides of 
the CLU promoter and their mean levels. In C666-1 cells the mean methylation was 84%, 17% in 
Ad-AH, CNE2 is 21%, 24% in SUNE1 and 12% in HONE1. The mean methylation in C666-1 
not treated with drugs was 77% across all 5 CpGs analysed, and post treatment with 5-Aza-
2’deoxycidine this was reduced to 51%. Of all 5 CpGs the most upstream one showed the highest 
levels of methylation (90%), and the level of methylation successively decreased across the 
adjacent CpGs. The controls behaved as expected throughout with unmethylated control DNA 
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showing a mean methylation of 5% and methylated control DNA 91%. All NPC cell lines were 
more methylated than the primary foreskin keratinocyte cell line, which showed a mean 
methylation of 10%.  
 
Further analysis of the Ad-AH cell line showed that compared to the 17% methylation in the 
parental cell line, methylation increased to 39% in LMP2A knockout cells, and 62% following 
infection with wild type EBV. LMP2A and LMP2B transfected cells showed 37% and 29% 
methylation respectively compared with 30% methylation in their neo counterpart.  EBNA1 
transfected cells showed 29% methylation compared to its neo counterpart at 40%, and LMP1 
19% compared with 5% in its neo counterpart.  In these runs, the unmethylated control was 9% 
methylated and the methylated control had a mean methylation of 71%.  
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 4.6. Allelic loss and epigenetic regulation of CLU expression in nasopharyngeal cancers 
A SNP analysis performed by Dr John Arrand in the Institute for Cancer Studies suggested a 
possible deletion at the CLU locus on 8p21 in 2 of 14 nasopharyngeal cancers from which 
epithelium had been removed by micro-dissection. Although this region includes 7 genes which 
are reported to have a tumour suppressive function (BNIP3L, CLU, NKX3-1, PPP2R2A, 
RHOBTB2, TNFRSF10A and TNFRSF10B), only CLU was found to be down-regulated in the 
gene expression array (Hui 2006). Unfortunately, this material had been exhausted, and therefore 
I have explored the methylation status of CLU in whole tissue taken from a separate series of 10 
nasopharyngeal tumours.  
 
4.6.1. Frequency of methylation of the CLU promoter in nasopharyngeal cancer as 
determined by pyrosequencing 
I next used 10 randomly selected NPC tumours from a larger cohort of nasopharyngeal cancers, 
for which we also have expression data from three probe sets on a microarray to investigate the 
mean methylation across all 5 CpG dinucleotides (Table 4.7).  The results show a mean 
methylation for all 10 tumours of 23%, with a range from 10 to 49%.  Three of the NPC tumours 
showed much higher levels of methylation than the other seven tumours (NPC 2, 39 and 62). 
However, this did not necessarily correlate with CLU expression since in some of the less 
methylated tumours expressed CLU at a lower level than others. The controls behaved as 
expected throughout with unmethylated control DNA showing a mean methylation of 5% and 
methylated control DNA 83%.   
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4.7. Summary of expression and methylation changes in oral cancer and NPC 
I have shown a high level of CLU expression in oral cancer cell lines at the RNA and protein 
level, however these cell lines were not representative of CLU expression in oral cancer. 
Immunohistochemistry of oral cancer confirmed what had been shown by microarray and Q RT-
PCR, which was a down-regulation or loss of CLU in oral cancer. The Q RT-PCR data is not 
entirely convincing, given the inherent problems of housekeeping gene normalisation (discussed 
further in 6.16.3). Protein expression data is more reliable as it is not subject to the same 
sensitivity issues when comparing gene expression to housekeeping gene expression. In oral 
cancer cell lines I showed a level of methylation, which was much lower in oral cancer, 
suggesting that methylation is unlikely to be the sole regulator of reduced CLU expression in oral 
cancer. It is also possible that in the tumour samples that adjacent normal cells may be 
contributing to the level of methylation detected and micro-dissected tumours would have 
provided a more accurate comparison. As in cervical cancer, methylation results were consistent 
with previous evidence suggesting that cell lines can acquire specific DNA methylation defects as 
a result of immortalisation and continuous culture that are unrelated to the tumour origin 
(discussed further in 6.17.4.1).  SNP analysis revealed a possible deletion encompassing the CLU 
locus on chromosome 8p21 which may play a role in the down-regulation of CLU in oral cancer.  
 
Contemporaneous in-house microarray experiments undertaken by other members of the 
department had shown that CLU was down-regulated in NPC cell lines, and in 19 (76%) of 25 
NPC biopsies compared with cancer free controls. CLU was also found to be down-regulated 
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when micro-dissected epithelium from patients with NPC was compared with tissue taken from 
the same cancer free controls. In NPC cell lines, I was only able to confirm the down regulation 
of CLU in one of the cell line at the RNA and protein level, which as in cervix and oral cancers, 
was not reflective of the expression in NPC tumours. As in oral cancer, the Q RT-PCR data is not 
entirely convincing  and protein expression data is more reliable for evaluating the expression of 
CLU. The lack of expression of CLU in C666-1, and its presence in Ad-AH could be because 
Ad-AH is an adenocarcinoma cell line, not squamous carcinoma. Using immunohistochemistry, a 
down-regulation of CLU was confirmed in 10 out of 12 cancers. Infection of the Ad-AH cell line 
with EBV appeared to up-regulated CLU, however, this did not correlate with methylation of the 
CLU promoter as there was also an increase in promoter methylation. Methylation frequencies 
were much higher in NPC cell lines than in NPC tumours and this is discussed in chapter 6 
(section 6.17.4.1).  The impact of EBV and its latent genes on CLU expression was not entirely 
convincing because although EBV and ∆LMP2A up-regulated CLU, transfection of LMP2 and 
LMP1 in Ad-AH cells did not have any effect on CLU; we would have expected LMP2 to down-
regulate CLU and LMP1 to up-regulate it. 
  
The NPC cell line C666-1 not only showed down-regulation of CLU but using genomic PCR had 
shown loss of one CLU allele in this cell line. I have shown using MSP, pyrosequencing and 
bisulphite genomic sequencing methylation of the CLU promoter in the remaining allele in the 
C666-1 cell line. The C666-1 cell line may be a more useful indicator of gene methylation status 
in vivo as tumour samples used were not micro-dissected and so there will be undoubtedly be a 
contribution from the surrounding normal cells masking the level of methylation detected. To 
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summarise, in this cell line I have shown loss of one CLU allele and epigenetic silencing by DNA 
methylation of the other. This is a novel observation, which is included in a manuscript being 
prepared for submission. 
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Overview 
In this chapter, I investigate the phenotypic changes which follow the transient transfection of 
nuclear and full-length CLU into the NPC cell line C666-1. I then investigate the regulation of 
NF-kB activity by CLU. Towards this end, I first measured NF-kB activity following knock-
down of CLU in the HeLa cell line and then measured NF-kB activity following its expression in 
C666-1. Both transfection and knockdown conditions were first optimized in HEK 293 cells. 
 
5. 1. Transient transfection of 293 with full length CLU and nCLU 
In order to determine whether the expression vectors were able to express the CLU proteins, I 
first transiently transfected HEK 293 cells with either a pIres plasmid containing  full length CLU 
or a pIres plasmid containing nCLU, which lacks the leader sequence. Both of these plasmids 
were provided by Prof. Bettuzzi and generated using the published sequence for transcript variant 
2. pIres mock plasmid was used as a transfection control, and expression levels of transcripts 
monitored at 12, 24 and 48 hours post transfection. 
 
5.1.1  RNA expression following transfection with full length CLU and nCLU 
In order to verify that transfection was successful, I examined the expression of transcript 
variants 1 and 2 in HEK 293 cells transiently transfected with full length CLU, nuclear CLU and 
empty vector by RT-PCR, using GAPDH as a loading control (Figure 5.1). Levels of transcript 
variant 1 do not change following transfection with either full length or nCLU. This observation 
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is not surprising because the plasmids used were generated from transcript variant 2 sequences. 
On the other hand, transcript variant 2, which is absent in the HEK 293 cell line, is expressed at 
12, 24 and 48 hours following transfection with full length and nuclear CLU but not following 
transfection with the empty vector. Expression decreased with falling concentrations of plasmid, 
but was still detectable at a concentration of 62.3ng/µl.  Expression levels appeared to be 
particularly high at 24 hours post transfection of nCLU and so an earlier time point of 12 hours 
was investigated. Plasmid concentrations from 250ng/µl to 37.3ng/µl were monitored by semi-
quantitative RT-PCR, resulting in a fall in expression, with expression still detectable using 
37.3ng/µl plasmid. 
 
5.1.2.   Protein expression following transfection with full length CLU and nCLU 
I next examined expression at the protein level in the HEK 293 cell line 12, 24 and 48 hours post 
transient transfected with nCLU and full length CLU, using western blot and 
immunofluorescence.  
 
5.1.2.1 Western blotting 
Using Western blotting and two antibodies a 60kDa protein, corresponding to the cytoplasmic 
precursor of secreted CLU, a 40kDa protein corresponding the α/βcleaved cytoplasmic protein 
and a 45kDa protein corresponding to nuclear CLU can be detected following transfection with 
full length CLU (Figure 5.2). The 45kDa protein but not the 60kDa protein is detectable 
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following transfection with nCLU. Of interest is the observation that the 45kDa protein can only 
be detected 24 hours post transfection with full length CLU, but is expressed earlier post-
transfection with nCLU. This is consistent with the possibility that the full length plasmid is also 
able to generate nuclear CLU by translocating to the nucleus and hence it not being detectable 
until 24 hours post transfection.  
 
5.1.2.2. Immunofluorescence 
To further verify CLU expression following transfection I used immunofluorescence (Figure 5.3). 
24 and 48 hours after transfection strong expression was observed with full length CLU but not 
empty vector, and it appears to be cytoplasmic in localisation.   
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5.2. Transient transfection of C666-1 cells with nCLU and full length CLU 
To evaluate the efficiency of transfection in C666-1 cells, I first transiently transfected C666-1 
cells with a pIres GFP plasmid. By fluorescent microscopy over 70% of cells were GFP-positive 
(Figure 5.4). I next transiently transfected C666-1 cells with the same CLU plasmids. Expression 
levels were monitored at 6, 12 and 24 hours post transfection in order to determine initial 
expression of the CLU proteins in the C666-1 line.  
 
5.2.1      RNA expression following transfection of C666-1 with full length and nCLU 
Figure 5.5 shows, as before, that expression of transcript variant 1 was not induced following 
transfection with full length CLU or nCLU. Transcript variant 2 was induced from 6 hours post 
transfection with full length CLU and nCLU. However, transfection with full length CLU and 
nuclear CLU generated amplicons of different molecular weight – full length CLU generated an 
amplicon of 240bp whereas nCLU 181bp.  This confirms that the nCLU plasmid is a truncated 
form of the full length CLU, but both of which arise from transcript variant 2.  
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5.2.2   Protein expression following transfection of C666-1 with full length and nCLU 
I next examined expression at the protein level in the C666-1 cell line transiently transfected with 
nCLU and full length CLU, using western blotting. Expression levels were monitored at 6, 12 
and 24 hours post transfection. 
 
5.2.2.1   Western blotting using whole cell lysates 
I evaluated the expression of CLU in lysates prepared from C666-1 cells at 6, 12, 24 and 48 hours 
post transfection with mock vector, nCLU or full length CLU using Western blotting and 2 
antibodies (Figure 5.6). A 60kDa protein, corresponding to the cytoplasmic precursor of secreted 
CLU, is detectable in C666-1 cells 24 hours post transfection with full length CLU but not with 
nCLU. In contrast to HEK 293 a 45kDa protein is detectable following transfection with nCLU 
but not full length CLU. A 50kDa protein band can also be seen using both antibodies at 24 hours 
post transfection with full length CLU; this is further discussed below. A weak 40kDa and an 
80kDa protein band can be detected using one or both antibodies in all lysates. This is likely to be 
80kDa secreted protein and the 40kDa doublet of bands representative of the alpha and beta chain 
of the mature protein. 
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5.2.2.2   Western blotting using nuclear and cytosolic extracts 
In order to determine whether the 45kDa band obtained by Western blotting of whole cell lysates 
was indeed nuclear CLU, I carried out western blotting on nuclear and cytosolic extracts prepared 
from C666-1 cells at 12 and 24 hours post transfection with mock vector, nCLU or full length 
CLU. SP1 was used as a loading and purification control for nuclear extracts, and tubulin for 
cytosolic extracts (Figure 5.7). Transfections were performed under both high and low serum 
conditions to assess whether low serum conditions induced expression of differentially processed 
proteins. Low serum condition did not induce differential expression of CLU proteins. 
 
The absence of SP1 from the cytosolic extract and the absence of tubulin from the nuclear extract 
suggest that these extracts have been successfully separated.  Using both antibodies a 60kDa 
protein, corresponding to the cytoplasmic precursor of secreted CLU, can clearly be detected in 
the cytoplasmic extracts at 24 hours post transfection with full length CLU but not with nCLU or 
with empty vector. A 45kDa protein can clearly be detected using both antibodies at 12 and 24 
hours post transfection with nCLU but not full length CLU in both cytosolic and nuclear extracts. 
It is therefore likely to be nuclear in localisation, with its presence in the cytosolic extract being 
the precursor for the nuclear protein that has not yet translocated to the nucleus. The 50kDa 
protein observed previously cannot be detected in nuclear and cytosolic extracts, and so is likely 
to be an artifact or break-down product. 
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5.2.3. Phenotypic changes following transfection with nCLU and full length CLU 
In order to investigate the phenotypic consequences of expression of nCLU and full length CLU 
in C666-1 cells I examined cell viability, proliferation and apoptosis. Figure 5.8 shows that 
compared to mock transfected cells at 12, 24 and 48 hours post transfection of C666-1 there is a 
decrease in the number of live viable cells. Decreased viability following transfection with nCLU 
was statistically significant at all time points, P-value <0.001 at 12, 24 and 48hrs and P-value 
<0.01 at 72hrs. There was a small increase in the number of viable cell transfected with length 
CLU, which is also able to generate nCLU by nuclear translocation. Figure 5.9 shows the number 
of proliferating cells as measured by MTS assay, where the number of proliferating cells in 
proportional to formazan production. Compared with mock transfected cells there is a 70% and 
50% reduction in the number of proliferating cells at 12 and 24 hours respectively post 
transfection of C666-1 with nCLU. 12 hours post transfection of C666-1 with full length CLU 
results in a 30% increase in the number of proliferating cells, which starts to return to baseline 
from 24 hours. A one-way ANOVA shows that transfection with nCLU and sCLU statistically 
significantly reduces (nCLU)/increases (sCLU) cell proliferation of C666-1, with a P-value 
<0.001. 
 
To determine the effect on apoptosis of transfection of CLU into C666-1 cells Annexin-V PI 
staining and subsequent analysis by flow cytometry was performed at 48 hours post transfection. 
Figure 5.10 shows results displayed as a bivariate distribution of Annexin V/FL1 and PI/FL3 
fluorescent intensity. PI positive cells represent the dead cell population (upper left quadrant), 
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Annexin-V positive cells are early apoptotic cells (lower right quadrant), PI and Annexin-V 
positive cells are late apoptotic cells (upper right quadrant) and unstained cells are viable cells 
(lower left quadrant). Bold figures in the upper right and lower right quadrants show the 
percentages early and late apoptotic cells. Figure 5.11 Panel B and D show an increase in the 
number of early and late apoptotic cells following transfection with both nCLU and full length 
CLU, an effect which is ameliorated following TGFβ stimulation. TGFβ stimulates nuclear 
translocation of CLU (Reddy, Jin et al. 1996) so I would have expected this to increase the 
number of apoptotic cells. This result was unexpected – I would have expected to see an increase 
in the number of apoptotic cells following stimulation of nCLU transfected C666-1with TGFβ. 
This is possibly because apoptosis assays were carried out 48 hours post transfection when the 
effect of nCLU is masked by that of sCLU and so an earlier time point would have been more 
appropriate to study the levels of TGFβ induced apoptosis by nCLU. To some extent this can be 
seen in panel C, following stimulation of CLU transfected cells there is an increased number of 
dead cells compared with unstimulated cells. 
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5.3. Regulation of NF-kB activity by CLU 
The up-regulation of NF-kB signalling is a common feature of malignant disease. NF-kB induced 
gene expression has been shown to contribute significantly to the pathogenesis of inflammatory 
disease. Santilli et al. proposed an explanation for the pro-apoptotic activity of CLU through an 
involvement in the regulation of NF-kB activity (Santilli, Aronow et al. 2003). Ectopic 
expression of CLU strongly inhibited NF-kB activity in human neuroblastoma cells and murine 
embryonic fibroblasts by stabilising inhibitors of NF-kB (IkBs).  I therefore first measured NF-
kB activity following the expression of CLU in the HEK 293 and C666-1 cell lines. 
 
NF-κB reporter assays were carried out using the Dual-Luciferase® Reporter activities of firefly 
and Renilla luciferases. NF-κB reporter assays are routinely used to monitor the activity of 
NFκB-regulated signal transduction pathways in cultured cells through use of an NFκB reporter 
construct and control constructs. The NFκB-responsive luciferase construct encodes the firefly 
luciferase reporter gene under the control of a minimal CMV promoter and tandem repeats of the 
NFκB transcriptional response element (TRE). Photon emission is brought about through the 
ATP/ Mg
2+
/O2 dependent oxidation of beetle luciferin, via a luciferyl-AMP intermediate that 
generates a luminescent signal for firefly luminescence which when quenched simultaneously 
initiates the Renilla luciferase reaction. NF-κB reporter assays are carried out following co-
transfection of NF-κB reporter plasmid and with a renilla plasmid and promoter activity 
calculated following normalization against internal renilla values.  
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To minimise the possibility of variability in this assay and to enable statistical analysis to be 
carried out on data, each individual transfection experiment was repeated on 6 occasions, each of  
which were all assayed in triplicate at separate times, with each individual sample per assay also 
being carried out in triplicate. 
 
5.3.1. Impact on NF-kB activity of CLU over-expression in 293 cells 
I co-transfected the CLU plasmids described with an NFkB luciferase reporter plasmid and 
measured luciferase activity. Basal activity in HEK 293 cells was determined by dividing the 
observed luminescence in cells transfected with the reporter plasmid with that observed in cells 
transfected with an empty vector. In order to exclude the impact on NF-kB activity of non-
specific stress responses, the CLU plasmids were titrated from concentrations of 1ug to 31.3ng. 
The results show that at 12 hours post transfection of HEK 293 with nCLU there is a 50% 
reduction in NF-kB activity, as measured by luciferase reporter assay, which was statistical 
significant, P-value <0.001 (Figure 5.12). This reduction in activity had returned to baseline by 
48 hours, with a slight increase in activity at 48 hours. However, at 12 hours post transfection of 
HEK 293 with full length CLU there is an increase in NF-ĸB activity with a return to baseline by 
48 hours (Figure 5.13).  Utilising these findings I have used plasmid concentrations of 1µg and 
100ng, and measured NF-kB activity from 6 hours post transfection in subsequent analysis of the 
C666-1 cell line (Figure 5.14).   
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5.3.2. Impact of clusterin expression on NF-kB activity in C666-1 cells  
I next examined the impact of nCLU and full length CLU expression on NF-kB activity in C666-
1 cells. Figure 5.15 shows that both nCLU and full length CLU down-regulated NF-kB activity in 
these cells from 12 hours post transfection and were statistical significant, P-value <0.001. Since 
in HEK 293 cells the impact of CLU on NF- kB activity was short lived, with a return to baseline 
by 48 hours post transfection, the time-course was extended to 96 hours post-transfection (Figure 
5.16). There is some evidence to suggest that NF-kB activity is returning to baseline following 24 
hours despite it not being fully reached.  The luciferase reporter assays were carried out in 
triplicate and repeated on 6 occasions in order to verify these results.  
 
5.3.3. IkBα stabilisation 
The activity of NF-kB is suppressed through interaction with the inhibitory molecule IkB which 
blocks the translocation of the to p55/p60 heterodimer to the nucleus and its transcriptional 
activity. Phosphorylation of IkB by IkB kinases (IKKs) marks the latter for degradation, which 
results in the release and translocation of the active NF-kB heterodimer (Pajak and Orzechowski 
2006). CLU has been shown to induce IkBα stabilisation by inhibiting E3 ubiquitin ligase 
binding to phosphorylated IkBα, resulting in decreased NF-kB activity. Following transfection of 
CLU into HEK 293 and C666-1 cells, expression of the IkBα protein was examined by 
restripping of the Western blot (Figures 5.2 and 5.6). The results showed an increase in the 
expression of IkBα in cells transfected with CLU up to 24 hours post transfection, and provides a 
possible mechanism for the down regulation of NF-kB activity by CLU in these cell lines.  
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IkB is able to suppress NF-kB activity by blocking its nuclear translocation, thereby rendering it 
inactive in the cytoplasm. Having observed suppression of NF-kB by CLU though stabilisation of 
IkBα, I sought to determine whether this would inhibit p50 and p65 nuclear translocation.  
Western blotting for p50 and p65 was carried out to confirmed the results obtained by luciferase 
reporter assays and to determine whether suppression of NF-kB by CLU though stabilisation of 
IkBα would inhibit p50 and p65 nuclear translocation. Western blotting of nuclear and cytosolic 
extracts showed an increase in cytoplasmic p50 and p65 post transfection with nCLU and a 
concurrent decrease in their nuclear localisation. Transfection with full length CLU showed little, 
if any, change in p50 and p65 localisation (Figure 5.17). 
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5.4.  Knockdown of CLU in HEK293 cells 
Following the observation that transient transfection of CLU down-regulated NF-kB activity 
through stabilization of IkBα, I set out to ascertain whether reduction of basal CLU levels 
through siRNA knockdown would have the converse effect of up-regulating NF-kB activity. I 
first transfected the HEK 293 cell line with siRNA targeted to full length CLU in order to 
optimize my knock down conditions. Scrambled siRNA was used as a negative control to ensure 
any effects seen were specific to knockdown. Both of these siRNA sequences were provided by 
Prof. Bettuzzi. Expression of transcript variant 1 was reduced post-transfection with CLU siRNA, 
but not with scrambled siRNA or lipofectamine alone (Figure 5.18). Transcript variant 2 could 
not be detected in these cells. 
 
5.5. Knockdown of full length CLU in HeLa cells  
I next attempted to knockdown CLU expression in HeLa cells which had previously been stably 
transfected with an NF-kB reporter plasmid to avoid any problems with co-transfecting siRNA 
with a plasmid. Expression was measured at 24, 48 and 72 hours post transfection with siRNA, 
scrambled siRNA and empty vector.  
 
5.5.1. RNA expression following knockdown of full length CLU in HeLa 
I evaluated the expression of CLU transcript variants 1 and 2 at 24, 48 and 72 hours post-
knockdown using RT-PCR and GAPDH as a loading control (Figure 5.19). Transcript variant 1 
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was knocked-down from 24 hours post transfection with CLU siRNA, but not with scramble 
siRNA. Transcript variant 2, which unlike in the 293 cell line is weakly expressed in HeLa cells, 
was also found to be knocked-down from 24 hours post transfection. These data were confirmed 
using Q RT-PCR, showing statistically significant 90% knockdown at the RNA level at 24 hours, 
P-value <0.001(Figure 5.20). 
 
5.5.2. Assessment of a possible interferon response 
Recent publications have shown that siRNA knockdown may invoke an interferon response, 
especially if duplexes are longer than 23bp and cell viability is affected (Reynolds, Anderson et 
al. 2006). To address this issue the interferon response genes, ISG 20 and OAS 1 were analysed 
by Q RT-PCR for all siRNA knockdowns of CLU to check that no interferon response was 
observed. An interferon response is that of 10-fold difference in expression or higher, however 
changes do not seem to be significant (Figure 5.21A and 5.21B), indicating that no such response 
occurred in the course of these experiments. 
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5.5.3. Protein expression following knockdown of full length CLU in HeLa cells 
I next examined CLU expression at the protein level following knockdown in the HeLa cell line. 
I investigated the expression of CLU in lysates prepared from HeLa cells at 24, 48 and 72 hours 
post transfection with mock vector, scrambled siRNA and CLU siRNA using Western blotting 
and two antibodies, β-actin was used as a loading control for all cell lysates (Figure 5.22). A 
60kDa protein, corresponding to the cytoplasmic precursor of secreted CLU, is clearly seen to be 
knocked-down from 24 hours post transfection with CLU siRNA but not with scrambled siRNA. 
A 45kDa protein is not expressed in control cells. However, it can be detected using both 
antibodies 12 hours post transfection with scrambled siRNA. This apparent induction of the 
nuclear isoform of CLU may reflect a non-specific stress response.  
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Figure 5.22: CLU expression in HeLa cells by Western 
blotting
A 60kDa protein, corresponding to the cytoplasmic
precursor of secreted CLU, is clearly seen to be knocked-
down from 24 hours post transfection with CLU siRNA but
not with scrambled siRNA. A 45kDa protein is not
expressed in control cells.  
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5.5.4.  Impact on NF-kB activity of CLU knockdown in HeLa cells 
I next set out to establish whether the knockdown of CLU in HeLa cells would have the predicted 
effect of up-regulating NF-ĸB activity. I first measured NF-ĸB activity following knock-down of 
CLU in a HeLa cell line stably expressing an NF-kB reporter plasmid. Since TNFα is known to 
induce NF-ĸB activity I assessed NF-kB activity with and without TNFα stimulation. Stimulation 
of NF-ĸB activity by TNFα in the HeLa cell line was tested at 10 minutes, 30 minutes, 1 hour and 
3 hours and stimulation, demonstrating that 3 hour incubation of HeLa cells with TNFα is 
sufficient to induce NF-ĸB (Figure 5.23). 
 
A luciferase reporter assay for NF-ĸB activity was carried out at 24, 48 and 72 hours post 
knockdown of CLU in HeLa cells (figure 5.24). At 24 hours following knockdown of CLU there 
is a 1.6 fold increase in NF-ĸB activity compared with mock transfected cells and cell transfected 
with scrambled siRNA, which is mirrored also at 48hours following knockdown. No effect was 
seen using scrambled siRNA at these time-points, although at 72 hours post transfection both 
CLU siRNA and scrambled siRNA had similar effects on NF-ĸB activity. This might suggest a 
non-specific stress response. These experiments were also performed following 3 hour TNFα 
stimulation of the HeLa cell line. The effects of CLU knockdown on NF-ĸB activity are very 
similar to those seen by TNFα stimulation. Therefore, the regulation of NF-ĸB activity by CLU 
does not appear to be TNF dependent. 
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5.6. Summary 
The defect in the C666-1 cell line has successfully been repaired by transiently transfecting both 
nCLU and full length CLU into the cell line. Expression of both transcripts has been 
demonstrated at the RNA level from 6 hours post transfection and this was also translated in the 
full length and truncated proteins.  Decreased viability and proliferation were observed following 
transient transfection of C666-1 with nCLU, with an increase in the number of proliferating cells 
following transfection with full length CLU. There was no convincing increase in viability 
following transfection with full length CLU, which I would have expected to see give its anti-
apoptotic function. The effects on cell proliferation when expressed as raw OD values are not 
convincing of any effect, compared with when this data is expressed as a percentage of that 
observed in the mock transfected cells. There was an increase in the number of early apoptotic 
cells and late apoptotic/necrotic cells following transfection with both nCLU and full length 
CLU. However, these results are not entirely convincing, especially given that no change was 
observed following stimulation with TGFβ as might have been expected due to the fact that this 
induces the nuclear translocation of CLU and apoptosis. Theses apoptosis assays were carried out 
48 hours post transfection when the effect of nCLU is masked by that of sCLU and so an earlier 
time point may in fact have been more appropriate to study the levels of induced apoptosis by 
nCLU.  
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Both nCLU and full length CLU down-regulated NF-ĸB activity from 12 hours post transfection 
of C666-1 and there is some evidence to suggest that NF-ĸB activity is returning to baseline from 
24 hours. A possible mechanism for the down regulation of NF-ĸB activity by CLU in C666-1 is 
through stabilization of the IkB molecule, and the results did indeed show an increase in the 
expression of IkB in cells transfected with CLU up to 24 hours post transfection. As proof of 
principle, endogenous levels of CLU were knocked down in the HeLa cell line, showing 90% 
knockdown at the RNA level which was translated at the protein level at 24 hours post 
transfection with siRNA, without generating an interferon response. Knockdown of CLU resulted 
in a TNF independent increase in NF-ĸB activity of 1.6 fold and lasted for up to 48 hours post 
knockdown. 
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6.1:  Identification and initial analysis of candidate genes in cervical neoplasia 
 
Cervical cancer carcinogenesis includes a number of genetic and epigenetic changes that 
result in numerous cellular abnormalities, with the contribution of the viral HPV oncogenes 
E6 ad E7 affecting cellular proliferation. A large number of genes have been identified to be 
tumour suppressors in cervical neoplasia, including p16 and p53, whose function is inhibited 
by E6 and E7 and results in apoptosis inhibition and impeded DNA repair. The pathogenesis 
of the disease also involves a number of epigenetic changes, in particular DNA methylation of 
genes, such as RASSF1A, involved in cell proliferation and differentiation resulting in gene 
expression changes (Kang, Kim et al. 2007; Kisseljov, Sakharova et al. 2008).  
 
The initial aim of this thesis was to identify novel tumour suppressor genes in cervical 
neoplasia. As a starting point for these investigations, genes which had been identified from a 
microarray experiment looking at expression changes post demethylation of 4 cervical cancer 
cell lines were narrowed down to a viable group of candidate genes. Detailed analysis of the 
results of these experiments combined with literature searches highlighted seven genes that 
were potentially epigenetically regulated in cervical cancer. The approach taken was 
successful and provided a large number of genes potentially epigenetically regulated in 
cervical cancer and used three replicates of four cervical cancer cell lines to allow statistical 
analysis. The microarray gave promising results, revealing a number of genes which have 
been previously identified to be tumour suppressors in cervical neoplasia, including p53, p16,  
DAPK and CADM1 (Anton, Horky et al. 2000; Steenbergen, Kramer et al. 2004; Jeong, 
Youm et al. 2006; de la Cruz-Hernandez, Perez-Cardenas et al. 2007). To take into 
consideration confounding factors such as infecting HPV type the cell lines used included a 
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HPV negative cell line (C33a), a HPV 18 positive cell line (HeLa) and HPV 16 positive cell 
lines (CaSki and SiHa). The two HPV 16 positive cell lines were used as these have different 
viral loads and transcription activities, with CaSki having more than 600 integrated HPV-16 
copies and SiHa having only about 2 (Rajeevan, Swan et al. 2006; Roberts, Ng et al. 2008). 
 
The genes that were selected for further investigation were DKK3, KLF4, TIMP1, AKAP12, 
RNASET2, CLU and CADM1, which were found to be increased in a post-treatment sample 
compared to at least one pre-treatment sample, following demethylation of cervical cancer 
cell lines. These were chosen if they were either up-regulated by the viral oncogenes HPV 
E6/E7; or up-regulated following HPV integration; or up-regulated in invasive cancer 
compared with normal tissue (Nees 2001, Duffy 2003, Alawazi 2002). To confirm that these 
were viable candidate genes to study further, baseline expression levels were evaluated in a 
range of cervical cell lines and compared with normal human foreskin keratinocytes, as this 
was the best control available to me at the time of the study.  
 
DKK3 is a secretory glycoprotein and Wnt antagonist that had shown tumour-specific DNA 
hypermethylation in prostate cancer, breast cancer and acute lymphoblastic leukaemia 
(Roman-Gomez, Jimenez-Velasco et al. 2004; Lodygin, Epanchintsev et al. 2005; Veeck, 
Bektas et al. 2008). DKK3 baseline expression in C33a was comparable to that of NHFK and 
it was not expressed in the three HPV positive cervical cell lines HeLa, CaSki and SiHa. This 
is not surprising because since the undertaking of this thesis the Wnt pathway has been shown 
to be activated in cervical carcinogenesis, facilitated through DKK3 negatively regulating 
beta catenin (Lee, Jo et al. 2009). HPV is thought to provide the initial hit and activation of 
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canonical Wnt pathway providing the second hit required for malignant transformation 
(Pahnke, Mix et al. 2004; Uren, Fallen et al. 2005; Perez-Plasencia, Vazquez-Ortiz et al. 
2007). In this study DKK3 was methylated in the three HPV positive cervical cell lines HeLa, 
CaSki and SiHa and hemi-methylated in C33a and was up-regulated post-demethylation of 
HeLa and two other HPV 18 positive cell lines. These findings are in accordance with a paper 
just published showing methylation of the DKK3 promoter in cervical cancer cell lines (Lee, 
Jo et al. 2009). 
 
KLF4 is a zinc-finger protein and an inhibitor of the cell cycle, blocking G1/S progression 
and suppressing cell proliferation through p21 (Shields, Christy et al. 1996; Chen, Johns et al. 
2001), and is down-regulated as a consequence of hypermethylation of its promoter and LOH 
(Wei, Gong et al. 2005). KLF4 has not been shown to be associated with cervical cancer or 
HPV infection. KLF4 was expressed at a lower level in SiHa and C33a compared with 
NHFK, HeLa and CaSki, which may be explained by the fact that it can act both as a tumour 
suppressor and oncogene through its regulation of p53 and p21 expression, both of which 
have been implicated in cervical cancer (Rowland, Bernards et al. 2005). I found no evidence 
for the up-regulation post-demethylation of HeLa, and KLF4 was unmethylated in all the 
cervical cell lines examined. The results obtained by RT-PCR and MSP contradict those 
obtained by the original gene expression microarray, which may be because the demethylation 
of candidate genes also included the use of trichostatin A, which is an acetylating agent. 
Acetylation has been shown to be important for KLF4-mediated transactivation, with KLF4 
differentially modulating histone H4 acetylation at the promoters of target genes. Evans et al. 
suggest that depending on whether KLF4 interacts with co-activators (e.g. p300 and CREB-
 Discussion 
 
 
285 
binding protein) or co-repressors (e.g.  HDAC3) it is able to function both as a transcriptional 
activator and a repressor (Evans, Zhang et al. 2007). 
 
RNASET2, a T2-Rnase glycoprotein, is able to bind actin in vitro (Smirnoff, Roiz et al. 
2006). Deletion at this locus has been demonstrated in a number of malignancies, including 
ovarian (Cooke, Shelling et al. 1996; Lin and Morin 2001), breast (Devilee, van den Broek et 
al. 1991; Devilee, van Vliet et al. 1991), stomach (Queimado, Seruca et al. 1995), uterine 
(Chappell, Lydon et al. 1997), kidney (Morita, Ishikawa et al. 1991), colon (Honchel, 
McDonnell et al. 1996) and liver (De Souza et al., 1995). RNASET2 is expressed at 
comparable levels in NHFK and in the HPV 16 positive cell lines CaSki and SiHa, but 
expression is not detectable in the HPV 18 cell line HeLa, and very high levels of expression 
were detected in the HPV negative cell line C33a. RNASET2 has not been associated with 
cervical cancer carcinogenesis, however it has been shown to be a tumour suppressor in 
ovarian cancers, which was not regulated by DNA methylation (Acquati, Morelli et al. 2001). 
This is in agreement with my data showing that RNASET2 is unmethylated in cervical cancer 
cell lines; however it is contradicted by its up-regulation post-demethylation of HeLa in which 
it was also not expressed.  
 
TIMP1 is an inhibitor of matrix metalloproteinases (MMPs) that has variable X-chromosome 
inactivation in females, which has been  suggested to be regulated by acetylation of histone 
H3 (Anderson et al., 2005). TIMP1 was equally expressed in all of the four cervical cell lines 
compared with NHFK, which is contradictory to preliminary data from one group has 
suggested that TIMP1 is up-regulated in cervical cancer (Vazquez-Ortiz, Pina-Sanchez et al. 
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2005). However, other matrix metalloproteinases, especially MMP2 and MMP9 have been 
associated with cervical cancer (Davidson, Goldberg et al. 1999; Mitra, Chakrabarti et al. 
2003), with MMP2 increased in CIN and invasive disease but TIMP2 down-regulated in 
cervical cancer (Branca, Ciotti et al. 2006). Although TIMP1 was methylated in all 3 cervical 
cell lines its regulation is thought to be through histone acetylation and not methylation. This 
would be in line with its up-regulation post-demethylation of HeLa and two other HPV18 
positive cell lines, as these were also treated with the acetylating agent trichostatin A. 
Nonetheless, methylation of the TIMP1 promoter has been correlated with X chromosme 
instability and low  expression, with TIMP1 methylation having been demonstrated in bladder 
cancer (Anderson and Brown 2002; Veerla, Panagopoulos et al. 2008).  
 
AKAP12, an anchoring protein controlling cell signalling, adhesion and differentiation 
(Gelman, Lee et al. 1998; Lin, Nelson et al. 2000), has not previously been reported to be 
methylated in cervical tissue but methylated forms have been reported in colorectal and 
gastric cancers (Kwak, Ma et al. 2004; Lau, Sham et al. 2006; Mori, Cai et al. 2006). 
AKAP12 is expressed weakly but at a comparable level to that of NHFK in HeLa and SiHa, 
highly expressed in C33a and expression was not detectable in CaSki. This variation in 
expression is unexpected because although AKAP12 it has not been correlated with cervical 
cancer it has been shown plays an important role in differentiation and metastasis at other 
sites. AKAP12 was unmethylated in HeLa and C33a, and hemi-methylated in CaSki, which 
correlates with their baseline expression. Although AKAP12 was found to be unmethylated 
by MSP the up-regulation post-demethylation of HeLa and HPV18 positive foreskin 
keratinocytes is supported by studies demonstrating AKAP12 to be an epigenetically 
regulated tumour suppressor gene at sites such as lung cancer (Jo, Whang et al. 2006). 
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CADM1 is a cell adhesion molecule involved in cell-cell interactions (Gomyo, Arai et al. 
1999). It has been shown to be inactivated by promoter methylation and LOH in non-small 
cell lung cancer and other sites (Murakami 2005; Murakami 2005). CADM1 expression in 
C33a is comparable to that in NHFK. It is not expressed in the three HPV positive cervical 
cancer cell lines HeLa, CaSki and SiHa, which is consistent with the data suggesting that it is 
epigenetically silenced in HPV positive cervical cell lines (Steenbergen, Kramer et al. 2004; 
Lee, Jo et al. 2009). It is up-regulated post-demethylation of HeLa and two other HPV 18 
positive cell lines, with methylation all cervical cell lines. All these data are in agreement with 
that of other groups showing that CADM1 gene silencing via promoter hypermethylation is a 
frequent event in the progression from high-risk HPV-containing, high-grade CIN lesions to 
invasive cervical cancer (Steenbergen, Kramer et al. 2004; Overmeer, Henken et al. 2008).  
 
CLU is a stress inducible glycoprotein regulating of apoptosis (Pajak and Orzechowski 2006) 
that is hypermethylated in prostate cancer (Rauhala, Porkka et al. 2008). CLU is expressed at 
a higher level in all of the cervical cell lines compared with NHFK, especially in C33a, which 
is suggested of an oncogene, not a tumour suppressor gene. These results are in agreement 
with data published since the undertaking of this thesis demonstrating CLU over-expression 
in invasive disease compared with normal cervical epithelium (Park, Yeo et al. 2006). 
However, another recent study has reported its down-regulation (Choi, Kim et al. 2007) and a 
further study also shows that there is no change in CLU expression in squamous and 
adenocarcinomas relative to disease free controls (Abdul-Rahman, Lim et al. 2007). The 
detection of methylation in all cervical cell lines and up-regulation post demethylation of 
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HeLa and HPV18 positive foreskin keratinocytes does not correlate with baseline expression, 
but is not surprising given the vast literature on the role of CLU in the pathogenesis of 
prostate cancer, illustrating it is an epigenetically silenced tumour suppressor gene (Rauhala, 
Porkka et al. 2008).   
 
Although we might have expected consistent expression levels across cell lines for strong 
candidate genes, these results show a varying pattern of expression between cell lines for most 
genes at baseline, notably with the exception of CLU, which was expressed consistently 
strongly in all cancer cell lines and only weakly in normal human foreskin keratinocytes, and 
TIMP1, which was expressed strongly in all cell lines. The fact that the baseline expression of 
CLU is identical in all cervical cell lines and correlates with a recently published study would 
suggest this to be a strong candidate for further investigation, even though it is suggestive of 
an oncogenic function and not a tumour suppressor gene. Although this study set out to 
identify an epigenetically regulated tumour suppressor gene, it was felt that it was just as 
worthy to investigate a potential oncogenic role in cervical neoplasia.  However, it is 
important to recognise that the mixed pattern of expression seen in these experiments may 
have been due to several variables. In particular, these various cell lines had different HPV 
statuses, which may well have potentially influenced their methylation status. Equally, when 
cell lines were demethylated they were also treated with the acetylating agent trichostatin A 
and so any expression changes seen may not solely be due methylation (see section 6.16.4).  
 
With the exception of KLF4, validation of candidate genes confirmed their up-regulation post 
demethylation of HeLa, although with differing degrees of intensity. KLF4 and RNASET2 
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were not methylated in the cervical cancer cell lines and so this stage not viable candidates. 
AKAP12 showed hemi methylation and DKK3, TIMP1, CLU and CADM1 showed high 
levels of methylation by MSP and warrant further investigation as epigenetically regulated 
candidate genes.  
 
Methylation Specific PCR was used to determine the methylation status of candidate genes in 
cervical cancer cell lines. This is a very sensitive technique, showing the methylation status of 
CpG dinucleodies in the candidate gene promoter within designed PCR primers. However, the 
technique is thought to be biased towards the detection of even low levels of methylation, 
which could potential give false positive results. Despite this, the approach taken is a means 
of initially determining gene methylation status in a series of candidate genes rapidly before 
further validation using other techniques such as bisulphite genomic sequencing.  
 
6.2. Further validation of candidate genes in disease progression models 
Having confirmed the baseline expression and methylation status of candidate genes in 
cervical cancer cell lines the W12 longitudinal model of disease progression was used to 
further examine changes in candidate gene expression. As in the cervical cancer cell lines 
examined methylated forms for KLF4 and RNASET2 cannot be detected in the W12; thus 
strengthening the conclusion that these are unlikely to be epigenetically regulated and hence 
not suitable candidate genes for further validation. AKAP12 showed variable methylation is 
cervical cancer cell lines, but since it was hemi-methylated in HPV16 positive CaSki the 
absence of any methylation in pre and post integration passages of W12 was unexpected. I 
might have expected to see methylation of AKAP12 in late but not early passages of W12, 
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with methylation being associated with viral integration since when it is methylated in CaSki 
there are more than 600 integrated HPV-16 copies present; however this was not the case. The 
candidate genes that were methylated in the cervical cancer cell lines, DKK3, CADM1, 
TIMP1 and CLU, were also methylated in W12. Furthermore, these genes showed an increase 
in methylation with serial passage of the cell line as it becomes increasingly dysplastic. These 
genes at this stage show great potential as epigenetically regulated genes in cervical neoplasia, 
strengthened by their increase in methylation in W12. However, no accompanying down-
regulation of candidate genes at the RNA level was observed with serial passage and 
increasing methylation status. It is possible that this observed methylation may precede 
transcriptional changes which will only become apparent in passages of the W12 beyond 
those tested here. 
 
6.3 Re-evaluation of potential candidate genes 
At this point in the investigation, since KLF4, RNASET2 and AKAP12 were all 
unmethylated and showed no change in expression in cervical cell lines they did not warrant 
further validation. DKK3, CADM1, TIMP1 and CLU showed notable promise as potential 
epigenetically regulated genes in cervical cancer given that they were methylated in cervical 
cell lines and increasingly in the disease progression model. However, on reflection, looking 
at their basal levels of expression in cervical cancer cell lines, CLU and TIMP1 were not 
down-regulated compared with normal keratinocytes, whereas DKK3 and CADM1 were, 
suggesting that the methylation observed in CLU and TIMP1 might not be detrimental to their 
transcriptional control in cervical neoplasia. 
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6.4. Investigation of candidate genes in cervical cancer, CIN and normal tissue  
In order to determine whether the candidate gene expression seen in vitro recapitulates the 
situation in patients, the expression of candidate genes that were found to be methylated in 
cervical cell lines was next examined in patient samples. Normal cervix was compared with 
CIN and invasive disease to identify whether epigenetic regulation of candidate genes was an 
early event in pre-invasive disease that could potentially be used as a diagnostic indicator for 
treatment before the disease becomes invasive, making it harder to eradicate. This provides a 
more realistic insight as it is known that cell lines undergo de novo methylation during in vitro 
cell culture and acquire methylation marks not associated with primary tumours (Jones and 
Laird 1999; Pantoja, de Los Rios et al. 2005). This is important given that two of the 
candidates, CLU and TIMP1 showed no correlation between methylation and transcription 
silencing in cell lines but DKK3 and CADM1 did.  
 
These studies revealed that TIMP1 was also expressed at the RNA level in CIN as it was in 
cell lines, whereas CLU which as expressed at the RNA level in cell lines was not detected in 
patients with CIN. This is in agreement with the recently published study by Choi et al. 
demonstrating down-regulation of CLU in RNA extracted from cervical cancer patients 
compared with that extracted  from normal cervical epithelium, thus CLU may still have 
potential as a candidate gene (Choi, Kim et al. 2007). The remaining genes showed very little 
or no expression in patient samples, adding to their worth as potential candidate genes. 
 
At the time of this study, commercial antibodies were available to DKK3, TIMP1, AKAP12 
and CLU and so paraffin fixed sections of normal cervix, CIN I to III and invasive disease 
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were stained for protein expression. DKK3 expression was not interpretable due to poor 
quality antibodies and the one published study of DKK3 expression in cervix only looked at 
RNA expression not protein expression. TIMP1 and AKAP12 showed no difference in 
expression between normal cervix and CIN, thus are not suitable candidates for epigenetically 
regulated genes in cervical cancer. It was surprising that the down-regulation of candidate 
genes at the RNA level did not translate to change at the protein level between normal cervix 
and CIN or invasive disease. CLU on the other hand was up-regulated in CIN compared to 
normal cervical epithelium and then down-regulated in invasive disease compared with CIN. 
This shift in protein expression provides a possible explanation for the contradictory studies 
regarding CLU expression in cervical neoplasia. The study by Park et al. showed up-
regulation of CLU in cervical cancers compared with normal cervical epithelium by 
immunohistochemical staining, which is what was found in the invasive samples examined in 
this study (Park, Yeo et al. 2006).  
 
CLU is down-regulated during the onset of cervical abnormality, possibly induced by HPV 
infection, and this lack of CLU then increases the susceptibility to tumourigenesis after 
carcinogenic challenge. Hence, CLU can be considered to be a tumour attenuator acting 
predominantly at early stages of neoplastic growth. It is probable that this down-regulation 
observed is of the nuclear isoform of the protein, as some studies discussed have indeed 
suggested. What is not known in these studies is whether the intracellular localization of the 
protein is cytoplasmic CLU or a pre-cursor for the nuclear isoform, not yet translocated to the 
nucleus. It would have been informative at this stage to have stained cervical sections for 
markers of proliferation and apoptosis given the opposing role of CLU in regulating apoptosis 
depending upon subcellular localisation.  
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6.5. Further validation of CLU as a target gene in cervical neoplasia 
Having identified CLU as potential tumour suppressor gene, it was necessary to confirm the 
results of previous RT-PCR using quantitative RT-PCR, to confirm the changes in protein 
expression in a wider cohort of cervical samples and with different CLU antibodies. 
Validation of expression using Q RT-PCR highlighted the importance of using a consistent 
housekeeping gene across all samples. Having validated a number of housekeeping genes and 
selected B2M because it showed least variability between samples, quantitative analysis of 
demethylation experiments confirmed those obtained using end point PCR. Had I used a 
different housekeeping gene for validation of expression changes by QPCR a completely 
different pattern of expression would have emerged. CLU transcriptional changes of were 
validated in serial passage of the W12 cell line showing CLU not to be down-regulated during 
serial passage of W12 cells, and so is not associated with the observed methylation.  
 
Having demonstrated that CLU was up-regulated in CIN compared with normal cervix using 
a commercially available antibody from Vector, the same cohort was examined with two 
further CLU antibodies and confirmed the increased staining for CLU in high grade CIN 
compared with normal cervical epithelium and its down-regulation in invasive cancer. In 
order to validate the specificity of the CLU antibodies, the expression of CLU at the protein 
level in cell lines was investigated using western blotting. This confirmed the expression of 
CLU proteins confirmed with a transfection control and showed increased expression in 
HeLa, CaSki and SiHa when compared with C33a and normal human foreskin keratinocytes, 
as was seen at the RNA level. Western blotting of W12 passage 15 and 56 cell lysates showed 
no change in CLU expression between the passages and confirmed results obtained by 
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immunohistochemistry of cell lines. Data obtained by western blotting is further strengthened 
by Park et al. demonstrating up-regulation of CLU in cervical cancer cell lines (Park, Yeo et 
al. 2006). 
 
The starting point of pursuing CLU as a candidate tumour suppressor gene in the pathogenesis 
of cervical neoplasia was the finding that CLU was up-regulated in the initial demethylation 
experiment performed in my laboratory. CLU was found to be methylated by MSP in cervical 
cancer cell lines and this was confirmed by pyrosequencing, with 50% of the cervical cell 
lines showing high levels of methylation of the CLU promoter. However, although 20 fold 
up-regulation of CLU was seen post-treatment of the HeLa cell line with 5-Aza-2’-
deoxycitidine and TSA, the cell line showed low levels of methylation between 5 and 15% by 
BGS and pyrosequencing. Additionally, when pyrosequencing was carried out on the 
demethylated HeLa, no significant change in methylation status was detected; this would 
suggest that the substantial up-regulation post-treatment of HeLa is more likely to be due to 
acetylation by the Trichostatin A.  In the W12 cell line model, there was variation in the 
methylation status of CLU with a distinct up-regulation of CLU between passages 9 and 11 
proceeded by a significant decrease in methylation in passage 12; these changes in the 
methylation status of the CLU promoter may be related to the loss of episomes and viral 
integration. 
 
In DNA extracted from cervical smears from women with CIN the majority showing an 
increase in methylation status correlating with disease progression from CIN I to CIN II and 
CIN III. All of the methylation frequencies seen in cervical smears were much lower than 
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those in the cervical cell lines, with the exception of the HeLa cell line, suggesting that cell 
lines do not accurately represent the gene methylation frequencies observed in vivo. Results 
are consistent with previous evidence suggesting that cell lines can acquire specific DNA 
methylation defects as a result of immortalisation and continuous culture that are unrelated to 
the tumour origin (Jones et al, 1990; Pantoja et al, 2005). Cell lines contain de novo 
methylation events not present in primary tumours and have higher methylation frequency for 
specific genes than primary tumours, but are still useful indicators of gene methylation status. 
However, the methylation status of the CLU promoter was only examined in CIN and not in 
invasive disease, and had we examined invasive tumour samples the methylation frequencies 
could have been much higher, especially given the expression of CLU was very low or lost in 
squamous and adeno-carcinoma samples examined. Alternatively, it is possible that high 
levels of methylation could be a feature of a small subset of cervical tumours.  
 
6.6.  Investigation of the expression of clusterin in oral carcinoma 
In cervix, there was a down-regulation of CLU in pre-invasive disease and an up-regulation in 
invasive disease compared with normal cervical tissue. The potential for a role for CLU in 
oral cancer was identified in a microarray showing down-regulation of CLU in oral cancers 
and compared with cancer-free controls, which was subsequently confirmed by Q RT-PCR. 
The down-regulation of CLU in oral cancers is consistent with what is observed in CIN, but 
not invasive cervical cancer. There are no studies published of human CLU expression in oral 
carcinoma, however one recent study used serum proteomics in mice bearing orthotopic 
human oral squamous cell carcinomas, which identified a disparity in expression of mouse 
CLU between control and cancer-bearing mice (Bijian, Mlynarek et al. 2009). 
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To validate and further investigate these results, I used Q RT-PCR and western blotting in 
oral cancer cell lines. However, my results, which showed a high level of CLU expression at 
both the RNA and protein levels, were contrary to expression levels in seen in oral cancers by 
microarray and Q RT-PCR in the original experiments. This suggests that the NHFK control 
available at the time of this study may not have been a representative control for these 
samples or that these cell lines are not representative of tumour samples from patients. 
Immunohistochemical staining of cytospins prepared from the same cell lines were consistent 
with those seen by western blot and Q RT-PCR, with strong 3+ staining in the oral cancer cell 
line SCC4.  
 
Contrary to these findings and in agreement with microarray results, immunohistochemical 
staining of oral cancers showed a down-regulation or loss of CLU in oral cancer. Where CLU 
expression was detected, it was the necrotic cells that stained positive for CLU, which is not 
surprising given the role of CLU in the regulation of apoptosis.  
 
As was observed in cervical cancer cell lines, different housekeeping genes used for 
normalisation of Q RT-PCR data resulted in different expression patterns and so selecting the 
correct housekeeping gene is essential. Protein expression data is more reliable as it is not 
subject to the same sensitivity issues when comparing gene expression to housekeeping gene 
expression. This is of course dependent upon the reliability of CLU antibodies, the specificity 
of which was confirmed following transfection of CLU proteins into 293 cells, which showed 
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the 60kDa and 40kDa CLU proteins that are well document (Park, Yeo et al. 2006; Chayka, 
Corvetta et al. 2009). 
 
6.7. Investigation of the epigenetic regulation of expression of clusterin in oral 
carcinoma 
SNP analysis revealed a possible deletion encompassing the CLU locus on chromosome 8p21 
which may play a role in the down-regulation of CLU in oral cancer. As epigenetic 
regulation, specifically DNA methylation, was demonstrated to play a role in cervical cancer 
carcinogenesis, I evaluated whether this phenomenon governed CLU expression at other sites 
of cancer, in this case oral carcinoma. All oral cancer cell lines were methylated by MSP, 
which was confirmed by pyrosequencing. Interestingly, SCC4 which appeared to have the 
highest level of CLU expression at the RNA and protein level of all the cell lines also had the 
lowest level of methylation of the 7 cell lines, suggesting that methylation is regulating gene 
expression in these cell lines to some extent. Although not shown for CLU, methylation has 
been shown to regulate expression of the cell lines used in this study in a variety of gene 
promoters, such as E-cadherin (Nakayama, Sasaki et al. 2001), with up-regulation of the 
p16ink4a gene following demethylation (Timmermann, Hinds et al. 1998; Lee, Kim et al. 
2004). 
 
MSP showed hemi-methylation of the CLU promoter in oral cancers that was comparable to 
that of methylation in disease-free oral epithelium. The presence of both unmethylated and 
methylated products, hemi-methylation, could be due to a mixed cell population with some 
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cells being methylated while others are not, or mixture of methylated and unmethylated 
alleles within these tumours reflecting that the population as a whole is heterogeneous. It is 
also possible that in the tumour samples that adjacent normal cells may be contributing to the 
level of methylation detected and micro-dissected tumours would have provided a more 
accurate comparison. Pyrosequencing identified low levels of methylation in a different 
cohort of oral cancers. Methylation frequencies were much lower in both cohorts of oral 
cancers using MSP and pyrosequencing than in oral cancer cell lines, suggesting that 
methylation is unlikely to be the sole regulator of reduced CLU expression in oral cancer. 
Problems inherent with studying methylation in cell lines are discussed in methodological 
considerations (section 6.16.4.1).  
 
6.8.  Investigation of the expression of clusterin in nasopharyngeal carcinoma 
Contemporaneous in-house microarray experiments showed that CLU was down-regulated in 
NPC cell lines, and in 19 (76%) of 25 NPC biopsies compared with cancer free controls. A 
review of the literature also revealed down-regulation of CLU in two published arrays of 
primary NPC, one of which included whole tissue samples, the other, micro-dissected 
epithelium (Shi 2006, Sriuranpong 2004). I therefore set out to validate these results to 
evaluate CLU as a potential tumour suppressor gene in NPC. 
 
In NPC cell lines, I was only able to confirm the down regulation of CLU in one of the cell 
lines with high level of CLU expression in others. This was not reflective of the expression I 
observed in NPC tumours, in which I confirmed down regulation of CLU in 10/12 tumours, 
confirming initial microarray and Q RT-PCR down-regulation. Q RT-PCR normalised against 
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B2M, showed CLU to be down regulated in only one cell line (C666-1), and up regulated in 
four others (CNE 1, SUNE 1, NPC TWO 1 and HONE 1). Western blotting and 
immunohistochemical staining of cytospins confirmed that C666-1 does not express any of 
the CLU proteins. The 60kDa and 40kDa CLU proteins are present in other all cell lines. The 
difference in expression of CLU between C666-1 and Ad-AH could be because Ad-AH is an 
adenocarcinoma cell line not squamous carcinoma. 
 
C666-1 was the only cell line in which the expression of CLU was representative of NPC 
tumours, which can be explained by the fact that it is the only NPC cell line consistently 
carrying the Epstein-Barr virus (EBV) in long-term culture (Cheung, Huang et al. 1999). A 
number of other tumour suppressor genes have been demonstrated to be only down regulated 
in this cell line model, but not in EBV negative cell lines, such as ATM and RASSF1A 
(Chow, Lo et al. 2004; Bose, Yap et al. 2009). However, in these studies in vitro infection 
with a recombinant EBV resulted in tumour suppressor gene down-regulation, whereas the 
opposite was found with regards to CLU expression.  
 
6.9. Investigation of the regulation of expression of clusterin in nasopharyngeal  
carcinoma by EBV and its latent genes 
As the C666-1 model is the only EBV positive cell line, and because in cervical cancer HPV 
possibly may play a role in clusterin expression, I decided to further investigate clusterin 
expression in a cell line model following infection with a recombinant EBV. 
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CLU RNA was significantly up-regulated following infection with EBV and ∆LMP2A EBV 
when compared with the parental Ad-AH cell line. This was mirrored at the protein level by 
both immunohistochemical staining and western blotting where compared with the parental 
cell line, the 60kDa and 40kDa CLU proteins are over-expressed following infection with 
EBV and ∆LMP2A EBV. Expression of the latent genes EBNA1, LMP2A, LMP2B and 
LMP1 in Ad-AH did not show any change in the expression of CLU at the RNA level 
compared with the parental cell line. This was surprising as I would have expected a down-
regulation following transfection with LMP2A and an up-regulation following transfection 
with LMP1, given that LMP1 has been known to have oncogenic properties during latent 
infection in NPC.  
 
LMP1 functions as a constitutively active tumour necrosis factor receptor activating signalling 
pathways such as NF-kappaB, MAPK, JNKand the JAK/STAT pathway (Tsao, Tramoutanis 
et al. 2002). It is the CTAR region of LMP1 that is able to directly activate multiple signalling 
pathways such as NF-kB, with the goal of preventing apoptosis. It has been shown that 
inhibition of LMP1 can increase the sensitivity of tumour cells to chemo and radiotherapy 
(Mei, Zhou et al. 2007). Studies have suggested that LMP1 acts in early stages of 
carcinogenesis to down-regulated tumour suppressor genes such as INK4a, induce anti-
apoptotic genes such as bcl-2 and promote more aggressive disease progression (Murono, 
Yoshizaki et al. 1999; Macdiarmid, Stevenson et al. 2003). LMP2A increases the invasiveness 
of NPC cells and has been shown to down-regulate both LMP1 and NF-kB (Pegtel, 
Subramanian et al. 2005). 
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Although RNA expression of CLU was not altered following transfection of Ad-AH with 
latent genes, it was found to be up-regulated following transfection with LMP1 at the protein 
level. Equally the 60kDa CLU protein was down-regulated following transfection of Ad-AH 
cells with LMP2A and LMP2B, which was not seen at the RNA level. Interesting the down-
regulation of the 60kDa CLU protein was accompanied by an induction of the 45kDa CLU 
protein that was not expressed in the parental cell line; this corresponds to the molecular 
weight of nuclear CLU. This correlates with the role of LMP2 in the pathogenesis of NPC 
where a recent study showed LMP2 down-regulated in the majority of NPC with a concurrent 
induction of apoptosis mediators FasL, Fas and IL-10 (Ogino, Moriai et al. 2007). Animal 
studies have shown that down-regulation of LMP2 prevents the proteolytic processing 
required for NF-kB activation and prevents it from increases the susceptibility to apoptosis 
induced by TNF-α (Hayashi and Faustman 2000). In this scenario it is possible that the 
reduction in active NF-kB induces expression of nuclear CLU to induce apoptosis. 
 
6.10. Investigation of the epigenetic regulation of expression of clusterin in 
nasopharyngeal  carcinoma 
I also wished to confirm whether there were any epigenetic mechanisms of clusterin 
regulation in NPC, as there had been some evidence for this mechanism in oral cancer. 
Although infection of the Ad-AH cell line with EBV appeared to up-regulate CLU, this did 
not correlate with methylation of the CLU promoter as there was also an increase in promoter 
methylation. Pyrosequencing showed that there actually was an increased level in methylation 
following infection of the parental line with EBV and its latent genes, suggesting methylation 
of CLU promoter is not regulating the expression of CLU in these transfected Ad-AH cells. 
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Pyrosequencing and bisulphite genomic sequencing of NPC cell lines showed only the EBV 
positive C666-1 to have a very high level of methylation of 84%. All other NPC cell lines still 
showed methylation that was greater than that observed in normal keratinocytes, ~20% 
compared with 10%, however this was not as high as that of C666-1.  
 
A study by Bakos et al. in C666-1 investigated DNA methylation and in vivo protein-DNA 
interactions at the latency promoters Qp and Cp. This revealed that the active, unmethylated 
Qp was marked with strong marks of cellular transcription factors and the viral protein EBNA 
1 which were not detectable in the methylated and silenced Cp promoter. The authors 
concluded that the epigenetic marks at Qp and Cp in C666-1 cells of epithelial origin 
resemble those of group I Burkitt's lymphoma cell lines not nasopharyngeal cell lines (Bakos, 
Banati et al. 2007). 
 
Pyrosequencing of NPC tumours show a mean methylation of 23%, with a range from 10 to 
49%, and 3 out of 10 tumours having high levels of methylation; however, this did not 
correlate with CLU expression in all cases. Methylation frequencies were much higher in 
NPC cell lines than in NPC tumours, which is discussed in methodological considerations 
(section 6.16.4.1).  
 
A SNP analysis showed a deletion at the CLU locus on 8p21 in 2 of 14 nasopharyngeal 
cancers from which epithelium had been removed by micro-dissection and in C666-1 there 
was a possible deletion encompassing the CLU locus (8p21), which was subsequently 
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confirmed using genomic PCR, a 7.6mb deletion with loss of one CLU allele in C666-1. This 
allelic loss was accompanied by methylation of the remaining CLU allele in C666-1 as 
determined by MSP, bisulphite genomic sequencing and pyrosequencing. Following 
demethylation of C666-1 RT-PCR showed transcriptional up-regulation of CLU, with a 
reduction in methylation from 77% to 51% as determined by pyrosequencing. Silencing of 
tumour suppressor genes, such as TIG1 by promoter hypermethylation has previously been 
observed in the NPC cell line C666-1 (Kwong, Lo et al. 2005). However, LOH of one allele 
with epigenetic silencing of the remaining allele has not been demonstrated before in NPC 
cell lines, nor has it been demonstrated for CLU at any other sites.  
 
6.11.  Phenotypic consequences of expression of clusterin in a nasopharyngeal carcinoma 
cell line model  
I next wished to examine the phenotypic effects of re-introducing clusterin into the C666-1 
cell line which did not express it. This is because the lack of expression of clusterin in this 
cell line recapitulates what we see in vivo in NPC tumours, which also makes it a particularly 
useful model in which to study the phenotypic effects of each individual CLU isoform, given 
the baseline absence of expression of both.  
 
HEK 293 were used to optimise transfection experiments as these cells are easy to transfect 
and so ideal to ensure CLU plasmids express the correct CLU proteins. CLU expression was 
seen at 12, 24 and 48 hours following transfection with full length and nuclear CLU. 
Transfection with full length CLU produced the characteristic 60kDa and 40kDa cytoplasmic 
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CLU proteins, and after 25 hours the 45kDa protein. The 45kDa protein but not the 60kDa 
protein is detectable 12 hours following transfection with nCLU. This is consistent with the 
possibility that the full length plasmid is also able to generate nuclear CLU by translocating to 
the nucleus and hence it not being detectable until 24 hours post transfection. It was important 
to carry out a number of timepoints to avoid missing the optimum or earliest time to see 
differences in transcript expression. Expression of the 60kDa CLU protein observed using full 
length CLU plasmids was equivalent to that reported by other groups at other sites (Bettuzzi, 
Scorcioni et al. 2002; Scaltriti, Bettuzzi et al. 2004; Moretti, Marelli et al. 2007).  
 
GFP transfection showed a transfection efficiency of 70% in C666-1 cells, and RNA 
expression post transfection with full length and nCLU showed expression of two transcripts 
from 6 hours post transfection. Western blotting of whole cell lystates showed the predicted 
60kDa and 40kDa cytoplasmic proteins post transfection with full length CLU, but not with 
nCLU. In contrast to HEK 293 a 45kDa protein is detectable following transfection with 
nCLU but not full length CLU, which is in agreement with transfection studies in prostate 
cancer cell lines (Bettuzzi, Scorcioni et al. 2002; Scaltriti, Bettuzzi et al. 2004; Moretti, 
Marelli et al. 2007). Western blotting of nuclear and cytosolic extracts confirmed that this 
45kDa CLU protein was nuclear in localisation. It was essential to confirm this localisation 
given that CLU functions as a pro-apoptotic protein when in the nucleus rather than an anti-
apoptotic protein when it resides in the cytoplasm (Caccamo, Scaltriti et al. 2003; Leskov, 
Klokov et al. 2003).  
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As I would have expected, decreased viability and proliferation was observed following 
transient transfection of C666-1 with nCLU, with an increase in the number of proliferating 
cells following transfection with full length CLU. These results are in agreement with 
published data regarding transient transfection of CLU (Scaltriti, Santamaria et al. 2004; 
Caccamo, Scaltriti et al. 2005). There was an increase in the number of early apoptotic cells 
and late apoptotic/necrotic cells following transfection with both nCLU and full length CLU, 
an effect which is ameliorated following TGFβ stimulation. TGFβ stimulates nuclear 
translocation of CLU (Reddy, Jin et al. 1996) so I would have expected this to increase the 
number of apoptotic cells. This result was unexpected – I would have expected to see an 
increase in the number of apoptotic cells following stimulation of nCLU transfected C666-1 
with TGFβ. This is possibly because apoptosis assays were carried out 48 hours post 
transfection when the effect of nCLU is masked by that of sCLU and so an earlier time point 
would have been more appropriate to study the levels of TGFβ induced apoptosis by nCLU.  
 
6.12. Regulation of NF-kB activity by CLU 
NF-kB is a transcription factor constitutively expressed in many cancer cell types that plays a 
pivotal role in numerous cellular processes including cell survival, stress response, immunity, 
cell motility, proliferation, and transformation (Cortes Sempere, Rodriguez Fanjul et al. 
2008), with the up-regulation of NF-kB signalling a common feature of malignant disease. 
Santilli et al. (2003) proposed an explanation for the pro-apoptotic activity of CLU through an 
involvement in the regulation of NF-kB activity, demonstrating that ectopic expression of 
CLU strongly inhibited NF-kB activity in human neuroblastoma cells and murine embryonic 
fibroblasts by stabilising inhibitors of NF-kB (IkBs).   
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Luciferase reporter assays following co-transfection of CLU with a NF-kB reporter construct 
were optimised in HEK 293 prior to carrying out in C666-1 cells, due to their ease of 
manipulation in cell culture. This showed down regulation of NF-kB post transfection of 
nCLU and an increase in NF-kB activity post transfection of full length CLU. In C666-1 both 
nCLU and full length CLU down-regulated NF-kB activity in these cells from 12 hours post 
transfection. Luciferase reporter assay for measuring NF-kB activity are notorious for 
showing variability between experiments and so these experiments were repeated 6 separate 
occasions with replicates on each occasion for each transfection to confirm that these data 
were statistically significant. Western blotting for p50 and p65 was carried out to confirm the 
results obtained by luciferase reporter assays and to determine whether suppression of NF-kB 
by CLU though stabilisation of IkBα would inhibit p50 and p65 nuclear translocation. 
Western blotting of nuclear and cytosolic extracts showed an increase in cytoplasmic p50 and 
p65 post transfection with nCLU and a concurrent decrease in their nuclear localisation. 
Transfection with full length CLU showed little, if any, change in p50 and p65 localisation. A 
more reliable assay for measuring NF-kB activity would have been to use the commercially 
available TransAM assay p50 and p65 ELISA kits, which were not used due to funding 
restraints of the project.  
 
The activity of NF-kB is suppressed through interaction with the inhibitory molecule IkB 
which blocks the translocation of the to p55/p60 heterodimer to the nucleus and its 
transcriptional activity. Phosphorylation of IkB by IkB kinases (IKKs) marks the latter for 
degradation, which results in the release and translocation of the active NF-kB heterodimer 
(Pajak et al, 2006). CLU has been shown to induce IkBα stabilisation by inhibiting E3 
ubiquitin ligase binding to phosphorylated IkBα, resulting in decreased NF-kB activity. 
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Following transfection of CLU into HEK 293 and C666-1 cells there was an increase in the 
expression of IkBα, supporting the published data in other cell lines as to the mechanism for 
the down regulation of NF-kB activity by CLU in these cell lines (Santilli, Aronow et al. 
2003; Pajak and Orzechowski 2006). Devauchelle et al. showed that CLU induces IKBα 
stabilisation by inhibiting E3 ubiquitin ligase binding to phosphorylated IkBα (Devauchelle, 
Essabbani et al. 2006). Loss of CLU expression in cells that depend on NF-kB activity for 
chemoresistance, proliferation, or invasion could lead to tumour progression. Data presented 
in this thesis suggests that CLU is a tumour suppressor gene required to regulation of 
tumourigenic signals emanating from the NF-kB pathway. 
 
Proof of principal experiments carried out in HEK 293 cells and HeLa cells showed that 
knockdown of CLU using siRNA resulted in increased NF-kB activity. These results are in 
agreement with a study in rheumatoid arthritis showing that CLU knock-down by siRNA 
promoted IL6 and IL8 production, which are transcriptionally regulated by NF-kB 
(Devauchelle, Essabbani et al. 2006). Santilli et al. showed that in the absence of CLU IkB 
stability is reduced leading to a TNF dependent increase in NF-kB activity and increased 
transcription of NF-kB target gene cIAP and down modulation of p53 (Santilli, Aronow et al. 
2003). However, the effects of CLU knockdown on NF-ĸB activity in HeLa cells were not 
affected by TNFα stimulation. Recent publications have shown that siRNA knockdown may 
invoke an interferon response, especially if duplexes are longer than 23bp and cell viability is 
affected (Reynolds, Anderson et al. 2006). Q RT-PCR for interferon response genes ISG 20 
and OAS post siRNA knockdowns of CLU ruled out the possibility of induction of an 
interferon response.  
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6.13.  Novel findings with regard to the pattern of expression of CLU in cervical, oral 
and nasopharyngeal cancer compared with normal epithelium 
I have demonstrated the down-regulation of CLU in biopsies taken from patients with oral 
and nasopharyngeal cancers, which has previously not been published. I was also able to 
show down regulation of CLU in cervical cancers, consistent one other study (Choi, Kim et 
al. 2007). However, over-expression of CLU has also been noted in two other studies of 
patients with cervical cancer (Park, Yeo et al. 2006); (Watari, Ohta et al. 2008). The reason 
for this discrepancy is not clear, but interestingly I found that CLU was up-regulated in CIN. 
An in-house SNP analysis revealed a possible deletion encompassing the CLU locus on 
chromosome 8p21 which may play a role in the down-regulation of CLU in oral cancer. It has 
previously been shown that LOH contributes to the pathogenesis of oral cancer and studies 
have shown this to include 8p and 11q22.2~q22.3 as frequent sites of loss of heterozygosity in 
head and neck SCC (Niu, Xin et al. 2005). This suggests that LOH might be a phenomenon 
affecting a number of tumour suppressor genes in this region and is not restricted to CLU, 
although in our analysis LOH of other TSGs at this locus were not identified. 
 
6.14. Novel findings with regard to the contribution of epigenetic regulation to the 
transcriptional control of CLU 
I have shown for the first time, using a variety of techniques, the presence of methylated form 
of CLU in cell lines and in whole tissue samples taken from patients with oral, 
nasopharyngeal and cervical cancer. In the NPC cell line C666-1 I was able to shown that loss 
of one CLU allele was accompanied by methylation of the remaining allele. I was also able to 
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show re-expression of CLU following treatment with the pharmacological demethylating 
agent, 5-Aza-2’-deoxycitidine.  Although CLU was shown to be methylated in a number of 
cervical cancer cell lines, and its expression to be up-regulated following treatment of these 
lines with 5-Aza-2’-deoxycitidine, I could find no compelling evidence to suggest that the 
presence of methylated forms of CLU in cervical material predicted the risk of progression to 
high grade CIN in a cohort of untreated women referred for investigation of minor cytological 
abnormality. Of course, it is possible that high levels of methylation are a feature of only a 
small subset of cervical tumours. 
 
6.15.   Novel findings with regard to the contribution of CLU to the regulation of NF-kB 
activity 
It has previously been postulated that CLU could be a tumour suppressor protein required to 
control tumourigenic signals emanating from the NF-kB pathway (Santilli, Aronow et al. 
2003). In suppressing NF-kB activity through stabilisation of IkBs CLU could induce tumour 
cells to undergo apoptosis and become more responsive to chemo-and radiotherapy (Kumar, 
Shirley et al. 2004).  However, these experiments were undertaken in normal and transformed 
cells that already expressed CLU, and moreover this was only in an inflammatory context. I 
was able to show for the first time, using a cell line model in which CLU was silenced that the 
ectopic expression of CLU downregulated NF-kB activity. Unlike the situation in HEK 293 
cells, both nCLU and full length CLU reduced NF-kB activity at 12 and 24 hours post 
transfection of C666-1 with CLU. This reduction in NF-kB activity was accompanied by the 
stabilisation of IkB determined by western blotting.  
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The regulation of NF-kB by CLU was confirmed following the knockdown of CLU in HeLa 
cells. These results are in accordance with those of Savkovic et al. who showed that down-
regulation of CLU resulted in a loss of IkB stability and a TNF dependent increase in NF-ĸB 
activity, with a consequential effect on NF-kB target genes (Savkovic, Gantzer et al. 2007).  
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6.16. Methodological considerations 
Although my results provide some insight into the regulation of CLU activity in cervical, oral, 
and nasopharyngeal cancers as well being more specifically defined in the C666-1 cell line, 
there are a few potential drawbacks to some of the methods and models that I have used 
which may have impacted upon my results and therefore the strength of the conclusions I 
have been able to draw within the context of this study. 
 
6.16.1. Use of 5-Aza and TSA 
The starting point for my thesis was the identification of candidate tumour suppressor genes 
from a demethylation experiment in which the cervical cell lines, HeLa, CaSki, SiHa and 
C33a has been treated with the demethylating agent 5-Aza-2’-deoxycitidine. 5-Aza-2’-
deoxycitidine (5-Aza) is frequently used in the laboratory and its derivatives have been tested 
in clinical trials. TSA is an acetylating agent which has no demethylating activity alone, 
although when used in combination with 5-Aza-2 it has an additive effect compared with 
using 5-Aza alone.   
 
Genes up-regulated by 5-Aza also may include genes known to poses tumour-promoting 
properties consistent with an oncogene function, such as sCLU. This indicates that 5-Aza may 
activate genes that promote a malignant phenotype, which may be of relevance when 
considering therapeutic interventions for cancer patients based on 5-Aza reactivation of 
epigenetically inactivated TSGs. Furthermore, 5-Aza is cytotoxic, and members of the 
interferon pathway are commonly up-regulated by 5-Aza treatment of cancer and normal cells 
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indicating a stress response (Karpf, Lasek et al. 2004). DNA methylation may not be confined 
to just one gene but have a wider effect on transcriptional activity. Several other chromosomal 
regions also appear to contain clusters of genes upregulated by 5-Aza in close proximity to 
one another (Ghoshal and Bai 2007). It is possible that DNA methylation spreads over large 
sections and can simultaneously regulate the expression of multiple genes clustered together. 
When using microarray analysis to identify genes in this context it is important to remember 
that this technique is limited towards the detection of specific transcripts with corresponding 
probe sets on the array, may be biased towards detection of only abundantly expressed 
transcripts, and is unlikely to be capable of detecting all gene reactivation events.  
 
6.16.2. Methylation analysis 
The analysis of promoter methylation status presents a number of difficulties. Firstly, the 
definition of a CpG island is arbitrary and has been defined by in silico analysis of the known 
gene sequence using the CpG plot programme (www.ebi.ac.uk/emboss/cpgplot). In some 
cases, more than one CpG island is predicted to occur near the transcriptional start site of the 
gene, so the criteria used to define a CpG island were gradually increased until only one 
island remains and the sequence of this island was then used to design MSP primers for 
methylation analysis. This approach will have biased analysis towards those islands which 
were the most CpG rich, but these were not necessarily the ones most likely to be methylated 
or play a potential role in controlling transcription. It is known that more than one CpG island 
can be present in a gene and control the expression of alternative transcripts.  For example, 
the RASSF1 gene contains 2 CpG islands, one at the 5’ end controlling isoform A expression, 
the other located downstream of this island and controlling RASSGF1 isoform C expression 
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(Chow, Lo et al. 2004). In rats it has been show that methylation of CLU also occurs in a CpG 
island 14.5kb upstream from the transcription start site and is responsible for gene silencing 
(Rosemblit and Chen 1994; Lund, Weisshaupt et al. 2006). 
 
There are also limitations with the detection methods used to analyse the methylation status of 
candidate genes. MSP was used to assess CpG island DNA methylation, and while this is a 
very sensitive technique, it is limited by the fact that it can only provide information based on 
a small number of CpG residues recognised by the methylated and unmethylatetd DNA 
specific PCR primers. However, methylation of specific CpG residues rather than entire CpG 
islands can be integral to transcriptional control. The technique of MSP is naturally biased 
towards the detection of methylated forms and the PCR for unmethylated forms is not as 
sensitive as that for the methylated, detecting methylated DNA even when only 0.1% of 
alleles are methylated (Herman, Graff et al. 1996; Liu and Maekawa 2003). MSP is not a 
quantitative method and small changes in methylation status will be easily missed, thus 
further analysis using a quantitative method such as bisulphite genomic sequencing is 
required before conclusions can be drawn. Bisulphite sequencing provides more detailed 
analysis of methylation across CpG islands, and can simultaneously assess the methylation of 
up to ~40 CpG sites. Cloning of PCR products into plasmids before bisulphite sequencing, 
sequencing of clones (BGS) would have given an idea of the relative proportions of 
methylated and unmethylated DNA present. However, the approach taken is a means of 
initially determining gene methylation status in a series of candidate genes.  
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MSP is useful as an initial screen as it is a quick method for qualitative analysis, however for 
a quantitative analysis of multiple adjacent CpG sites bisulphite genomic sequencing is 
frequently used, which is highly labour intensive. There are several other technologies 
available for the detection of methylation in both cell lines and tumours, including COBRA, 
SnuPE, SnaPmeth, MethyLight, Mass spectrometry and global methylation by MeDIP. In this 
study, the methylation initially detected was validated using the relatively new technology of 
pyrosequencing, which has many advantages over pre-existing techniques. It provides 
consistent, individual quantification of multiple CpG sites with a range of analyses, from 
single CpGs to global methylation. There are built in controls to confirm complete bisulfite 
modification and it is very high throughput with the potential to analyse up to 96 samples in 
parallel in 1 hour after their amplification by PCR (Biotage, 2007).  
 
To address these issues, methylation of the CLU promoter was initial confirmed by MSP and 
then validated extensively using bisulphite genomic sequencing in order to determine not only 
the level of methylation but also the frequency of methylation at each individual CpG 
dinucleotide in the CLU promoter and adjacent CpG rich region. For high throughput analysis 
of the frequency of methylation of CLU in multiple cell lines and DNA from tumours I used 
pyrosequencing, which had the advantage of the built in controls for efficient bisulphite 
modification. 
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6.16.3. Q PCR confirmation of changes in gene expression 
RT-PCR is used to study transcriptional regulation in vitro; gene expression in normal and 
tumour tissue; cDNA array validation; and pathogen detection e.g. viral/ bacterial 
contamination and genotyping. Previously gene expression was analysed by northern blotting 
which is cumbersome, slow and not very sensitive. Semi-quantitative RT-PCR is a more 
modern technique that is quicker, more sensitive, but not quantitative and potentially 
inaccurate as only the end point of the reaction. There are also multiple error points and using 
scanning densitometry to normalise expression on an agarose gel is notoriously inaccurate and 
subjective. Most studies of gene expression are now validated by Q RT-PCR that is very 
sensitive with the potential to detect a single copy of a gene and is high through-put (Terra, 
Murta et al. 2007). One of the major problems with validating gene expression by Q RT-PCR 
is finding a suitable housekeeping gene for normalisation of data sets (McNeill, Miller et al. 
2007). It is essential to test a number of housekeeping genes to determine which one shows 
least variation in cell types or data sets. There is a requirement to identify housekeeping type 
genes that show sample independent stability and studies have found that newly identified 
genes were more stably expressed in individual samples with similar ranges. Thus, statistical 
analysis of microarray data can be used to identify new candidate housekeeping genes 
showing consistent expression across tissues and diseases.  
 
I attempted to address this problem by validating 4 commonly used housekeeping genes in my 
dataset, but continually found differences when expression values were normalised to each of 
the genes. I then went on to study protein levels in order to define the gene which showed 
most reliable expression. My results indicated that B2M was the most appropriate gene to use 
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in this case. However, even with this gene results were variable, and where a one cycle 
difference in expression is sufficient to create a fold-change in final expression level readings 
this is a matter of concern. It may in future be more appropriate to identify genes expressed on 
microarrays which are unchanged between specific cancer cell lines and use these as internal 
controls in appropriate experiments. 
 
6.16.4. Use of cell lines as models in which to identify and characterise epigenetically 
inactivated genes in squamous cancer 
Through continuous culture, cell lines provide a resource of unlimited amounts of high quality 
tumour-derived DNA. However, there are notable and well-documented problems with their 
reliability as perfect models of the events which take (or have taken) place in primary tumour 
cells. In this thesis, the cervical, oral and nasopharyngeal cell lines that i used were not all 
reflective of the tumour environment and other studies have shown that cell lines grown in 
culture show changes in gene expression from the tissues they are derived from. 
 
6.16.4.1. Cell lines for the study of hypermethylation events 
Cell lines are commonly used for the initial screening of genes for evidence of methylation in 
cancer, and provide invaluable tools for functional assays in which to investigate the role of 
aberrantly methylated genes. Cell lines are known to undergo de novo methylation during in 
vitro cell culture and acquire methylation marks not associated with primary tumours, 
suggesting that their use in methylation studies should be viewed with caution (Jones and 
Laird 1999; Pantoja, de Los Rios et al. 2005). Most types of primary mammalian cells 
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proliferate for only a short number of doublings before entering into a stable proliferative 
arrest, so de novo epigenetic events in immortilised cells may occur as part of a stress 
response or mechanism of adaption to the culture environment. 
 
Results obtained in this study suggest that the cell lines i used do not accurately represent the 
gene methylation frequencies observed in vivo. Results are consistent with previous evidence 
suggesting that cell lines can acquire specific DNA methylation defects as a result of 
immortalisation and continuous culture that are unrelated to the tumour origin (Jones and 
Buckley 1990; Jones, Wolkowicz et al. 1990; Jones, Wolkowicz et al. 1990; Pantoja, de Los 
Rios et al. 2005). Cell lines contain de novo methylation events not present in primary 
tumours and have higher methylation frequency for specific genes than primary tumours. 
However, finding an appropriate cell line model, such as the NPC cell line C666-1, is a useful 
indicator of gene methylation status. It must be noted that in this study the methylation status 
of the CLU promoter was only examined in CIN and not in invasive disease, and had we 
examined invasive tumour samples the methylation frequencies could have been much higher, 
especially given the expression of CLU was very low or lost in squamous and adeno-
carcinoma samples examined. Alternatively, it is possible that high levels of methylation 
could be a feature of a small subset of cervical tumours.  
 
6.16.4.2. Cell lines for the study of transcriptional silencing  
Once evidence of DNA methylation has been established in primary tumours, it is next 
important to determine whether methylation leads to epigenetic inactivation of the 
 Discussion 
 
 
318 
corresponding transcript(s). This is because methylation of certain CpG islands downstream 
from the promoter of mammalian genes which did not block transcription have been 
previously identified (Jones et al 1999), demonstrating that gene hypermethylation does not 
always lead to transcriptional inactivation. Direct evidence of methylation-dependent 
silencing comes from the culture of cell lines with demethylating agents such as 5-Aza-2’-
deoxycitidine, which can be used to reactivate genes transcriptionally silenced by methylation 
in cell lines.  
 
In the W12 cell line model of disease progression changes in methylation status of CLU and 
other candidate tumour suppressor genes was identified, yet there was no compelling evidence 
of transcriptional down-regulation on serial passage of W12. However, in all other cell line 
models demethylated in this study; HeLa, C666-1, HPV18 positive NHFK and NHCK, 
methylation of CLU was accompanied by transcriptional downregulation. The C666-1 cell 
line may be a more useful indicator of gene methylation status in vivo. 
 
6.16.4.3. Cell lines for functional analysis 
The use of cell lines as models in which to investigate gene function may be limited as it is 
becoming increasingly apparent that tumours are a heterogeneous mix of different cell types, 
which may influence each other through paracrine signalling pathways and interactions with 
each other and with the extracellular matrix (Lyons, Lobo et al. 2008). In contrast, cell lines 
consist of clonal populations of cells that lack interactions with other cell types when grown 
in vitro and have been selected for their ability to grow under non-physiological conditions. 
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Studies have shown that cell lines grown in culture show changes in gene expression from the 
tissues they are derived from. Genes differing were associated with higher proliferation rates 
and disrupted tissue organisation in vitro, as many genes involved in processes such as  cell 
cycle progression and energy metabolism were upregulated, whilst cell adhesion molecules 
and membrane signalling proteins were downregulated (Sandberg and Ernberg 2005; 
Sandberg and Ernberg 2005).  
 
6.17. Summary 
Clusterin is a multifunctional glycoprotein widely expressed as two isoforms. One isoform, 
sCLU is secreted, cytoplasmic and anti-apoptotic, the other nCLU is nuclear and pro-
apoptotic (nCLU). Pre-nuclear CLU translocates to nucleus in response to various cytotoxic 
stimuli. nCLU is down-regulated in colon cancer and its over-expression in a prostate cancer 
cell line causes G2-M arrest. The pro-apoptotic function of CLU may be due to its interaction 
with XRCC6, a component of the DNA double strand break repair complex. HRAS 
suppresses clusterin expression through promoter hypermethylation.   
 
I have investigated the regulation and expression of CLU at three sites of squamous cancer; 
the oral cavity, cervix and nasopharynx. Transcriptional downregulation of CLU was 
demonstrated in nasopharyngeal cancer (NPC) and oral cancer, and downregulation of CLU 
was also shown at the protein level at these sites. I have shown loss of one CLU allele and 
methylation of the other in the NPC cell lines C666-1. I have gone on to repair this defect in 
this NPC cell line and found that CLU overexpression of the nuclear isoform of CLU resulted 
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in reduced proliferation and decreased cell viability. I have also shown using luciferase 
reporter assays that the overexpression of both isoforms of CLU in C666-1 cells and their 
knockdown in HeLa cells regulates NF-kB activity. Further evidence that CLU may regulate 
NF-kB activity was suggested by the finding that its overexpression in C666-1 resulted in the 
stabilisation of IkBα.  
 
Although sCLU is now considered a promising therapeutic target because of its anti-apoptotic 
function, with an antisense oligonucleotide currently undergoing clinical evaluation, my 
results suggest that further consideration needs to be given to the possible tumour suppressor 
function of nCLU. 
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The mechanism of production of nCLU is still a matter of much debate. According to Leskov et 
al. nCLU is the result of alternative splicing events, however it has been suggested by  Caccamo 
et al. that nCLU is produced by post-translational modification of the cytoplasmic precursor 
(Leskov, Klokov et al. 2003; Caccamo, Desenzani et al. 2006). It has also been seen that not only 
nCLU is able to enter the nucleus but full length cytoplasmic CLU, which is more stable, also has 
the ability to translocate to the nucleus (Pajak and Orzechowski 2006). The antisense 
oligonucleotide in clinical trials for breast and prostate cancer, OGX-011 is targeted to exon II, in 
a region common to both CLU isoform 1 and isoform 2 mRNAs. This strategy is effective for 
depletion of the secreted/cytoplasm CLU but if nCLU is produced by alternative splicing, 
skipping exon II, this would have no effect on the pro-apoptotic activity of nCLU. Thus tumour 
cells would be depleted of the pro-survival effects of sCLU with a concurrent accumulation of 
pro-apoptotic nCLU. This ASO strategy is tenuous given that clinical results obtained show that 
OGX-011 by itself has not been shown to actually induce apoptosis.  
 
It has been shown that the turnover of CLU is tightly regulated by ubiquitin-proteasome mediated 
degradation, with CLU half life being 115 mins (Rizzi, Caccamo et al. 2009). In prostate cancer 
cells proteasome inhibition by MG132 resulted in an accumulation of the nuclear form of CLU, 
committing cells to caspase-dependent death. Therefore, the use of proteosome inhibitors or gene 
therapy to deliver an expression cassette driving the production of a truncated form of CLU 
lacking the leader export sequence would be worth exploring in combination with the anti-sense 
oligonucleotide.  
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My work has suggested a number of additional lines of enquiry. However, in the first instance it 
would be crucial to generate other models for the study of the impact of CLU down-regulation. 
Although I was able to use the C666-1 cell line, which recapitulated the changes seen in vivo, 
these experiments would have been facilitated had I access to an inducible system for the 
expression of CLU. It would also be important to study the phenotypic and transcriptional 
consequences of deregulation of CLU in untransformed cells. Towards this end CLU knockdown 
experiments should be conducted in normal and transformed keratinocytes. Gene expression 
arrays performed pre and post knock-down of CLU would help to determine the transcriptional 
consequences of deregulated CLU expression. It would also be of interest to examine, in normal 
and in transformed cells, the impact of environmental stresses, for example heat shock in cells in 
which the expression of CLU had been ablated.  
 
The development of such cell line models would allow for a more detailed examination of the 
regulation of NF-kB by CLU in disease-free and in abnormal transformed cells. Such an 
examination should include other assays for NF-kB activity which take into consideration the 
specific NF-kB subunits and both the canonical and non-canonical pathways. In order to 
determine the mechanism of regulation of NF-kB by CLU, it would be useful to identify CLU 
binding partners. Of course the interpretation of these findings would be dependent upon a clear 
understanding of the physiological roles of nCLU and sCLU, and their contribution to disease 
pathogenesis 
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